<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38789443</article-id><article-id pub-id-type="pmc">11126717</article-id><article-id pub-id-type="publisher-id">61991</article-id><article-id pub-id-type="doi">10.1038/s41598-024-61991-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Bioinformatics approach for structure modeling, vaccine design, and molecular docking of <italic>Brucella</italic> candidate proteins BvrR, OMP25, and OMP31</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Elrashedy</surname><given-names>Alyaa</given-names></name><address><email>Alyaa.elrashedy.ms@vet.usc.edu.eg</email><email>alyaaelrshedy96@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nayel</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Salama</surname><given-names>Akram</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Salama</surname><given-names>Mohammed M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hasan</surname><given-names>Mohamed E.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05p2q6194</institution-id><institution-id institution-id-type="GRID">grid.449877.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 4652 351X</institution-id><institution>Department of Animal Medicine and Infectious Diseases (Infectious Diseases), Faculty of Veterinary Medicine, </institution><institution>University of Sadat City, </institution></institution-wrap>Sadat City, Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00h55v928</institution-id><institution-id institution-id-type="GRID">grid.412093.d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9853 2750</institution-id><institution>Physics Department, Medical Biophysics Division, Faculty of Science, </institution><institution>Helwan University, </institution></institution-wrap>Cairo, Egypt </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05p2q6194</institution-id><institution-id institution-id-type="GRID">grid.449877.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 4652 351X</institution-id><institution>Bioinformatics Department, </institution><institution>Genetic Engineering and Biotechnology Research Institute, University of Sadat City, </institution></institution-wrap>Sadat City, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><elocation-id>11951</elocation-id><history><date date-type="received"><day>12</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2024</year></date></history><permissions><copyright-statement>&#xA9; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Brucellosis is a zoonotic disease with significant economic and healthcare costs. Despite the eradication efforts, the disease persists. Vaccines prevent disease in animals while antibiotics cure humans with limitations. This study aims to design vaccines and drugs for brucellosis in animals and humans, using protein modeling, epitope prediction, and molecular docking of the target proteins (BvrR, OMP25, and OMP31). Tertiary structure models of three target proteins were constructed and assessed using RMSD, TM-score, C-score, Z-score, and ERRAT. The best models selected from AlphaFold and I-TASSER due to their superior performance according to CASP 12 &#x2013; CASP 15 were chosen for further analysis. The motif analysis of best models using MotifFinder revealed two, five, and five protein binding motifs, however, the Motif Scan identified seven, six, and eight Post-Translational Modification sites (PTMs) in the BvrR, OMP25, and OMP31 proteins, respectively. Dominant B cell epitopes were predicted at (44&#x2013;63, 85&#x2013;93, 126&#x2013;137, 193&#x2013;205, and 208&#x2013;237), (26&#x2013;46, 52&#x2013;71, 98&#x2013;114, 142&#x2013;155, and 183&#x2013;200), and (29&#x2013;45, 58&#x2013;82, 119&#x2013;142, 177&#x2013;198, and 222&#x2013;251) for the three target proteins. Additionally, cytotoxic T lymphocyte epitopes were detected at (173&#x2013;181, 189&#x2013;197, and 202&#x2013;210), (61&#x2013;69, 91&#x2013;99, 159&#x2013;167, and 181&#x2013;189), and (3&#x2013;11, 24&#x2013;32, 167&#x2013;175, and 216&#x2013;224), while T helper lymphocyte epitopes were displayed at (39&#x2013;53, 57&#x2013;65, 150&#x2013;158, 163&#x2013;171), (79&#x2013;87, 95&#x2013;108, 115&#x2013;123, 128&#x2013;142, and 189&#x2013;197), and (39&#x2013;47, 109&#x2013;123, 216&#x2013;224, and 245&#x2013;253), for the respective target protein. Furthermore, structure-based virtual screening of the ZINC and DrugBank databases using the docking MOE program was followed by ADMET analysis. The best five compounds of the ZINC database revealed docking scores ranged from (&#x2212;&#xA0;16.8744 to &#x2212;&#xA0;15.1922), (&#x2212;&#xA0;16.0424 to &#x2212;&#xA0;14.1645), and (&#x2212;&#xA0;14.7566 to &#x2212;&#xA0;13.3222) for the BvrR, OMP25, and OMP31, respectively. These compounds had good ADMET parameters and no cytotoxicity, while DrugBank compounds didn't meet Lipinski's rule criteria. Therefore, the five selected compounds from the ZINC20 databases may fulfill the pharmacokinetics and could be considered lead molecules for potentially inhibiting <italic>Brucella&#x2019;s</italic> proteins.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Brucellosis</kwd><kwd>Outer membrane protein</kwd><kwd>BvrR</kwd><kwd>Bioinformatics</kwd><kwd>Protein modeling</kwd><kwd>Epitopes prediction</kwd><kwd>Molecular docking</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Protein structure predictions</kwd><kwd>Virtual drug screening</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Sadat City</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#xA9; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par2">Brucellosis is considered one of the most hazardous infectious zoonotic diseases all over the world<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. The disease is caused by <italic>Brucella,</italic> which is a Gram-negative, intracellular bacterial pathogen<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. In contrast to other Gram-negative bacteria, <italic>Brucella</italic> has unique antigenic components that allow it to establish intracellular infection and induce virulence<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. The BvrR/BvrS system, which is conserved among members of the <italic>Alphaproteobacteria</italic> class, is one of these virulence factors. It is the master regulator of gene expression required for host interaction, intracellular survival, expression of outer membrane proteins (OMPs), and lipopolysaccharides (LPS) structure. It also controls the expression of the virB operon, which encodes for the type IV secretion system (T4SS), responsible for secreting bacterial factors necessary for modulating the maturation of the <italic>Brucella</italic>-containing vacuoles (BCVs)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. In addition, OMP25, a <italic>Brucella</italic> outer membrane protein that triggers a potent immunological response, is highly conserved among different types and subtypes of Brucellae<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. OMP25 protein has a role in macrophages thriving intracellularly in the TNF-&#x3B1; production reduced and IL-12-negative regulation at both the transcriptional and post-transcriptional levels achieved<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. It plays multiple roles which are inhibition of interferon &#x3B2; (INF-&#x3B2;) and activation of IFN-stimulated genes (ISGs)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p>
      <p id="Par3">Moreover, OMP31 is a key component of <italic>Brucella's</italic> most important virulence factors and is essential for the defense against <italic>Brucella</italic> infection<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. It plays a role in mediating attachment, entry, survival within host cells, and avoiding immune cell detection and suppressing their function. In addition, it interferes with dendritic cell maturation and function, and induces programmed cell death of infected macrophages, thereby helping <italic>Brucella</italic> to persist in the host<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Moreover, it has high antigenicity which allows it to be more candidate for peptide vaccine development<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Therefore, the identification of these virulence genes that encode different important proteins is crucial for vaccine design in controlling brucellosis.</p>
      <p id="Par4">Bioinformatics plays important roles not only in handling large volumes of data, but also in predicting, analyzing, or interpreting clinical and preclinical findings, drug discovery, drug assessment, and drug development<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Protein structure prediction approaches have emerged as important proteomic analysis for understanding phenomena in modern molecular and cell biology, and have significant applications in biotechnology and medicine<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. These approaches revolve around predicting the three-dimensional (3-D) structure of a protein from its primary structure (amino acid sequence) and are divided into three groups: Comparative modeling (also known as Homology modeling), Fold recognition (also known as Threading), and <italic>Ab-initio</italic> prediction (also known as Free modeling). The homology modeling technique tries to predict the unknown structure based on a template (a known structure), whose similarity to the sequence is higher than 35% <sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. On the other hand, for domains that have no homology, fold recognition uses a library of templates, or <italic>ab-initio</italic> techniques are used. <italic>Ab-initio</italic> approaches can be used to predict the protein structure from the sequence data when suitable structure templates are unavailable<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p>
      <p id="Par5">There are considerable knowledge deficits in creating new vaccines or drug molecules. Bioinformatics capabilities can help overcome these shortcomings of the live attenuated <italic>Brucella&#x2019;s</italic> vaccine and develop a safe and powerful subunit vaccine<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Another one of the most important applications in bioinformatics is epitope prediction, which predicts a variety of specific epitopes for B cell recognition and T cell through MHC class I and II molecules<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Various techniques and resources are utilized in epitope prediction, encompassing sequence-based methodologies (like ABCpred), structural approaches (such as DiscoTope), immunoinformatics-based strategies (involving NetMHC, NetMHCII, and SYFPEITHI), and machine learning-based models (likewise incorporating SVM)<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. This approach is cost and time-efficient compared to laboratory testing and allows the selection of immunogenic regions from the pathogen genomes<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p>
      <p id="Par6">In this study, we plan to utilize multi-techniques like protein structure prediction, epitope prediction and vaccine design, molecular docking, and ADMET prediction. The main emphasis is used for three protein targets (BvrR, OMP25, and OMP31) as potential vaccine candidates and medicines for the development of new human and animal brucellosis drugs and vaccines. Through the utilization of these advanced tools and techniques, the research aims to develop next-generation drugs and vaccines for this disease.</p>
    </sec>
    <sec id="Sec2">
      <title>Results</title>
      <sec id="Sec3">
        <title>Domain separation</title>
        <p id="Par7">Domain separation of the three proteins (BvrR, OMP25, and OMP31) is carried out through CDD and SMART servers. CDD showed that BvrR, OMP25, and OMP31 proteins had only one domain (10&#x2013;236, 5&#x2013;213, and 9&#x2013;261) with E-value (1.27e&#x2013;81, 1.44e&#x2013;42, and 1.91e&#x2013;36) for the three proteins, respectively (Table <xref rid="Tab1" ref-type="table">1</xref>). SMART displayed two, three, and five domains for BvrR, OMP25, and OMP31 proteins, respectively as listed in (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Domain assessment of three target proteins using CDD server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Name</th><th align="left">Accession</th><th align="left">Description</th><th align="left">Interval</th><th align="left">E-value</th></tr></thead><tbody><tr><td align="left">BvrR</td><td align="left">OmpR</td><td align="left">COG0745</td><td align="left">DNA-binding response regulator, the OmpR family, contains REC and winged-helix (wHTH) domain</td><td align="left">10&#x2013;236</td><td align="left">1.27e&#x2013;81</td></tr><tr><td align="left">OMP25</td><td align="left" rowspan="2">LomR</td><td align="left" rowspan="2">COG3637</td><td align="left" rowspan="2">Opacity protein and related surface antigens [membrane/envelope biosynthesis/Cell wall]</td><td align="left">5&#x2013;213</td><td align="left">1.44e&#x2013;42</td></tr><tr><td align="left">OMP31</td><td align="left">9&#x2013;261</td><td align="left">1.91e&#x2013;36</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Domain assessment of three target proteins using SMART server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Proteins</th><th align="left">Name</th><th align="left">Accession</th><th align="left">Description</th><th align="left">Interval</th><th align="left">E-value</th><th align="left">Gene ontology (GO)</th></tr></thead><tbody><tr><td align="left" rowspan="2">BvrR</td><td align="left">REC</td><td align="left">SM000448</td><td align="left">cheY-homologous receiver domain regulates the clockwise rotation of <italic>E. coli</italic> flagellar motors. This domain contains a phosphoacceptor site that is phosphorylated by histidine kinase homologues</td><td align="left">8&#x2013;118</td><td align="left">2.03e&#x2013;38</td><td align="left">Phosphorelay signal transduction system (GO:0000160)</td></tr><tr><td align="left">Trans_reg_C</td><td align="left">SM000862</td><td align="left">Transcriptional regulatory protein, C terminal. This domain is almost always associated with the response regulator receiver domain. It may play a role in DNA binding</td><td align="left">158&#x2013;234</td><td align="left">3.54e&#x2013;20</td><td align="left">Phosphorelay signal transduction system (GO:0000160), regulation of transcription, DNA-templated (GO:0006355), DNA binding (GO:0003677)</td></tr><tr><td align="left" rowspan="3">OMP25</td><td align="left">OMP_b-brl</td><td align="left">PF13505</td><td align="left">This domain is found in a wide range of outer membrane proteins. This domain assumes a membrane-bound beta-barrel fold</td><td align="left">9&#x2013;213</td><td align="left">2.3e&#x2013;26</td><td align="left">&#x2013;</td></tr><tr><td align="left">OmpA_membrane</td><td align="left">PF01389</td><td align="left">&#x2013;</td><td align="left">46&#x2013;213</td><td align="left">2.6e&#x2013;9</td><td align="left">Cell outer membrane (GO:0009279), an integral component of the membrane (GO:0016021)</td></tr><tr><td align="left">Opacity</td><td align="left">PF02462</td><td align="left">&#x2013;</td><td align="left">78&#x2013;213</td><td align="left">0.0000012</td><td align="left">Membrane (GO:0016020), porin activity (GO:0015288)</td></tr><tr><td align="left" rowspan="4">OMP31</td><td align="left">OMP_b-brl</td><td align="left">PF13505</td><td align="left">This domain is found in a wide range of outer membrane proteins. This domain assumes a membrane-bound beta-barrel fold</td><td align="left">13&#x2013;261</td><td align="left">2.5e&#x2013;26</td><td align="left">&#x2013;</td></tr><tr><td align="left">Autotransporter</td><td align="left">PF03797</td><td align="left">&#x2013;</td><td align="left">40&#x2013;222</td><td align="left">4.2e&#x2013;07</td><td align="left">&#x2013;</td></tr><tr><td align="left">OmpA_membrane</td><td align="left">PF01389</td><td align="left">&#x2013;</td><td align="left">45&#x2013;261</td><td align="left">5.4e&#x2013;11</td><td align="left">Integral component of membrane (GO:0016021), cell outer membrane (GO:0009279)</td></tr><tr><td align="left">Opacity</td><td align="left">PF02462</td><td align="left">&#x2013;</td><td align="left">115&#x2013;261</td><td align="left">7.8e&#x2013;09</td><td align="left">Membrane (GO:0016020), porin activity (GO:0015288)</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title>Secondary structure prediction</title>
        <p id="Par8">To increase the accuracy of secondary structure prediction, the result was obtained from nine neural network prediction servers: PSIPRED, NPS@ SOPMA, CFSSP, PSSpred, Lambada Predict Protein, GOR, PredictProtein, PROTEUS2, and RaptorX secondary structure prediction for the three target proteins. The predictprotein was the best and most accurate server for secondary structure prediction, composed of alpha helix 36.29%, 11.74%, and 8.05%; beta sheet 22.36%, 43.19%, and 38.70%; random coil 41.35%, 45.07% and 53.26%; exposed 59.92%, 46.48% and 45.98% and buried 40.08%, 53.52% and 54.02% for BvrR, OMP25 and, OMP31 proteins, respectively (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Secondary structure and solvent accessibility prediction.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Server</th><th align="left">protein</th><th align="left">Helix (H)</th><th align="left">Sheet (E)</th><th align="left">Turn (T)/coil (C)</th><th align="left">Exposed (e)</th><th align="left">Buried (b)</th></tr></thead><tbody><tr><td align="left" rowspan="3">CFSSP</td><td align="left">BvrR</td><td align="left">82.7%</td><td align="left">59.1%</td><td align="left">14.3%</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">OMP25</td><td align="left">62.4%</td><td align="left">65.3%</td><td align="left">13.6%</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">OMP31</td><td align="left">65.5%</td><td align="left">68.6%</td><td align="left">15.7%</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left" rowspan="3">PredictProtein</td><td align="left"><bold>BvrR</bold></td><td align="left"><bold>36.29%</bold></td><td align="left"><bold>22.36%</bold></td><td align="left"><bold>41.35%</bold></td><td align="left"><bold>59.92%</bold></td><td align="left"><bold>40.08%</bold></td></tr><tr><td align="left"><bold>OMP25</bold></td><td align="left"><bold>11.74%</bold></td><td align="left"><bold>43.19%</bold></td><td align="left"><bold>45.07%</bold></td><td align="left"><bold>46.48%</bold></td><td align="left"><bold>53.52%</bold></td></tr><tr><td align="left"><bold>OMP31</bold></td><td align="left"><bold>8.05%</bold></td><td align="left"><bold>38.70%</bold></td><td align="left"><bold>53.26%</bold></td><td align="left"><bold>45.98%</bold></td><td align="left"><bold>54.02%</bold></td></tr><tr><td align="left" rowspan="3">SOPMA</td><td align="left">BvrR</td><td align="left">32.91%</td><td align="left">20.68%</td><td align="left">46.41%</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">OMP25</td><td align="left">22.07%</td><td align="left">22.07%</td><td align="left">55.87%</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">OMP31</td><td align="left">17.62%</td><td align="left">18.77%</td><td align="left">63.60%</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr></tbody></table><table-wrap-foot><p>Significant values are in <bold>bold</bold>.</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec5">
        <title>3-D protein structure</title>
        <p id="Par9">To construct the 3-D model, initial models were built, refined, and evaluated, and finally, the model with the highest quality was chosen (Tables <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab6" ref-type="table">6</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Assessment of predicted 3-D Structure of BvrR protein using different servers according to CASP15.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left">RMSD</th><th align="left">TM-score</th><th align="left">Z-score</th><th align="left">QMEAN</th><th align="left">ERRAT</th><th align="left">MolProbity score</th><th align="left">Clash score</th><th align="left">Ramachandran favored</th></tr></thead><tbody><tr><td align="left" rowspan="8">DeepRefiner</td><td align="left">Alphafold colab</td><td align="left">1.30</td><td align="left">0.769</td><td align="left">16.943</td><td align="left">0.74</td><td align="left">92.8889</td><td align="left">2.82</td><td align="left">183.84</td><td align="left">97.55%</td></tr><tr><td align="left">CEthreader</td><td align="left">1.49</td><td align="left">0.731</td><td align="left">17.069</td><td align="left">0.75</td><td align="left">99.5614</td><td align="left">2.75</td><td align="left">194.88</td><td align="left">98.16%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.17</td><td align="left">0.771</td><td align="left">16.940</td><td align="left">0.79</td><td align="left">98.6784</td><td align="left">3.29</td><td align="left">184.73</td><td align="left">89.57%</td></tr><tr><td align="left">I-TASSER</td><td align="left">1.75</td><td align="left">0.9212</td><td align="left">16.876</td><td align="left">0.70</td><td align="left">97.8166</td><td align="left">2.81</td><td align="left">180.75</td><td align="left">97.55%</td></tr><tr><td align="left">LOMETS</td><td align="left">1.36</td><td align="left">0.769</td><td align="left">17.024</td><td align="left">0.73</td><td align="left">98.2456</td><td align="left">2.98</td><td align="left">190.81</td><td align="left">96.34%</td></tr><tr><td align="left">Phyre2</td><td align="left">3.46</td><td align="left">0.906</td><td align="left">31.161</td><td align="left">0.58</td><td align="left">57.4324</td><td align="left">2.93</td><td align="left">152.71</td><td align="left">95.87%</td></tr><tr><td align="left">Robetta</td><td align="left">1.05</td><td align="left">0.733</td><td align="left">17.115</td><td align="left">0.74</td><td align="left">96.5066</td><td align="left">2.71</td><td align="left">178.77</td><td align="left">100.00%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">1.13</td><td align="left">0.765</td><td align="left">16.894</td><td align="left">0.73</td><td align="left">95.5357</td><td align="left">2.91</td><td align="left">184.57</td><td align="left">96.89%</td></tr><tr><td align="left" rowspan="8">ModRefiner</td><td align="left">Alphafold colab</td><td align="left">1.20</td><td align="left">0.9953</td><td align="left">16.825</td><td align="left">0.74</td><td align="left">90.583</td><td align="left">2.10</td><td align="left">42.18</td><td align="left">99.15%</td></tr><tr><td align="left">CEthreader</td><td align="left">1.50</td><td align="left">0.9872</td><td align="left">16.826</td><td align="left">0.70</td><td align="left">92.5439</td><td align="left">2.57</td><td align="left">56.85</td><td align="left">96.60%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.11</td><td align="left">0.9939</td><td align="left">16.935</td><td align="left">0.70</td><td align="left">82.9694</td><td align="left">3.04</td><td align="left">64.19</td><td align="left">90.21%</td></tr><tr><td align="left">I-TASSER</td><td align="left">0.61</td><td align="left">0.9896</td><td align="left">17.045</td><td align="left">0.71</td><td align="left">85.1528</td><td align="left">2.54</td><td align="left">58.95</td><td align="left">95.74%</td></tr><tr><td align="left">LOMETS</td><td align="left">1.34</td><td align="left">0.90</td><td align="left">16.824</td><td align="left">0.71</td><td align="left">79.9107</td><td align="left">2.43</td><td align="left">60.70</td><td align="left">97.83%</td></tr><tr><td align="left">Phyre2</td><td align="left">3.14</td><td align="left">0.9852</td><td align="left">31.318</td><td align="left">0.61</td><td align="left">71.3178</td><td align="left">2.34</td><td align="left">36.49</td><td align="left">95.67%</td></tr><tr><td align="left">Robetta</td><td align="left">1.06</td><td align="left">0.9932</td><td align="left">17.015</td><td align="left">0.74</td><td align="left">89.9563</td><td align="left">2.07</td><td align="left">38.77</td><td align="left">98.72%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">1.17</td><td align="left">0.9885</td><td align="left">16.716</td><td align="left">0.73</td><td align="left">78.5714</td><td align="left">2.26</td><td align="left">60.96</td><td align="left">98.26%</td></tr><tr><td align="left" rowspan="8">GalaxyWeb</td><td align="left">Alphafold colab</td><td align="left">1.13</td><td align="left">0.781</td><td align="left">17.083</td><td align="left">0.75</td><td align="left">95.9641</td><td align="left">1.20</td><td align="left">4.19</td><td align="left">99.15%</td></tr><tr><td align="left">CEthreader</td><td align="left">1.46</td><td align="left">0.774</td><td align="left">17.019</td><td align="left">0.73</td><td align="left">93.8053</td><td align="left">1.57</td><td align="left">7.33</td><td align="left">97.02%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.08</td><td align="left">0.735</td><td align="left">17.008</td><td align="left">0.71</td><td align="left">87.3362</td><td align="left">2.37</td><td align="left">11.00</td><td align="left">91.06%</td></tr><tr><td align="left">I-TASSER</td><td align="left">0.38</td><td align="left">0.9957</td><td align="left">17.139</td><td align="left">0.73</td><td align="left">96.9298</td><td align="left">1.73</td><td align="left">8.64</td><td align="left">96.17%</td></tr><tr><td align="left">LOMETS</td><td align="left">1.01</td><td align="left">0.817</td><td align="left">16.781</td><td align="left">0.74</td><td align="left">95.9276</td><td align="left">1.55</td><td align="left">6.02</td><td align="left">96.60%</td></tr><tr><td align="left">phyre2</td><td align="left">3.32</td><td align="left">0.908</td><td align="left">31.221</td><td align="left">0.60</td><td align="left">82.4742</td><td align="left">1.39</td><td align="left">2.26</td><td align="left">94.23%</td></tr><tr><td align="left">Robetta</td><td align="left">1.00</td><td align="left">0.756</td><td align="left">16.646</td><td align="left">0.75</td><td align="left">99.095</td><td align="left">1.20</td><td align="left">4.19</td><td align="left">98.72%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">1.00</td><td align="left">0.769</td><td align="left">16.996</td><td align="left">0.76</td><td align="left">91.3636</td><td align="left">1.71</td><td align="left">9.09</td><td align="left">98.26%</td></tr><tr><td align="left" rowspan="8">trRosetta</td><td align="left">Alphafold colab</td><td align="left">3.03</td><td align="left">0.897</td><td align="left">27.896</td><td align="left">0.62</td><td align="left">71.5</td><td align="left">1.29</td><td align="left">3.49</td><td align="left">97.16%</td></tr><tr><td align="left">CEthreader</td><td align="left">1.26</td><td align="left">0.780</td><td align="left">17.067</td><td align="left">0.76</td><td align="left">97.7679</td><td align="left">0.84</td><td align="left">1.09</td><td align="left">97.87%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.23</td><td align="left">0.725</td><td align="left">16.897</td><td align="left">0.77</td><td align="left">93.2432</td><td align="left">0.69</td><td align="left">0.54</td><td align="left">99.15%</td></tr><tr><td align="left">I-TASSER</td><td align="left">1.05</td><td align="left">0.775</td><td align="left">17.118</td><td align="left">0.76</td><td align="left">98.2063</td><td align="left">0.98</td><td align="left">1.36</td><td align="left">97.45%</td></tr><tr><td align="left">LOMETS</td><td align="left">1.32</td><td align="left">0.818</td><td align="left">16.755</td><td align="left">0.77</td><td align="left">96</td><td align="left">0.81</td><td align="left">1.09</td><td align="left">98.72%</td></tr><tr><td align="left">phyre2</td><td align="left">3.40</td><td align="left">0.902</td><td align="left">31.154</td><td align="left">0.69</td><td align="left">79.6875</td><td align="left">1.16</td><td align="left">3.68</td><td align="left">98.08%</td></tr><tr><td align="left">Robetta</td><td align="left">1.27</td><td align="left">0.773</td><td align="left">16.866</td><td align="left">0.77</td><td align="left">96.4286</td><td align="left">0.87</td><td align="left">1.36</td><td align="left">98.30%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.22</td><td align="left">0.783</td><td align="left">16.940</td><td align="left">0.78</td><td align="left">99.0868</td><td align="left">0.60</td><td align="left">0.28</td><td align="left">98.70%</td></tr><tr><td align="left" rowspan="8">PREFMD</td><td align="left">Alphafold colab</td><td align="left">1.59</td><td align="left">0.813</td><td align="left">16.945</td><td align="left">0.72</td><td align="left">96</td><td align="left">0.86</td><td align="left">0.26</td><td align="left">96.17%</td></tr><tr><td align="left">CEthreader</td><td align="left">1.25</td><td align="left">0.776</td><td align="left">16.972</td><td align="left">0.72</td><td align="left">98.6842</td><td align="left">0.76</td><td align="left">0.00</td><td align="left">96.17%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.23</td><td align="left">0.791</td><td align="left">17.015</td><td align="left">0.70</td><td align="left">95.4955</td><td align="left">1.07</td><td align="left">0.26</td><td align="left">92.34%</td></tr><tr><td align="left">I-TASSER</td><td align="left">1.68</td><td align="left">0.9224</td><td align="left">16.863</td><td align="left">0.71</td><td align="left">90.2222</td><td align="left">0.67</td><td align="left">0.00</td><td align="left">97.02%</td></tr><tr><td align="left">LOMETS</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">phyre2</td><td align="left">3.60</td><td align="left">0.863</td><td align="left">31.035</td><td align="left">0.60</td><td align="left">68.7117</td><td align="left">1.47</td><td align="left">1.29</td><td align="left">87.02%</td></tr><tr><td align="left">Robetta</td><td align="left">1.30</td><td align="left">0.820</td><td align="left">16.931</td><td align="left">0.73</td><td align="left">93.7778</td><td align="left">0.53</td><td align="left">0.00</td><td align="left">97.87%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">1.39</td><td align="left">0.804</td><td align="left">16.843</td><td align="left">0.74</td><td align="left">93.578</td><td align="left">0.50</td><td align="left">0.00</td><td align="left">98.26%</td></tr><tr><td align="left" rowspan="8">ReFOLD</td><td align="left">Alphafold colab</td><td align="left">1.21</td><td align="left">0.797</td><td align="left">16.832</td><td align="left">0.75</td><td align="left">96.9432</td><td align="left">1.65</td><td align="left">9.44</td><td align="left">97.87%</td></tr><tr><td align="left">CEthreader</td><td align="left">1.55</td><td align="left">0.795</td><td align="left">16.860</td><td align="left">0.71</td><td align="left">97.3568</td><td align="left">2.86</td><td align="left">18.34</td><td align="left">94.47%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.10</td><td align="left">0.816</td><td align="left">16.860</td><td align="left">0.71</td><td align="left">96.5066</td><td align="left">2.70</td><td align="left">9.43</td><td align="left">91.49%</td></tr><tr><td align="left">I-TASSER</td><td align="left">0.72</td><td align="left">0.9847</td><td align="left">16.844</td><td align="left">0.72</td><td align="left">93.0131</td><td align="left">2.98</td><td align="left">20.96</td><td align="left">94.89%</td></tr><tr><td align="left">LOMETS</td><td align="left">0.97</td><td align="left">0.801</td><td align="left">17.099</td><td align="left">0.73</td><td align="left">96.9432</td><td align="left">2.11</td><td align="left">10.22</td><td align="left">97.02%</td></tr><tr><td align="left">Phyre2</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">Robetta</td><td align="left">1.10</td><td align="left">0.786</td><td align="left">16.888</td><td align="left">0.75</td><td align="left">90.625</td><td align="left">1.73</td><td align="left">3.40</td><td align="left">97.45%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">1.01</td><td align="left">0.781</td><td align="left">16.943</td><td align="left">0.74</td><td align="left">95.5357</td><td align="left">2.56</td><td align="left">13.37</td><td align="left">95.22%</td></tr></tbody></table></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Assessment of predicted 3-D structure of OMP25 protein using different servers according to CASP15.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left">RMSD</th><th align="left">TM-score</th><th align="left">Z-score</th><th align="left">QMEAN</th><th align="left">ERRAT</th><th align="left">MolProbity score</th><th align="left">Clash score</th><th align="left">Ramachandran favored</th></tr></thead><tbody><tr><td align="left" rowspan="8">DeepRefiner</td><td align="left">Alphafold colab</td><td align="left">1.94</td><td align="left">0.888</td><td align="left">27.890</td><td align="left">0.55</td><td align="left">53.2967</td><td align="left">3.18</td><td align="left">156.92</td><td align="left">90.98%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.50</td><td align="left">0.883</td><td align="left">27.893</td><td align="left">0.52</td><td align="left">81.2183</td><td align="left">3.09</td><td align="left">168.15</td><td align="left">93.98%</td></tr><tr><td align="left">C-QUARK</td><td align="left">2.75</td><td align="left">0.883</td><td align="left">27.895</td><td align="left">0.45</td><td align="left">76.0976</td><td align="left">3.37</td><td align="left">171.28</td><td align="left">84.21%</td></tr><tr><td align="left">I-TASSER</td><td align="left">0.84</td><td align="left">0.9765</td><td align="left">27.889</td><td align="left">0.48</td><td align="left">80.1105</td><td align="left">3.71</td><td align="left">193.99</td><td align="left">77.44%</td></tr><tr><td align="left">LOMETS</td><td align="left">2.17</td><td align="left">0.5969</td><td align="left">28.073</td><td align="left">0.48</td><td align="left">90.8163</td><td align="left">3.28</td><td align="left">153.97</td><td align="left">86.36%</td></tr><tr><td align="left">Phyre2</td><td align="left">3.81</td><td align="left">0.960</td><td align="left">20.836</td><td align="left">0.90</td><td align="left">71.5278</td><td align="left">2.64</td><td align="left">151.41</td><td align="left">98.10%</td></tr><tr><td align="left">Robetta</td><td align="left">2.03</td><td align="left">0.880</td><td align="left">27.887</td><td align="left">0.65</td><td align="left">58.4158</td><td align="left">2.69</td><td align="left">169.97</td><td align="left">98.50%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.34</td><td align="left">0.981</td><td align="left">22.555</td><td align="left">0.62</td><td align="left">77.0833</td><td align="left">3.04</td><td align="left">166.78</td><td align="left">94.79%</td></tr><tr><td align="left" rowspan="8">ModRefiner</td><td align="left">Alphafold colab</td><td align="left">1.95</td><td align="left">0.9569</td><td align="left">27.904</td><td align="left">0.52</td><td align="left">73.6264</td><td align="left">2.33</td><td align="left">32.64</td><td align="left">95.26%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.78</td><td align="left">0.9810</td><td align="left">27.895</td><td align="left">0.51</td><td align="left">92.5439</td><td align="left">2.54</td><td align="left">46.18</td><td align="left">95.26%</td></tr><tr><td align="left">C-QUARK</td><td align="left">2.91</td><td align="left">0.9832</td><td align="left">27.895</td><td align="left">0.40</td><td align="left">65.8537</td><td align="left">3.20</td><td align="left">59.73</td><td align="left">85.31%</td></tr><tr><td align="left">I-TASSER</td><td align="left">0.94</td><td align="left">0.9760</td><td align="left">27.891</td><td align="left">0.49</td><td align="left">57.6087</td><td align="left">3.21</td><td align="left">67.12</td><td align="left">87.20%</td></tr><tr><td align="left">LOMETS</td><td align="left">2.06</td><td align="left">0.9727</td><td align="left">27.895</td><td align="left">0.53</td><td align="left">76.4103</td><td align="left">2.40</td><td align="left">33.87</td><td align="left">94.31%</td></tr><tr><td align="left">Phyre2</td><td align="left">3.27</td><td align="left">0.9899</td><td align="left">20.828</td><td align="left">0.91</td><td align="left">72.2222</td><td align="left">2.32</td><td align="left">30.11</td><td align="left">94.77%</td></tr><tr><td align="left">Robetta</td><td align="left">2.02</td><td align="left">0.9917</td><td align="left">27.883</td><td align="left">0.62</td><td align="left">65.1515</td><td align="left">2.27</td><td align="left">32.34</td><td align="left">96.68%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.21</td><td align="left">0.9882</td><td align="left">22.558</td><td align="left">0.59</td><td align="left">64.7436</td><td align="left">2.19</td><td align="left">26.16</td><td align="left">95.83%</td></tr><tr><td align="left" rowspan="8">GalaxyWeb</td><td align="left">Alphafold colab</td><td align="left">1.94</td><td align="left">0.880</td><td align="left">27.892</td><td align="left">0.54</td><td align="left">86.5169</td><td align="left">1.16</td><td align="left">3.69</td><td align="left">99.05%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.66</td><td align="left">0.893</td><td align="left">27.884</td><td align="left">0.49</td><td align="left">68.1564</td><td align="left">1.82</td><td align="left">8.62</td><td align="left">94.79%</td></tr><tr><td align="left">C-QUARK</td><td align="left">2.90</td><td align="left">0.882</td><td align="left">27.888</td><td align="left">0.43</td><td align="left">63.4146</td><td align="left">2.24</td><td align="left">12.31</td><td align="left">86.26%</td></tr><tr><td align="left">I-TASSER</td><td align="left">0.75</td><td align="left">0.9892</td><td align="left">27.892</td><td align="left">0.48</td><td align="left">80.791</td><td align="left">2.35</td><td align="left">15.39</td><td align="left">84.83%</td></tr><tr><td align="left">LOMETS</td><td align="left">2.02</td><td align="left">0.882</td><td align="left">27.887</td><td align="left">0.49</td><td align="left">79.7814</td><td align="left">1.84</td><td align="left">3.69</td><td align="left">87.20%</td></tr><tr><td align="left">phyre2</td><td align="left">3.06</td><td align="left">0.917</td><td align="left">30.979</td><td align="left">0.61</td><td align="left">85.1485</td><td align="left">1.46</td><td align="left">2.58</td><td align="left">93.75%</td></tr><tr><td align="left">Robetta</td><td align="left">2.01</td><td align="left">0.889</td><td align="left">27.895</td><td align="left">0.63</td><td align="left">78.0612</td><td align="left">1.21</td><td align="left">4.31</td><td align="left">98.58%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.21</td><td align="left">0.982</td><td align="left">22.552</td><td align="left">0.61</td><td align="left">89.1156</td><td align="left">1.29</td><td align="left">1.92</td><td align="left">95.24%</td></tr><tr><td align="left" rowspan="8">trRosetta</td><td align="left">Alphafold colab</td><td align="left">3.29</td><td align="left">0.885</td><td align="left">27.699</td><td align="left">0.63</td><td align="left">78.3898</td><td align="left">1.08</td><td align="left">2.90</td><td align="left">98.07%</td></tr><tr><td align="left">CEthreader</td><td align="left">1.97</td><td align="left">0.880</td><td align="left">27.893</td><td align="left">0.60</td><td align="left">71.8593</td><td align="left">1.25</td><td align="left">2.22</td><td align="left">96.21%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.98</td><td align="left">0.891</td><td align="left">27.892</td><td align="left">0.61</td><td align="left">64.5833</td><td align="left">1.12</td><td align="left">2.54</td><td align="left">97.63%</td></tr><tr><td align="left">I-TASSER</td><td align="left">1.96</td><td align="left">0.879</td><td align="left">27.893</td><td align="left">0.62</td><td align="left">64.433</td><td align="left">1.04</td><td align="left">2.54</td><td align="left">98.10%</td></tr><tr><td align="left">LOMETS</td><td align="left">2.01</td><td align="left">0.892</td><td align="left">27.887</td><td align="left">0.62</td><td align="left">64.5503</td><td align="left">1.19</td><td align="left">2.54</td><td align="left">97.16%</td></tr><tr><td align="left">phyre2</td><td align="left">3.42</td><td align="left">0.930</td><td align="left">30.965</td><td align="left">0.68</td><td align="left">73.8462</td><td align="left">1.13</td><td align="left">2.01</td><td align="left">97.12%</td></tr><tr><td align="left">Robetta</td><td align="left">1.98</td><td align="left">0.892</td><td align="left">27.894</td><td align="left">0.62</td><td align="left">63.4921</td><td align="left">1.08</td><td align="left">2.22</td><td align="left">97.63%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">3.15</td><td align="left">0.985</td><td align="left">22.556</td><td align="left">0.72</td><td align="left">69.1824</td><td align="left">1.15</td><td align="left">2.79</td><td align="left">97.62%</td></tr><tr><td align="left" rowspan="8">PREFMD</td><td align="left">Alphafold colab</td><td align="left">2.08</td><td align="left">0.878</td><td align="left">27.893</td><td align="left">0.55</td><td align="left">67.3575</td><td align="left">1.06</td><td align="left">0.00</td><td align="left">89.57%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.61</td><td align="left">0.879</td><td align="left">27.892</td><td align="left">0.48</td><td align="left">78.4946</td><td align="left">0.95</td><td align="left">0.00</td><td align="left">92.89%</td></tr><tr><td align="left">C-QUARK</td><td align="left">2.89</td><td align="left">0.895</td><td align="left">27.892</td><td align="left">0.44</td><td align="left">68.5</td><td align="left">1.11</td><td align="left">0.00</td><td align="left">87.68%</td></tr><tr><td align="left">I-TASSER</td><td align="left">3.47</td><td align="left">0.914</td><td align="left">27.887</td><td align="left">0.53</td><td align="left">57.513</td><td align="left">1.12</td><td align="left">0.00</td><td align="left">87.20%</td></tr><tr><td align="left">LOMETS</td><td align="left">2.06</td><td align="left">0.880</td><td align="left">27.899</td><td align="left">0.51</td><td align="left">59.7938</td><td align="left">1.24</td><td align="left">0,62</td><td align="left">90.52%</td></tr><tr><td align="left">phyre2</td><td align="left">3.19</td><td align="left">0.954</td><td align="left">20.823</td><td align="left">0.86</td><td align="left">53.2374</td><td align="left">0.66</td><td align="left">0.00</td><td align="left">98.04%</td></tr><tr><td align="left">Robetta</td><td align="left">3.07</td><td align="left">0.885</td><td align="left">27.895</td><td align="left">0.63</td><td align="left">66.1765</td><td align="left">0.65</td><td align="left">0.00</td><td align="left">97.16%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">3.01</td><td align="left">0.976</td><td align="left">22.552</td><td align="left">0.63</td><td align="left">66.4474</td><td align="left">0.95</td><td align="left">0.00</td><td align="left">92.86%</td></tr><tr><td align="left" rowspan="8">ReFOLD</td><td align="left">Alphafold colab</td><td align="left">3.39</td><td align="left">0.894</td><td align="left">27.892</td><td align="left">0.56</td><td align="left">62.1053</td><td align="left">2.36</td><td align="left">14.17</td><td align="left">91.47%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.62</td><td align="left">0.887</td><td align="left">27.892</td><td align="left">0.49</td><td align="left">65.3266</td><td align="left">2.54</td><td align="left">11.70</td><td align="left">95.73%</td></tr><tr><td align="left">C-QUARK</td><td align="left">3.65</td><td align="left">0.888</td><td align="left">27.892</td><td align="left">0.44</td><td align="left">88.2927</td><td align="left">3.34</td><td align="left">30.51</td><td align="left">83.41%</td></tr><tr><td align="left">I-TASSER</td><td align="left">2.97</td><td align="left">0.880</td><td align="left">27.892</td><td align="left">0.53</td><td align="left">74.1294</td><td align="left">3.16</td><td align="left">22.48</td><td align="left">85.31%</td></tr><tr><td align="left">LOMETS</td><td align="left">2.06</td><td align="left">0.6024</td><td align="left">27.894</td><td align="left">0.52</td><td align="left">69.2308</td><td align="left">2.86</td><td align="left">11.70</td><td align="left">88.15%</td></tr><tr><td align="left">Phyre2</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">Robetta</td><td align="left">3.46</td><td align="left">0.889</td><td align="left">27.900</td><td align="left">0.65</td><td align="left">73.1707</td><td align="left">2.45</td><td align="left">18.48</td><td align="left">96.68%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">3.59</td><td align="left">0.985</td><td align="left">22.553</td><td align="left">0.61</td><td align="left">80.6452</td><td align="left">2.56</td><td align="left">13.08</td><td align="left">93.45%</td></tr></tbody></table></table-wrap><table-wrap id="Tab6"><label>Table 6</label><caption><p>Assessment of predicted 3-D Structure of OMP31 protein using different servers according to CASP15.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left">RMSD</th><th align="left">TM-score</th><th align="left">Z-score</th><th align="left">QMEAN</th><th align="left">ERRAT</th><th align="left">MolProbity score</th><th align="left">Clash score</th><th align="left">Ramachandran favored</th></tr></thead><tbody><tr><td align="left" rowspan="8">DeepRefiner</td><td align="left">Alphafold colab</td><td align="left">2.42</td><td align="left">0.898</td><td align="left">27.691</td><td align="left">0.55</td><td align="left">75.4717</td><td align="left">2.84</td><td align="left">139.11</td><td align="left">96.41%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.77</td><td align="left">0.894</td><td align="left">27.694</td><td align="left">0.55</td><td align="left">66.9323</td><td align="left">2.94</td><td align="left">174.00</td><td align="left">96.41%</td></tr><tr><td align="left">C-QUARK</td><td align="left">3.03</td><td align="left">0.895</td><td align="left">27.688</td><td align="left">0.36</td><td align="left">53.7849</td><td align="left">3.40</td><td align="left">171.33</td><td align="left">82.04%</td></tr><tr><td align="left">I-TASSER</td><td align="left">2.68</td><td align="left">0.876</td><td align="left">27.699</td><td align="left">0.34</td><td align="left">77.6699</td><td align="left">3.46</td><td align="left">176.89</td><td align="left">78.44%</td></tr><tr><td align="left">LOMETS</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">Phyre2</td><td align="left">2.49</td><td align="left">0.892</td><td align="left">27.894</td><td align="left">0.65</td><td align="left">57.7689</td><td align="left">2.94</td><td align="left">152.89</td><td align="left">95.81%</td></tr><tr><td align="left">Robetta</td><td align="left">2.76</td><td align="left">0.982</td><td align="left">21.731</td><td align="left">0.52</td><td align="left">80.814</td><td align="left">2.91</td><td align="left">134.49</td><td align="left">95.45%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.45</td><td align="left">0.9488</td><td align="left">27.686</td><td align="left">0.50</td><td align="left">78.744</td><td align="left">1.88</td><td align="left">24.62</td><td align="left">98.07%</td></tr><tr><td align="left" rowspan="8">ModRefiner</td><td align="left">Alphafold colab</td><td align="left">2.51</td><td align="left">0.9834</td><td align="left">27.699</td><td align="left">0.51</td><td align="left">56.5957</td><td align="left">2.91</td><td align="left">70.74</td><td align="left">92.66%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.95</td><td align="left">0.9850</td><td align="left">27.694</td><td align="left">0.41</td><td align="left">49.2063</td><td align="left">3.01</td><td align="left">62.97</td><td align="left">79.54%</td></tr><tr><td align="left">C-QUARK</td><td align="left">1.11</td><td align="left">0.9065</td><td align="left">27.693</td><td align="left">0.37</td><td align="left">59.1398</td><td align="left">3.18</td><td align="left">64.01</td><td align="left">84.17%</td></tr><tr><td align="left">I-TASSER</td><td align="left">3.87</td><td align="left">0.9778</td><td align="left">17.601</td><td align="left">0.86</td><td align="left">88.6792</td><td align="left">2.36</td><td align="left">39.33</td><td align="left">95.89%</td></tr><tr><td align="left">LOMETS</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">Phyre2</td><td align="left">2.95</td><td align="left">0.9898</td><td align="left">21.740</td><td align="left">0.50</td><td align="left">71.4286</td><td align="left">2.38</td><td align="left">38.13</td><td align="left">95.37%</td></tr><tr><td align="left">Robetta</td><td align="left">2.42</td><td align="left">0.906</td><td align="left">27.692</td><td align="left">0.51</td><td align="left">82.3834</td><td align="left">1.24</td><td align="left">4.66</td><td align="left">99.61%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.55</td><td align="left">0.875</td><td align="left">27.691</td><td align="left">0.50</td><td align="left">58.296</td><td align="left">2.29</td><td align="left">12.69</td><td align="left">93.05%</td></tr><tr><td align="left" rowspan="8">GalaxyWeb</td><td align="left">Alphafold colab</td><td align="left">2.92</td><td align="left">0.890</td><td align="left">27.700</td><td align="left">0.40</td><td align="left">52.6316</td><td align="left">2.50</td><td align="left">13.21</td><td align="left">79.92%</td></tr><tr><td align="left">CEthreader</td><td align="left">0.66</td><td align="left">0.9881</td><td align="left">27.694</td><td align="left">0.37</td><td align="left">47.9532</td><td align="left">2.99</td><td align="left">41.19</td><td align="left">77.99%</td></tr><tr><td align="left">C-QUARK</td><td align="left">3.21</td><td align="left">0.916</td><td align="left">31.016</td><td align="left">0.61</td><td align="left">87.6289</td><td align="left">1.26</td><td align="left">1.94</td><td align="left">95.67%</td></tr><tr><td align="left">I-TASSER</td><td align="left">2.39</td><td align="left">0.884</td><td align="left">27.689</td><td align="left">0.62</td><td align="left">74.4589</td><td align="left">1.33</td><td align="left">4.92</td><td align="left">97.68%</td></tr><tr><td align="left">LOMETS</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">phyre2</td><td align="left">2.37</td><td align="left">0.894</td><td align="left">27.696</td><td align="left">0.63</td><td align="left">83.0579</td><td align="left">1.28</td><td align="left">2.64</td><td align="left">96.53%</td></tr><tr><td align="left">Robetta</td><td align="left">2.38</td><td align="left">0.900</td><td align="left">27.691</td><td align="left">0.64</td><td align="left">81.07</td><td align="left">1.25</td><td align="left">2.11</td><td align="left">96.14%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.41</td><td align="left">0.888</td><td align="left">27.689</td><td align="left">0.64</td><td align="left">80.1619</td><td align="left">1.23</td><td align="left">2.64</td><td align="left">96.91%</td></tr><tr><td align="left" rowspan="8">trRosetta</td><td align="left">Alphafold colab</td><td align="left">2.38</td><td align="left">0.893</td><td align="left">27.699</td><td align="left">0.65</td><td align="left">81.8182</td><td align="left">1.05</td><td align="left">2.11</td><td align="left">97.68%</td></tr><tr><td align="left">CEthreader</td><td align="left">3.26</td><td align="left">0.880</td><td align="left">17.458</td><td align="left">0.86</td><td align="left">94.8357</td><td align="left">1.00</td><td align="left">1.78</td><td align="left">97.72%</td></tr><tr><td align="left">C-QUARK</td><td align="left">2.35</td><td align="left">0.894</td><td align="left">27.692</td><td align="left">0.64</td><td align="left">76.4463</td><td align="left">1.02</td><td align="left">2.38</td><td align="left">98.07%</td></tr><tr><td align="left">I-TASSER</td><td align="left">2.77</td><td align="left">0.956</td><td align="left">21.756</td><td align="left">0.68</td><td align="left">71.9388</td><td align="left">1.04</td><td align="left">2.53</td><td align="left">99.54%</td></tr><tr><td align="left">LOMETS</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">phyre2</td><td align="left">2.81</td><td align="left">0.895</td><td align="left">27.695</td><td align="left">0.52</td><td align="left">50.2146</td><td align="left">1.11</td><td align="left">0.26</td><td align="left">91.12%</td></tr><tr><td align="left">Robetta</td><td align="left">3.15</td><td align="left">0.888</td><td align="left">27.692</td><td align="left">0.41</td><td align="left">70</td><td align="left">1.15</td><td align="left">0.00</td><td align="left">85.33%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">3.04</td><td align="left">0.892</td><td align="left">27.696</td><td align="left">0.36</td><td align="left">72</td><td align="left">1.50</td><td align="left">0.00</td><td align="left">82.24%</td></tr><tr><td align="left" rowspan="8">PREFMD</td><td align="left">Alphafold colab</td><td align="left">3.91</td><td align="left">0.857</td><td align="left">17.517</td><td align="left">0.86</td><td align="left">97.6526</td><td align="left">0.75</td><td align="left">0.00</td><td align="left">97.65%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.42</td><td align="left">0.903</td><td align="left">27.692</td><td align="left">0.60</td><td align="left">73.5931</td><td align="left">0.82</td><td align="left">0.00</td><td align="left">95.37%</td></tr><tr><td align="left">C-QUARK</td><td align="left">2.66</td><td align="left">0.949</td><td align="left">21.734</td><td align="left">0.50</td><td align="left">72.2826</td><td align="left">0.93</td><td align="left">0.00</td><td align="left">93.52%</td></tr><tr><td align="left">I-TASSER</td><td align="left">2.52</td><td align="left">0.910</td><td align="left">27.700</td><td align="left">0.53</td><td align="left">61.9469</td><td align="left">2.40</td><td align="left">9.84</td><td align="left">93.44%</td></tr><tr><td align="left">LOMETS</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">phyre2</td><td align="left">2.90</td><td align="left">0.900</td><td align="left">27.700</td><td align="left">0.40</td><td align="left">67.9842</td><td align="left">3.15</td><td align="left">19.69</td><td align="left">81.08%</td></tr><tr><td align="left">Robetta</td><td align="left">1.59</td><td align="left">0.9403</td><td align="left">27.684</td><td align="left">0.36</td><td align="left">75.9563</td><td align="left">3.24</td><td align="left">16.84</td><td align="left">73.75%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.68</td><td align="left">0.876</td><td align="left">27.699</td><td align="left">0.34</td><td align="left">77.6699</td><td align="left">3.46</td><td align="left">176.89</td><td align="left">78.44%</td></tr><tr><td align="left" rowspan="8">ReFOLD</td><td align="left">Alphafold colab</td><td align="left">2.53</td><td align="left">0.871</td><td align="left">27.688</td><td align="left">0.64</td><td align="left">68.3794</td><td align="left">2.59</td><td align="left">16.08</td><td align="left">95.75%</td></tr><tr><td align="left">CEthreader</td><td align="left">2.73</td><td align="left">0.934</td><td align="left">21.755</td><td align="left">0.51</td><td align="left">73.2759</td><td align="left">1.82</td><td align="left">1.24</td><td align="left">92.59%</td></tr><tr><td align="left">C-QUARK</td><td align="left">2.42</td><td align="left">0.898</td><td align="left">27.691</td><td align="left">0.55</td><td align="left">75.4717</td><td align="left">2.84</td><td align="left">139.11</td><td align="left">96.41%</td></tr><tr><td align="left">I-TASSER</td><td align="left">2.77</td><td align="left">0.894</td><td align="left">27.694</td><td align="left">0.55</td><td align="left">66.9323</td><td align="left">2.94</td><td align="left">174.00</td><td align="left">96.41%</td></tr><tr><td align="left">LOMETS</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">Phyre2</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">Robetta</td><td align="left">3.84</td><td align="left">0.842</td><td align="left">17.514</td><td align="left">0.88</td><td align="left">95.7143</td><td align="left">2.65</td><td align="left">154.17</td><td align="left">98.60%</td></tr><tr><td align="left">SWISS-MODEL</td><td align="left">2.49</td><td align="left">0.892</td><td align="left">27.894</td><td align="left">0.65</td><td align="left">57.7689</td><td align="left">2.94</td><td align="left">152.89</td><td align="left">95.81%</td></tr></tbody></table></table-wrap></p>
        <sec id="Sec6">
          <title>Construction of initial model using target-template alignment</title>
          <p id="Par10">While Swiss-Model, AlphaFold, CEthreader, and LOMETS were intended for the aligned regions, I-TASSER, C-QUARK, Robetta, and Phyre2 were designed for low-similarity regions to construct the structural models for the unaligned regions. I-TASSER developed the top five models based on the confidence score (C-score) of each model, which was equal to -0.18 for BvrR protein, &#x2212;&#xA0;2.14 for OMP25 protein, and &#x2212;&#xA0;3.19 for OMP31 protein which was typically in the range of (&#x2212;&#xA0;5, 2). The TM-score (0.36&#x2009;&#xB1;&#x2009;0.12) and RMSD (13.5&#x2009;&#xB1;&#x2009;4.0&#xA0;&#xC5;) were estimated based on the C-score and protein length. C-QUARK server constructed the best ten correct protein 3-D models from amino acid sequences based on estimated TM-score (0.634&#x2009;&#xB1;&#x2009;0.006, 0.563&#x2009;&#xB1;&#x2009;0.027, and 0.494&#x2009;&#xB1;&#x2009;0.076) for BvrR, OMP25, and OMP31 proteins, respectively. Each query sequence was given five models by GalaxyWEB, which also chose templates for modeling by rescoring HHsearch results. While Phyre2 built 3-D models using sophisticated distant homology detection techniques, SWISS-MODEL provided ten models for BvrR protein, eight models for OMP25 protein, and six models for OMP31 protein based on QMEAN score (0.74, 0.59, and 0.49), respectively. LOMETS created the top 10 models based on the C-score (medium) and Z-score (7.10, 1.98) of the template for BvrR and OMP25 proteins, respectively. Also, based on the Z-score (2.16) (normalized Z-score&#x2009;&#x2265;&#x2009;1&#xA0;means a good alignment) for the three proteins, CEthreader created the top 20 templates.</p>
        </sec>
        <sec id="Sec7">
          <title>Reduced-level structure assembly and refinement simulations</title>
          <p id="Par11">The second stage of structure prediction involved the refining of the three proteins (BvrR, OMP25, and OMP31). In terms of hydrogen bonds, backbone structure, and side-chain positioning, the results from the DeepRefiner, Modrefiner, Galaxy WEB, trRosetta, PREFMD, and ReFOLD servers succeed in bringing the basic starting models closer to their native state. Our results from the I-TASSER server revealed improved topology of the predicted 3-D structure by lowering the RMSD score (0.38, 0.75, and 0.661), the clash score (8.64, 15.39, and 41.19) and increasing the TM-score (0.9997, 0.9892 and 0.9881), for BvrR, OMP25 and, OMP31 proteins, respectively. In addition, the refinement process of the initial model from AlphaFold decreased the RMSD score (1.13, 1.94, and 2.42), the clash score (4.19, 3.69, and 4.66) and increased the TM-score (0.781, 0.880 and 0.906), for BvrR, OMP25 and OMP31 proteins, respectively. It also provided a significant enhancement in the physical quality of local and global structures compared to the initial model produced by a chosen server, such as the I-TASSER and AlphaFold servers for the target proteins.</p>
        </sec>
        <sec id="Sec8">
          <title>Model evaluation and selection</title>
          <p id="Par12">The best 3-D models of the correct fold were chosen through model evaluation out of all the feasible conformations that were the most similar to the original structure<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The results of the various evaluation servers' scores were summarized in (Tables <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab6" ref-type="table">6</xref>). The TM value of the selected modified model was higher than 0.5, suggesting high accuracy. If a value is between 0.5 and 0.17 or less than 0.17, this yields a model with a topology that is appropriately accurate whatever the size of the protein<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. The QMEANDisCo score provides an estimate of the absolute quality of a model by relating it to reference structures solved by X-ray crystallography. It uses the single terms of QMEAN as a basis. All terms are combined using neural networks trained to predict per-residue lDDT scores in range [0, 1]<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. According to the server section from CASP11 to CASP15 tests, I-TASSER and AlphaFold servers were positioned as the best approach. The I-TASSER server provides the best model according to RMSD (0.38, 0.75, and 0.66), TM-score (0.9957, 0.9892, and 0.9881), Z-score (17.139, 27.892, and 27.689), QMEAN (0.73, 0.48, and 0.62), ERRAT score (96.9298, 80.791, and 74.4589), and Ramachandran plot for the three target proteins, respectively (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The AlphaFold server provides the best model with RMSD (1.13, 1.94, and 2.42), TM-score (0.781, 0.880, and 0.906), Z-score (17.083, 27.892, and 27.700), QMEAN (0.75, 0.54 and 0.40), ERRAT score (95.9641, 86.5169 and 52.6316), and Ramachandran plot for the three target proteins, respectively (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). These scores were chosen from the GalaxyWeb server as it has shown the best-refined results (Tables <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab6" ref-type="table">6</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>The Ramachandran plot of (<bold>a</bold>) BvrR protein of I-TASSER, (<bold>b</bold>) OMP25 protein of I-TASSER. (<bold>c</bold>) OMP31 of I-TASSER, (<bold>d</bold>) BvrR protein of AlphaFold, (<bold>e</bold>) OMP25 protein of AlphaFold, and (f) OMP31 protein of AlphaFold.</p></caption><graphic xlink:href="41598_2024_61991_Fig1_HTML" id="MO1"/></fig></p>
        </sec>
      </sec>
      <sec id="Sec9">
        <title>Motifs prediction</title>
        <p id="Par13">Using motifFinder, ScanProsite, and Motif Scan servers, the motifs in the BvrR, OMP25, and OMP31 proteins were analyzed and listed in (Tables <xref rid="Tab7" ref-type="table">7</xref> and <xref rid="Tab8" ref-type="table">8</xref>). MotifFinder server showed that the BvrR protein has two motifs: Response_reg (PF00072, 10..119) and Trans_reg_C (PF00486, 158..234), OMP25 and OMP31 proteins have the same four motifs but in a different position: OMP_b-brl (PF13505, 12..213, 16..261), ompA_membrane (PF01389, 49..213, 77..261), opacity (PF02462, 117..213, 179..244), and Porin_2 (PF02530, 143..209, 189..245 ), respectively. Otherwise, there is one unique motif for each protein: surface_Ag_2 (PF01617, 128..190) for OMP25 protein and autotransporter (PF03797, 52..222) for OMP31 protein (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Furthermore, the ScanProsite server displayed two motifs for only BvrR protein: RESPONSE_REGULATORY (PS50110, 9..122) and OmpR/PhoB-type (PS51755, 137..236).<table-wrap id="Tab7"><label>Table 7</label><caption><p>Motif prediction of three target proteins using servers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Category</th><th align="left">Server</th><th align="left">Protein</th><th align="left">ID</th><th align="left">Signature</th><th align="left">Matching Position</th><th align="left">E-value</th></tr></thead><tbody><tr><td align="left" rowspan="14">DNA associated protein motif posttranslational modifications</td><td align="left" rowspan="12">MotifFinder</td><td align="left" rowspan="2">BvrR</td><td align="left">Response_reg</td><td align="left">PF00072, Response regulator receiver domain</td><td align="left">10..119</td><td align="left">1.2e&#x2013;28</td></tr><tr><td align="left">Trans_reg_C</td><td align="left">PF00486, Transcriptional regulatory protein, C terminal</td><td align="left">158..234</td><td align="left">3.7e&#x2013;22</td></tr><tr><td align="left" rowspan="5">OMP25</td><td align="left">OMP_b-brl</td><td align="left">PF13505, Outer membrane protein beta-barrel domain</td><td align="left">12..213</td><td align="left">7.3e&#x2013;24</td></tr><tr><td align="left">OmpA_membrane</td><td align="left">PF01389, OmpA-like transmembrane domain</td><td align="left">49..213</td><td align="left">3.4e&#x2013;07</td></tr><tr><td align="left">Opacity</td><td align="left">PF02462, Opacity family porin protein</td><td align="left">117..213</td><td align="left">0.00034</td></tr><tr><td align="left">Porin_2</td><td align="left">PF02530, Porin subfamily</td><td align="left">143..209</td><td align="left">0.00072</td></tr><tr><td align="left">Surface_Ag_2</td><td align="left">PF01617, Surface antigen</td><td align="left">128..190</td><td align="left">0.19</td></tr><tr><td align="left" rowspan="5">OMP31</td><td align="left">OMP_b-brl</td><td align="left">PF13505, Outer membrane protein beta-barrel domain</td><td align="left">16..261</td><td align="left">2.8e&#x2013;23</td></tr><tr><td align="left">OmpA_membrane</td><td align="left">PF01389, OmpA-like transmembrane domain</td><td align="left">77..261</td><td align="left">1.8e&#x2013;08</td></tr><tr><td align="left">Opacity</td><td align="left">PF02462, Opacity family porin protein</td><td align="left">179..244</td><td align="left">1.3e&#x2013;06</td></tr><tr><td align="left">Porin_2</td><td align="left">PF02530, Porin subfamily</td><td align="left">189..245</td><td align="left">3.7e&#x2013;05</td></tr><tr><td align="left">Autotransporter</td><td align="left">PF03797, Autotransporter beta-domain</td><td align="left">52..222</td><td align="left">0.00021</td></tr><tr><td align="left" rowspan="2">ScanProsite</td><td align="left" rowspan="2">BvrR</td><td align="left">PS50110</td><td align="left">RESPONSE_REGULATORY Response regulatory domain profile</td><td align="left">9..122</td><td align="left">&#x2013;</td></tr><tr><td align="left">PS51755</td><td align="left">OMPR_PHOB OmpR/PhoB-type DNA-binding domain profile</td><td align="left">137..236</td><td align="left">&#x2013;</td></tr></tbody></table></table-wrap><table-wrap id="Tab8"><label>Table 8</label><caption><p>Prediction of post-translation modification site of three target proteins using motif scan server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Signature</th><th align="left" colspan="3">Position of proteins</th></tr><tr><th align="left">BvrR</th><th align="left">OMP25</th><th align="left">OMP31</th></tr></thead><tbody><tr><td align="left" rowspan="4">CK2_PHOSPHO_SITE&#x2014;Casein kinase II phosphorylation site</td><td align="left">36&#x2013;39</td><td align="left" rowspan="4">&#x2013;</td><td align="left">66&#x2013;69</td></tr><tr><td align="left">42&#x2013;45</td><td align="left">136&#x2013;139</td></tr><tr><td align="left">85&#x2013;88</td><td align="left">160&#x2013;163</td></tr><tr><td align="left">164&#x2013;167</td><td align="left">183&#x2013;186</td></tr><tr><td align="left" rowspan="8">MYRISTYL&#x2014;N-myristoylation site</td><td align="left" rowspan="2">96&#x2013;101</td><td align="left">47&#x2013;52</td><td align="left">47&#x2013;52</td></tr><tr><td align="left">77&#x2013;82</td><td align="left">89&#x2013;94</td></tr><tr><td align="left" rowspan="6">179&#x2013;184</td><td align="left">117&#x2013;122</td><td align="left">102&#x2013;107</td></tr><tr><td align="left" rowspan="5">137&#x2013;142</td><td align="left">130&#x2013;135</td></tr><tr><td align="left">151&#x2013;156</td></tr><tr><td align="left">172&#x2013;177</td></tr><tr><td align="left">194&#x2013;199</td></tr><tr><td align="left">207&#x2013;212</td></tr><tr><td align="left" rowspan="6">PKC_PHOSPHO_SITE&#x2014;Protein kinase C phosphorylation site</td><td align="left">85&#x2013;87</td><td align="left">3&#x2013;5</td><td align="left">3&#x2013;5</td></tr><tr><td align="left">110&#x2013;112</td><td align="left">68&#x2013;70</td><td align="left">115&#x2013;117</td></tr><tr><td align="left" rowspan="4">155&#x2013;157</td><td align="left">118&#x2013;120</td><td align="left">152&#x2013;154</td></tr><tr><td align="left" rowspan="3">195&#x2013;197</td><td align="left">162&#x2013;164</td></tr><tr><td align="left">217&#x2013;219</td></tr><tr><td align="left">252&#x2013;254</td></tr><tr><td align="left">BIG1&#x2014;Big-1 (bacterial Ig-like domain 1) domain profile</td><td align="left">1&#x2013;13</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left" rowspan="2">RESPONSE_REGULATORY&#x2014;Response regulatory domain profile</td><td align="left">9&#x2013;122</td><td align="left" rowspan="2">&#x2013;</td><td align="left" rowspan="2">&#x2013;</td></tr><tr><td align="left">10&#x2013;119</td></tr><tr><td align="left">SRR&#x2014;Seven residue repeat</td><td align="left">212&#x2013;225</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">Trans_reg_C&#x2014;Transcriptional regulatory protein, C terminal</td><td align="left">158&#x2013;234</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left">DUF1344&#x2014;Protein of unknown function (DUF1344)</td><td align="left">&#x2013;</td><td align="left">2&#x2013;26</td><td align="left"/></tr><tr><td align="left" rowspan="2">OmpA_membrane&#x2014;OmpA-like transmembrane domain</td><td align="left" rowspan="2">&#x2013;</td><td align="left">161&#x2013;182</td><td align="left">162&#x2013;225</td></tr><tr><td align="left">8&#x2013;213</td><td align="left">26&#x2013;261</td></tr><tr><td align="left" rowspan="2">Porin_2&#x2014;Porin subfamily</td><td align="left" rowspan="2">&#x2013;</td><td align="left">158&#x2013;209</td><td align="left">8&#x2013;51</td></tr><tr><td align="left">1&#x2013;209</td><td align="left">8&#x2013;243</td></tr><tr><td align="left" rowspan="2">Opacity&#x2014;Opacity family porin protein</td><td align="left" rowspan="2">&#x2013;</td><td align="left" rowspan="2">97&#x2013;213</td><td align="left">93&#x2013;261</td></tr><tr><td align="left">189&#x2013;261</td></tr><tr><td align="left">AMIDATION&#x2014;Amidation site</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">227&#x2013;230</td></tr><tr><td align="left" rowspan="2">ASN_GLYCOSYLATION&#x2014;N-glycosylation site</td><td align="left" rowspan="2">&#x2013;</td><td align="left" rowspan="2">&#x2013;</td><td align="left">134&#x2013;137</td></tr><tr><td align="left">215&#x2013;218</td></tr><tr><td align="left">CBM_2&#x2014;Cellulose binding domain</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">206&#x2013;216</td></tr></tbody></table></table-wrap><fig id="Fig2"><label>Figure 2</label><caption><p>The best predicted three-dimensional structure of BvrR (1), OMP25 (2) and OMP31 (3) proteins. (<bold>1a</bold>) Backbone view of the best-predicted model. (<bold>1b</bold>) The cartoon view showed known and predicted motifs: The Response_reg (PF00072, 10..119) in yellow, Trans_reg_C (PF00486, 158..234) in red, and the rest of the predicted model in gray. (<bold>1c</bold>) Solvent-accessible surface view showed the exposed regions. (<bold>2a</bold>) Backbone view of best-predicted model. (<bold>2b</bold>) The cartoon view showed known and predicted motifs: OMP_b-brl (PF13505, 12..213) in green, OmpA_membrane (PF01389, 49..213) in red, Opacity (PF02462, 117..213) in yellow, Porin_2 (PF02530, 143..209) in purple, Surface_Ag_2 (PF01617, 128..190) in blue and the rest of predicted model in gray. (<bold>2c</bold>) Solvent-accessible surface view showed the exposed regions. (<bold>3a</bold>) Backbone view of best-predicted model. (<bold>3b</bold>) The cartoon view showed known and predicted motifs: OMP_b-brl (PF13505, 16..261) in green, OmpA_membrane (PF01389, 77..261) in red, Opacity (PF02462, 179..244) in yellow, Porin_2 (PF02530, 189..245) in purple, Autotransporter (PF03797, 52..222) in blue and the rest of predicted model in gray. (<bold>3c</bold>) Solvent-accessible surface view showed the exposed regions.</p></caption><graphic xlink:href="41598_2024_61991_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec10">
        <title>Identification, annotation, and analysis of domain architectures</title>
        <p id="Par14">Using the superfamily server, the BvrR protein has two hits matched at 7..130 that are categorized in CheY-like superfamily and family. The other hit, located in 133..235, was classified as the C-terminal effector domain of the bipartite response regulators superfamily and PhoB-like family. On the other hand, OMP25 and OMP31 proteins have the same match in the OMPA-like superfamily and outer membrane protein family within different locations at 43..213 and 43..261, respectively (Table <xref rid="Tab9" ref-type="table">9</xref>).<table-wrap id="Tab9"><label>Table 9</label><caption><p>Structural classification of three target proteins using superfamily server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Domain</th><th align="left">Region</th><th align="left">Superfamily</th><th align="left">Family</th><th align="left">E-value</th></tr></thead><tbody><tr><td align="left" rowspan="2">BvrR</td><td align="left">1</td><td align="left">7&#x2013;130</td><td align="left">CheY-like</td><td align="left">CheY-related</td><td char="." align="char">0.00014</td></tr><tr><td align="left">2</td><td align="left">133&#x2013;235</td><td align="left">The C-terminal effector domain of the bipartite response regulators</td><td align="left">PhoB-like</td><td char="." align="char">0.0014</td></tr><tr><td align="left">OMP25</td><td align="left">1</td><td align="left">43&#x2013;213</td><td align="left">OMPA-like</td><td align="left">Outer membrane protein</td><td char="." align="char">0.0045</td></tr><tr><td align="left">OMP31</td><td align="left">1</td><td align="left">43&#x2013;261</td><td align="left">OMPA-like</td><td align="left">Outer membrane protein</td><td char="." align="char">0.005</td></tr></tbody></table></table-wrap></p>
        <p id="Par15">Using CATH, the BvrR protein was classified as alpha&#x2013;beta (3), 3-Layer (aba) Sandwich (3.40) architecture, Rossmann fold (3.40.50) topology, and response regulator (3.40.50.2300) homologous superfamily. On the other hand, there were no results matched for the OMP25 protein. The OMP31 protein was classified as Mainly Beta (2), Beta Barrel (2.40) architecture, Porin (2.40.160) topology, and (2.40.160.20) homologous superfamily (Table <xref rid="Tab10" ref-type="table">10</xref>).<table-wrap id="Tab10"><label>Table 10</label><caption><p>Structural classification of three target proteins using the CATH Server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Level</th><th align="left">Description</th><th align="left">Match</th><th align="left">E-value</th></tr></thead><tbody><tr><td align="left" rowspan="11">BvrR</td><td align="left">Class</td><td align="left">Alpha Beta (3)</td><td align="left">Two-component system response regulator (3.40.50.2300/FF/328)</td><td align="left">1.6e&#x2013;23</td></tr><tr><td align="left">Architecture</td><td align="left">3-Layer(aba) Sandwich (3.40)</td><td align="left">Two-component system sensor histidine kinase/response regulator (3.40.50.2300/FF/138)</td><td align="left">1.3e&#x2013;25</td></tr><tr><td align="left">Topology</td><td align="left">Rossmann fold (3.40.50)</td><td align="left">DNA-binding transcriptional regulator NtrC (3.40.50.2300/FF/18)</td><td align="left">6.2e&#x2013;24</td></tr><tr><td align="left" rowspan="8">Homologous superfamily</td><td align="left" rowspan="8">Response regulator (3.40.50.2300)</td><td align="left">Response regulator GraR (3.40.50.2300/FF/232)</td><td align="left">1.4e&#x2013;21</td></tr><tr><td align="left">Sensory transduction histidine kinase (3.40.50.2300/FF/444)</td><td align="left">3.7e&#x2013;21</td></tr><tr><td align="left">Two-component system KDP operon response regulator KdpE (3.40.50.2300/FF/194)</td><td align="left">6.7e&#x2013;21</td></tr><tr><td align="left">Unplaced genomic scaffold supercont1.240, whole genome shotgun sequence (3.40.50.2300/FF/230)</td><td align="left">1.0e&#x2013;18</td></tr><tr><td align="left">Sporulation initiation phosphotransferase F (3.40.50.2300/FF/700)</td><td align="left">3.9e&#x2013;17</td></tr><tr><td align="left">Diguanylate cyclase response regulator (3.40.50.2300/FF/346)</td><td align="left">6.3e&#x2013;17</td></tr><tr><td align="left">Stress response regulator/HFS transcription factor (3.40.50.2300/FF/212)</td><td align="left">9.4e&#x2013;16</td></tr><tr><td align="left">Fis family transcriptional regulator (3.40.50.2300/FF/74)</td><td align="left">1.2e&#x2013;15</td></tr><tr><td align="left">OMP25</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td><td align="left">&#x2013;</td></tr><tr><td align="left" rowspan="4">OMP31</td><td align="left">Class</td><td align="left">Mainly Beta (2)</td><td align="left" rowspan="4">Putative outer membrane protein (2.40.160.20/FF/32)</td><td align="left" rowspan="4">5.3e&#x2013;15</td></tr><tr><td align="left">Architecture</td><td align="left">Beta Barrel (2.40)</td></tr><tr><td align="left">Topology</td><td align="left">Porin (2.40.160)</td></tr><tr><td align="left">Homologous superfamily</td><td align="left">2.40.160.20</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec11">
        <title>Epitopes prediction</title>
        <p id="Par16">Linear B cell epitopes of the three target proteins of <italic>Brucella</italic> were done using SVMTriP, and Bepipred Linear Epitope Prediction 2.0 servers, while discontinuous B cell epitopes were identified using ElliPro (Tables <xref rid="Tab11" ref-type="table">11</xref>, <xref rid="Tab12" ref-type="table">12</xref>, <xref rid="Tab13" ref-type="table">13</xref> and <xref rid="Tab14" ref-type="table">14</xref>). Additionally, Prediction of MHC-I or CD8&#x2009;+&#x2009;T cell (HLA-A) and MHC-II or CD4&#x2009;+&#x2009;T cell binding epitopes (HLA-DRB) for cytotoxic T lymphocyte (CTL) and T helper lymphocyte (THL), respectively, were performed using RANKPEP, SYFPEITHI and MHCII-NP servers (Tables <xref rid="Tab15" ref-type="table">15</xref> and <xref rid="Tab16" ref-type="table">16</xref>). The antigenicity of epitopes was assayed using VaxiJen v2.0 and the allergenic and toxic probability of each epitope were evaluated using AllergenFP and ToxinPred servers. The epitopes with antigenicity higher than 0.4 and non-allergen were selected.<table-wrap id="Tab11"><label>Table 11</label><caption><p>B cell prediction of three target proteins using SVMTriP server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Location</th><th align="left">Epitope</th><th align="left">Score</th><th align="left">Antigenicity</th><th align="left">Allergenicity</th><th align="left">Toxicity</th></tr></thead><tbody><tr><td align="left">BvrR</td><td align="left">44&#x2013;63</td><td align="left">LDGLMARPPNLAIFDIKMPR</td><td char="." align="char">0.430</td><td char="." align="char">1.2410</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="2">OMP25</td><td align="left">52&#x2013;71</td><td align="left">LYLGYGWNKAKTSTVGSIKP</td><td char="." align="char">1.000</td><td char="." align="char">0.6012</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">87&#x2013;106</td><td align="left">DQIVYGVEGDAGYSWAKKSK</td><td char="." align="char">0.947</td><td char="." align="char">0.6073</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr></tbody></table></table-wrap><table-wrap id="Tab12"><label>Table 12</label><caption><p>B cell prediction of three target proteins using bepipred linear epitope prediction 2.0.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Location</th><th align="left">Peptide</th><th align="left">Average</th><th align="left">Minimum</th><th align="left">Maximum</th><th align="left">Antigenicity</th><th align="left">Allergenicity</th><th align="left">Toxicity</th></tr></thead><tbody><tr><td align="left">BvrR</td><td align="left">125&#x2013;139</td><td align="left">VARRHAKPAGQQAKS</td><td align="left">0.463</td><td align="left">0.288</td><td align="left">0.676</td><td char="." align="char">0.7755</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="4">OMP25</td><td align="left">26&#x2013;46</td><td align="left">AIQEQPPVPAPVEVAPQYSWA</td><td align="left" rowspan="4">0.510</td><td align="left" rowspan="4">0.243</td><td align="left" rowspan="4">0.656</td><td char="." align="char">0.7219</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">98&#x2013;115</td><td align="left">GYSWAKKSKDGLEVKQGF</td><td char="." align="char">0.9518</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">141&#x2013;157</td><td align="left">SQIKLNNGLDDESKFRV</td><td char="." align="char">0.8627</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">178&#x2013;203</td><td align="left">EYRYTQYGNKNYDLAGTTVRNKLDTQ</td><td char="." align="char">1.0258</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="5">OMP31</td><td align="left">29&#x2013;45</td><td align="left">DIIVAEPAPVAVDTFSW</td><td align="left" rowspan="5">0.530</td><td align="left" rowspan="5">0.252</td><td align="left" rowspan="5">0.725</td><td char="." align="char">0.9679</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">57&#x2013;85</td><td align="left">AGGKFKHPFSGIEQDGAQDFSGSLDVTAS</td><td char="." align="char">0.7610</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">111&#x2013;144</td><td align="left">FQGSTVKSKLVDNGDLSDIGVAGNLSGDESFVLE</td><td char="." align="char">0.6632</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">177&#x2013;199</td><td align="left">KVKTSLSAYDDGESFSAGNSKTK</td><td char="." align="char">0.9342</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">222&#x2013;251</td><td align="left">YLYTDLGKRSFNYIDEENVNINMENKVNFH</td><td char="." align="char">0.6510</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr></tbody></table></table-wrap><table-wrap id="Tab13"><label>Table 13</label><caption><p>ElliPro antibody epitope prediction of I-TASSER and AlphaFold models of target proteins.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Server</th><th align="left">Protein</th><th align="left">Location</th><th align="left">Peptide</th><th align="left">No. of residues</th><th align="left">Score</th><th align="left">Antigenicity</th><th align="left">Allergenicity</th><th align="left">Toxicity</th></tr></thead><tbody><tr><td align="left" rowspan="14">I-TASSER</td><td align="left" rowspan="4">BvrR</td><td align="left">85&#x2013;94</td><td align="left">TSKDDEIDEL</td><td align="left">10</td><td char="." align="char">0.816</td><td char="." align="char">0.7267</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">208&#x2013;237</td><td align="left">KRLRKKFKAVDDSFEMIETLYGVGYRFREA</td><td align="left">30</td><td char="." align="char">0.69</td><td char="." align="char">0.4274</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">193&#x2013;205</td><td align="left">DEQVYVDDRTIDS</td><td align="left">13</td><td char="." align="char">0.674</td><td char="." align="char">0.8660</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">126&#x2013;137</td><td align="left">ARRHAKPAGQQA</td><td align="left">12</td><td char="." align="char">0.652</td><td char="." align="char">0.6334</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="5">OMP25</td><td align="left">102&#x2013;114</td><td align="left">AKKSKDGLEVKQG</td><td align="left">13</td><td char="." align="char">0.788</td><td char="." align="char">1.8858</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">142&#x2013;155</td><td align="left">QIKLNNGLDDESKF</td><td align="left">14</td><td char="." align="char">0.785</td><td char="." align="char">0.7871</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">59&#x2013;73</td><td align="left">NKAKTSTVGSIKPDD</td><td align="left">15</td><td char="." align="char">0.748</td><td char="." align="char">0.7941</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">23&#x2013;47</td><td align="left">AADAIQEQPPVPAPVEVAPQYSWAG</td><td align="left">25</td><td char="." align="char">0.746</td><td char="." align="char">0.5963</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">182&#x2013;200</td><td align="left">TQYGNKNYDLAGTTVRNKL</td><td align="left">19</td><td char="." align="char">0.669</td><td char="." align="char">0.8759</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="5">OMP31</td><td align="left">177&#x2013;198</td><td align="left">KVKTSLSAYDDGESFSAGNSKT</td><td align="left">22</td><td char="." align="char">0.823</td><td char="." align="char">0.8254</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">58&#x2013;82</td><td align="left">GGKFKHPFSGIEQDGAQDFSGSLDV</td><td align="left">25</td><td char="." align="char">0.79</td><td char="." align="char">0.6199</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">116&#x2013;143</td><td align="left">VKSKLVDNGDLSDIGVAGNLSGDESFVL</td><td align="left">28</td><td char="." align="char">0.786</td><td char="." align="char">0.5532</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">28&#x2013;46</td><td align="left">ADIIVAEPAPVAVDTFSWT</td><td align="left">19</td><td char="." align="char">0.715</td><td char="." align="char">0.9214</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">209&#x2013;216</td><td align="left">EYAVTNNW</td><td align="left">8</td><td char="." align="char">0.585</td><td char="." align="char">0.9221</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="4">AlphaFold</td><td align="left" rowspan="2">OMP25</td><td align="left">183&#x2013;202</td><td align="left">QYGNKNYDLAGTTVRNKLDT</td><td align="left">20</td><td char="." align="char">0.671</td><td char="." align="char">0.9411</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">147&#x2013;159</td><td align="left">NGLDDESKFRVGW</td><td align="left">13</td><td char="." align="char">0.659</td><td char="." align="char">0.9067</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="2">OMP31</td><td align="left">1&#x2013;39</td><td align="left">MFSLKGTVMKTALLASVAMLFTSSAMAADIIVAEPAPVA</td><td align="left">39</td><td char="." align="char">0.823</td><td char="." align="char">0.4288</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">119&#x2013;142</td><td align="left">KLVDNGDLSDIGVAGNLSGDESFV</td><td align="left">24</td><td char="." align="char">0.642</td><td char="." align="char">0.5128</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr></tbody></table></table-wrap><table-wrap id="Tab14"><label>Table 14</label><caption><p>Predicted discontinuous epitope using ElliPro server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Server</th><th align="left">Protein</th><th align="left">Residues</th><th align="left">No. of residues</th><th align="left">Score</th></tr></thead><tbody><tr><td align="left" rowspan="18">I-TASSER</td><td align="left" rowspan="3">BvrR</td><td align="left">A:M1, A:K2, A:E3, A:A4, A:S5, A:A6, A:T7, A:Q8, A:D14, A:D15, A:D16, A:R17, A:N18, A:I19, A:L20, A:T21, A:S22, A:S24, A:I25, A:A26, A:E28, A:S29, A:E30, A:G31, A:Y32, A:T38, A:D39, A:I59, A:R63, A:M64, A:T85, A:S86, A:K87, A:D88, A:D89, A:E90, A:I91, A:D92, A:E93, A:L94, A:T106, A:K107, A:P108, A:F109, A:S110, A:Q111, A:R112, A:L113, A:V115, A:E116, A:K119, A:A120, A:R123, A:A126, A:R127, A:R128, A:H129, A:A130, A:K131, A:P132, A:A133, A:G134, A:Q135, A:Q136, A:A137A:M1, A:K2, A:E3, A:A4, A:S5, A:A6, A:T7, A:Q8, A:D14, A:D15, A:D16, A:R17, A:N18, A:I19, A:L20, A:T21, A:S22, A:S24, A:I25, A:A26, A:E28, A:S29, A:E30, A:G31, A:Y32, A:T38, A:D39, A:I59, A:R63, A:M64, A:T85, A:S86, A:K87, A:D88, A:D89, A:E90, A:I91, A:D92, A:E93, A:L94, A:T106, A:K107, A:P108, A:F109, A:S110, A:Q111, A:R112, A:L113, A:V115, A:E116, A:K119, A:A120, A:R123, A:A126, A:R127, A:R128, A:H129, A:A130, A:K131, A:P132, A:A133, A:G134, A:Q135, A:Q136, A:A137</td><td align="left">65</td><td char="." align="char">0.699</td></tr><tr><td align="left">A:E141, A:G143, A:Q144, A:L145, A:V146, A:T155, A:W156, A:K157, A:G158, A:E159, A:P160, A:V161, A:T162, A:L163, A:K213, A:F214</td><td align="left">16</td><td char="." align="char">0.688</td></tr><tr><td align="left">A:R177, A:P178, A:G179, A:V180, A:V181, A:K182, A:S183, A:R184, A:D185, A:D193, A:E194, A:Q195, A:V196, A:Y197, A:V198, A:D199, A:D200, A:R201, A:T202, A:D204, A:S205, A:K208, A:R209, A:R211, A:K212, A:K215, A:A216, A:V217, A:D218, A:D219, A:S220, A:F221, A:E222, A:M223, A:I224, A:E225, A:T226, A:L227, A:Y228, A:G229, A:V230, A:G231, A:Y232, A:R233, A:F234, A:R235, A:E236, A:A237</td><td align="left">48</td><td char="." align="char">0.677</td></tr><tr><td align="left" rowspan="6">OMP25</td><td align="left">A:T63, A:S64, A:T65, A:V66, A:G67, A:S68, A:I69, A:K70, A:P71, A:D72, A:D73, A:W74, A:A102, A:K103, A:K104, A:S105, A:K106, A:D107, A:G108, A:L109</td><td align="left">20</td><td char="." align="char">0.786</td></tr><tr><td align="left">A:E110, A:V111, A:K112, A:Q113, A:G114, A:Q142, A:I143, A:K144, A:L145, A:N146, A:N147, A:G148, A:L149, A:D150, A:D151, A:E152, A:S153, A:K154</td><td align="left">18</td><td char="." align="char">0.783</td></tr><tr><td align="left">A:I27, A:Q28, A:E29, A:Q30, A:P31, A:P32, A:V33, A:P34, A:A35, A:P36, A:V37, A:E38, A:V39, A:A40, A:P41, A:Q42, A:S44, A:W45, A:A46, A:G47, A:N83, A:F84, A:Q85, A:Q86, A:D87, A:Q88, A:I89, A:V90</td><td align="left">28</td><td char="." align="char">0.716</td></tr><tr><td align="left">A:T182, A:Q183, A:Y184, A:G185, A:N186, A:K187, A:N188, A:D190, A:L191, A:A192, A:G193, A:T194, A:T195, A:V196, A:R197, A:N198, A:K199, A:L200, A:D201</td><td align="left">19</td><td char="." align="char">0.657</td></tr><tr><td align="left">A:W58, A:N59, A:K60, A:A61, A:K62</td><td align="left">5</td><td char="." align="char">0.577</td></tr><tr><td align="left">A:I9, A:V10, A:S11, A:A12, A:A13, A:L14, A:L15, A:P16, A:F17, A:S18, A:A19, A:T20, A:A21, A:F22, A:A23, A:A24, A:D25, A:A26, A:D126, A:L127, A:N128, A:P129, A:K168, A:L169, A:T170, A:D171, A:N172, A:I173, A:Y211, A:K212</td><td align="left">30</td><td char="." align="char">0.521</td></tr><tr><td align="left" rowspan="9">OMP31</td><td align="left">A:F65, A:S66, A:G67, A:I68, A:E69</td><td align="left">5</td><td char="." align="char">0.969</td></tr><tr><td align="left">A:Q70, A:D71, A:G72, A:A73, A:Q74, A:D75</td><td align="left">6</td><td char="." align="char">0.898</td></tr><tr><td align="left">A:G176, A:V178, A:K179, A:T180, A:S181, A:L182, A:S183, A:A184, A:Y185, A:D187, A:G188, A:E189, A:S190, A:F191, A:S192, A:A193, A:G194, A:N195, A:S196, A:K197, A:T198</td><td align="left">21</td><td char="." align="char">0.812</td></tr><tr><td align="left">A:K62, A:H63, A:P64</td><td align="left">3</td><td char="." align="char">0.806</td></tr><tr><td align="left">A:T115, A:V116, A:K117, A:S118, A:K119, A:L120, A:V121, A:D122, A:N123, A:G124, A:D125, A:L126, A:S127, A:D128, A:I129, A:G130, A:V131, A:A132, A:G133, A:N134, A:L135, A:S136, A:G137, A:D138, A:E139, A:S140, A:F141, A:V142, A:L143</td><td align="left">29</td><td char="." align="char">0.77</td></tr><tr><td align="left">A:F76, A:S77, A:G78, A:S79, A:L80, A:D81, A:V82</td><td align="left">7</td><td char="." align="char">0.666</td></tr><tr><td align="left">A:G58, A:G59, A:K60, A:F61</td><td align="left">4</td><td char="." align="char">0.613</td></tr><tr><td align="left">A:L227, A:G228, A:K229, A:R230, A:S231, A:F232, A:N233, A:Y234, A:I235, A:E237, A:E238, A:N239, A:V240, A:N241, A:I242, A:N243, A:M244, A:E245</td><td align="left">18</td><td char="." align="char">0.598</td></tr><tr><td align="left">A:M1, A:F2, A:S3, A:L4, A:G6, A:T7, A:V8, A:T11, A:A12, A:L13, A:L14, A:M19, A:L20, A:F21, A:A27, A:A28, A:D29, A:I30, A:I31, A:V32, A:A33, A:E34, A:P35, A:A36, A:P37, A:V38, A:A39, A:V40, A:D41, A:T42, A:F43, A:S44, A:T46, A:W97, A:Q98, A:L99, A:A100, A:N101, A:G102, A:L103, A:V104, A:L105, A:G158, A:F159, A:T160, A:P161, A:T162, A:E163, A:R164, A:L165, A:M166, A:E209, A:Y210, A:A211, A:V212, A:T213, A:N214, A:N215, A:Y259, A:K260</td><td align="left">60</td><td char="." align="char">0.575</td></tr><tr><td align="left" rowspan="18">AlphaFold</td><td align="left" rowspan="4">BvrR</td><td align="left">A:G143, A:Q144, A:W156, A:K157</td><td align="left">4</td><td char="." align="char">0.771</td></tr><tr><td align="left">A:A130, A:K131, A:P132, A:A133, A:G134, A:Q135, A:Q136, A:A137, A:K138, A:S139, A:E141, A:R142, A:V146, A:Q149, A:E150, A:R151</td><td align="left">16</td><td char="." align="char">0.742</td></tr><tr><td align="left">A:G158, A:E159, A:P160, A:Q176, A:R177, A:P178, A:G179, A:V180, A:V181, A:K182, A:S183, A:R184, A:D185, A:V198, A:D199, A:D200, A:R201, A:K215, A:A216, A:V217, A:D218, A:D219, A:S220, A:F221, A:E222, A:M223, A:E225, A:T226, A:L227, A:Y228, A:G229, A:V230, A:G231, A:R233, A:R235, A:E236, A:A237</td><td align="left">37</td><td char="." align="char">0.731</td></tr><tr><td align="left">A:E3, A:A4, A:S5, A:A6, A:T7, A:Q8, A:D14, A:D15, A:D16, A:N18, A:I19, A:L20, A:T21, A:S22, A:S24, A:I25, A:A26, A:E28, A:S29, A:E30, A:G31, A:Y32, A:R33, A:E35, A:T36, A:T38, A:D39, A:G40, A:A41, A:S42, A:L44, A:D45, A:G46, A:M48, A:A49, A:R50, A:M61, A:P62, A:R63, A:M64, A:D65, A:E68, A:R72, A:Q75, A:K76, A:S86, A:K87, A:D88, A:D89, A:I91, A:K107, A:P108, A:F109, A:S110, A:Q111</td><td align="left">55</td><td char="." align="char">0.69</td></tr><tr><td align="left" rowspan="6">OMP25</td><td align="left">A:M1, A:R2, A:T3, A:L4, A:K5, A:S6, A:L7, A:V8, A:I9, A:V10, A:S11, A:A12, A:A13, A:L14, A:L15, A:P16, A:F17, A:S18, A:A19, A:T20</td><td align="left">20</td><td char="." align="char">0.947</td></tr><tr><td align="left">A:A21, A:F22, A:A23, A:A24, A:D25, A:A26, A:I27, A:Q28</td><td align="left">8</td><td char="." align="char">0.872</td></tr><tr><td align="left">A:K60, A:K62, A:T63, A:S64, A:T65, A:V66, A:G67, A:S68, A:K106, A:D107, A:G108, A:N147, A:G148, A:L149, A:D150, A:D151, A:E152, A:S153, A:K154, A:W159, A:Q183, A:G185, A:N186, A:K187, A:N188, A:Y189, A:D190, A:L191, A:A192, A:G193, A:T194, A:T195, A:V196, A:R197, A:N198, A:K199, A:L200, A:D201</td><td align="left">38</td><td char="." align="char">0.706</td></tr><tr><td align="left">A:Q30, A:P31, A:P32</td><td align="left">3</td><td char="." align="char">0.613</td></tr><tr><td align="left">A:Y43, A:T50, A:L52, A:N128, A:P129, A:V130, A:A167, A:L169, A:T170, A:D171, A:N172, A:I173, A:V177, A:V207, A:G208, A:I209, A:G210, A:Y211, A:K212</td><td align="left">19</td><td char="." align="char">0.613</td></tr><tr><td align="left">A:Y56, A:W58, A:W74, A:Q203</td><td align="left">4</td><td char="." align="char">0.587</td></tr><tr><td align="left" rowspan="8">OMP31</td><td align="left">A:M1, A:F2, A:S3, A:L4, A:K5, A:G6, A:T7, A:V8, A:M9, A:K10, A:T11</td><td align="left">11</td><td char="." align="char">0.972</td></tr><tr><td align="left">A:A12, A:L13, A:L14, A:A15, A:S16, A:V17, A:A18, A:M19, A:L20, A:F21</td><td align="left">10</td><td char="." align="char">0.938</td></tr><tr><td align="left">A:F65, A:S66, A:G67, A:I68, A:E69, A:Q70, A:D71, A:G72, A:A73, A:Q74, A:D75, A:F76, A:S77, A:G78, A:G228, A:K229, A:R230, A:S231, A:F232, A:N233, A:Y234, A:I235, A:D236, A:E237, A:E238, A:N239, A:V240, A:N241, A:I242, A:N243, A:E245, A:K247</td><td align="left">32</td><td char="." align="char">0.753</td></tr><tr><td align="left">A:S23, A:S24, A:A25, A:M26, A:A27, A:A28, A:D29, A:I30, A:V32, A:A33, A:E34, A:P35, A:A36</td><td align="left">13</td><td char="." align="char">0.715</td></tr><tr><td align="left">A:K119, A:V121, A:D122, A:N123, A:G124, A:D125, A:L126, A:S127, A:D128, A:V131, A:A132, A:G133, A:N134, A:L135, A:S136, A:G137, A:D138, A:E139, A:S140, A:V142, A:Q148, A:K177, A:S183, A:A184, A:Y185, A:D186, A:D187, A:G188, A:E189, A:S190, A:F191, A:S192, A:A193, A:G194, A:N195, A:S196, A:K197</td><td align="left">37</td><td char="." align="char">0.687</td></tr><tr><td align="left">A:Y56, A:F87, A:T115</td><td align="left">3</td><td char="." align="char">0.609</td></tr><tr><td align="left">A:I52, A:R164, A:Y210, A:V212, A:T213, A:N215, A:W216, A:G256, A:L257, A:N258, A:Y259</td><td align="left">11</td><td char="." align="char">0.564</td></tr><tr><td align="left">A:L99, A:A100, A:N101, A:G102, A:F159, A:P161, A:T162</td><td align="left">7</td><td char="." align="char">0.531</td></tr></tbody></table></table-wrap><table-wrap id="Tab15"><label>Table 15</label><caption><p>The CD8&#x2009;+&#x2009;T cell epitopes of the three target proteins using different servers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Servers</th><th align="left">Protein</th><th align="left">Allele</th><th align="left">RANK</th><th align="left">POS</th><th align="left">SEQUENCE</th><th align="left">SCORE</th><th align="left">Antigenicity</th><th align="left">Allergenicity</th><th align="left">Toxicity</th></tr></thead><tbody><tr><td align="left" rowspan="9">RANKPEP</td><td align="left" rowspan="6">OMP25</td><td align="left" rowspan="4">HLA_A01</td><td align="left">1</td><td align="left">181</td><td align="left">YTQYGNKNY</td><td align="left">16.517</td><td char="." align="char">0.5172</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">2</td><td align="left">91</td><td align="left">YGVEGDAGY</td><td align="left">12.453</td><td char="." align="char">1.7710</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">3</td><td align="left">176</td><td align="left">RVEYRYTQY</td><td align="left">5.577</td><td char="." align="char">1.3330</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">4</td><td align="left">159</td><td align="left">WTAGAGLEA</td><td align="left">5.331</td><td char="." align="char">1.4452</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="2">HLA_A0201</td><td align="left">1</td><td align="left">137</td><td align="left">GIAGSQIKL</td><td align="left">70</td><td char="." align="char">1.8042</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">2</td><td align="left">61</td><td align="left">AKTSTVGSI</td><td align="left">56</td><td char="." align="char">0.6583</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="3">OMP31</td><td align="left" rowspan="2">HLA_A01</td><td align="left">1</td><td align="left">167</td><td align="left">VYGTGGLAY</td><td align="left">10.33</td><td char="." align="char">0.4684</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">2</td><td align="left">108</td><td align="left">EADFQGSTV</td><td align="left">7.767</td><td char="." align="char">1.1171</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">HLA_A0201</td><td align="left">1</td><td align="left">3</td><td align="left">SLKGTVMKT</td><td align="left">74</td><td char="." align="char">1.0532</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="13">Syfpeithi</td><td align="left" rowspan="3">BvrR</td><td align="left">HLA-A*01</td><td align="left">1</td><td align="left">189</td><td align="left">DAAYDEQVY</td><td align="left">16</td><td char="." align="char">0.6631</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="2">HLA-A*02:01</td><td align="left">1</td><td align="left">173</td><td align="left">SLAQRPGVV</td><td align="left">24</td><td char="." align="char">0.4381</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">2</td><td align="left">202</td><td align="left">TIDSHIKRL</td><td align="left">21</td><td char="." align="char">1.0243</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="6">OMP25</td><td align="left" rowspan="3">HLA_A01</td><td align="left">1</td><td align="left">176</td><td align="left">RVEYRYTQY</td><td align="left">23</td><td char="." align="char">1.3330</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">2</td><td align="left">181</td><td align="left">YTQYGNKNY</td><td align="left">23</td><td char="." align="char">0.5172</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">3</td><td align="left">91</td><td align="left">YGVEGDAGY</td><td align="left">17</td><td char="." align="char">1.7710</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="3">HLA_A0201</td><td align="left">1</td><td align="left">137</td><td align="left">GIAGSQIKL</td><td align="left">25</td><td char="." align="char">1.8042</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">2</td><td align="left">130</td><td align="left">VMPYLTAGI</td><td align="left">22</td><td char="." align="char">0.4643</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">3</td><td align="left">161</td><td align="left">AGAGLEAKL</td><td align="left">21</td><td char="." align="char">2.4411</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="4">OMP31</td><td align="left" rowspan="3">HLA_A01</td><td align="left">1</td><td align="left">216</td><td align="left">WTLKSEYLY</td><td align="left">22</td><td char="." align="char">1.1851</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">2</td><td align="left">167</td><td align="left">VYGTGGLAY</td><td align="left">20</td><td char="." align="char">0.4684</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">3</td><td align="left">214</td><td align="left">NNWTLKSEY</td><td align="left">17</td><td char="." align="char">1.4935</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">HLA_A0201</td><td align="left">1</td><td align="left">3</td><td align="left">SLKGTVMKT</td><td align="left">23</td><td char="." align="char">1.0532</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr></tbody></table></table-wrap><table-wrap id="Tab16"><label>Table 16</label><caption><p>The CD4&#x2009;+&#x2009;T cell epitopes of the three target proteins using the RANKPEP server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Allele</th><th align="left">RANK</th><th align="left">POS</th><th align="left">SEQUENCE</th><th align="left">SCORE</th><th align="left">Antigenicity</th><th align="left">Allergenicity</th><th align="left">Toxicity</th></tr></thead><tbody><tr><td align="left" rowspan="5">BvrR</td><td align="left" rowspan="2">HLA-DRB * 0701</td><td align="left">1</td><td align="left">150</td><td align="left">ERHTCTWKG</td><td char="." align="char">10.821</td><td char="." align="char">0.5180</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">2</td><td align="left">163</td><td align="left">LTVTEFLIL</td><td char="." align="char">6.347</td><td char="." align="char">1.0405</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left" rowspan="3">HLA-DRB * 0901</td><td align="left">1</td><td align="left">202</td><td align="left">TIDSHIKRL</td><td char="." align="char">7.329</td><td char="." align="char">1.0243</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">2</td><td align="left">57</td><td align="left">FDIKMPRMD</td><td char="." align="char">7.312</td><td char="." align="char">2.2813</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">3</td><td align="left">189</td><td align="left">DAAYDEQVY</td><td char="." align="char">5.269</td><td char="." align="char">0.6631</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left" rowspan="5">OMP25</td><td align="left" rowspan="2">HLA-DRB * 0701</td><td align="left">1</td><td align="left">79</td><td align="left">FAGWNFQQD</td><td char="." align="char">18.575</td><td char="." align="char">1.0670</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">2</td><td align="left">189</td><td align="left">YDLAGTTVR</td><td char="." align="char">5.395</td><td char="." align="char">1.5360</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left" rowspan="3">HLA-DRB * 0901</td><td align="left">1</td><td align="left">115</td><td align="left">FEGSLRARV</td><td char="." align="char">16.405</td><td char="." align="char">0.8448</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">2</td><td align="left">189</td><td align="left">YDLAGTTVR</td><td char="." align="char">10.014</td><td char="." align="char">1.5360</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">3</td><td align="left">181</td><td align="left">YTQYGNKNY</td><td char="." align="char">9.05</td><td char="." align="char">0.5172</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left" rowspan="3">OMP31</td><td align="left" rowspan="2">HLA-DRB * 0701</td><td align="left">1</td><td align="left">39</td><td align="left">AVDTFSWTG</td><td char="." align="char">13.766</td><td char="." align="char">0.5343</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">2</td><td align="left">245</td><td align="left">ENKVNFHTV</td><td char="." align="char">9.507</td><td char="." align="char">0.8534</td><td align="left">NON-ALLERGEN</td><td align="left">&#x2013;</td></tr><tr><td align="left">HLA-DRB * 0901</td><td align="left">1</td><td align="left">216</td><td align="left">WTLKSEYLY</td><td char="." align="char">6.98</td><td char="." align="char">1.1851</td><td align="left">Non-ALLERGEN</td><td align="left">&#x2013;</td></tr></tbody></table></table-wrap></p>
        <p id="Par17">SVMTriP and Bepipred 2.0 servers clarified that (1, 2, and 0) and (1, 4, and 5) dominant B cell epitopes for the BvrR, OMP25, and OMP31 proteins, respectively (Tables <xref rid="Tab11" ref-type="table">11</xref> and <xref rid="Tab12" ref-type="table">12</xref>). On the other hand, the Ellipro server detected (4, 5, and 5) and (0, 2, and 2) dominant linear B cell epitopes for the BvrR, OMP25, and OMP31 proteins produced from I-TASSER and AlphaFold servers, respectively (Table <xref rid="Tab13" ref-type="table">13</xref>). The prediction of discontinuous B cell epitopes using the Ellipro server revealed the presence of 129, 120, and 163 total residues for BvrR, OMP25, and OMP31 proteins of the I-TASSER model, and their average scores were 0.688, 0.673, and 0.745, respectively. The AlphaFold model had 112, 92, and 124 total residues, and their average scores were 0.733, 0.723, and 0.599 for the BvrR, OMP25, and OMP31 proteins, respectively (Table&#xA0;<xref rid="Tab14" ref-type="table">14</xref>).</p>
        <p id="Par18">For CD8&#x2009;+&#x2009;T cell epitope prediction, 9-mer alleles (HLA_A01 and HLA_A0201) were used. Through the RankPep server, the BvrR protein was found to have one CD8&#x2009;+&#x2009;T cell epitope at position 173..181 (SLAQRPGVV) only in the case of the HLA_A0201 allele. OMP25 protein showed four and two CD8&#x2009;+&#x2009;T cell epitopes, and OMP31 protein displayed two CD8&#x2009;+&#x2009;T cell epitopes for each allele, respectively. Furthermore, using the Syfpeithi server clarified one and two CD8&#x2009;+&#x2009;T cell epitopes of BvrR protein, three CD8&#x2009;+&#x2009;T cell epitopes of OMP25 protein, and three and one CD8&#x2009;+&#x2009;T cell epitopes of OMP31 protein for each allele, respectively <bold>(</bold>Table <xref rid="Tab15" ref-type="table">15</xref>).</p>
        <p id="Par19">For CD4&#x2009;+&#x2009;T cell epitope prediction, the RankPep server used two 9-mer alleles (HLA-DRB * 0701 and HLA-DRB * 0901). BvrR protein detected two and three CD4&#x2009;+&#x2009;T cell epitopes, OMP25 protein showed two and three CD4&#x2009;+&#x2009;T cell epitopes, and OMP31 protein displayed two and one CD4&#x2009;+&#x2009;T cell epitopes for each allele, respectively (Table <xref rid="Tab16" ref-type="table">16</xref>). Moreover, the MHCII-NP server predicted three, four, and three CD4&#x2009;+&#x2009;T cell epitopes for the three target proteins, respectively (Table <xref rid="Tab17" ref-type="table">17</xref>).<table-wrap id="Tab17"><label>Table 17</label><caption><p>MHCII-NP prediction for the three target proteins.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Location</th><th align="left">Peptide</th><th align="left">N motif</th><th align="left">C motif</th><th align="left">Cleavage probability score</th><th align="left">Cleavage probability percentile rank</th><th align="left">Antigenicity</th><th align="left">Allergenicity</th><th align="left">Toxicity</th></tr></thead><tbody><tr><td align="left" rowspan="3">BvrR</td><td align="left">50&#x2013;63</td><td align="left">RPPNLAIFDIKMPR</td><td align="left">ARP</td><td align="left">PRM</td><td char="." align="char">1.23746</td><td char="." align="char">0.00</td><td char="." align="char">1.4171</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">39&#x2013;53</td><td align="left">DGASALDGLMARPPN</td><td align="left">TDG</td><td align="left">PNL</td><td char="." align="char">0.81440</td><td char="." align="char">0.13</td><td char="." align="char">0.6988</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">193&#x2013;208</td><td align="left">DEQVYVDDRTIDSHIK</td><td align="left">YDE</td><td align="left">IKR</td><td char="." align="char">0.79870</td><td char="." align="char">0.17</td><td char="." align="char">1.0873</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="4">OMP25</td><td align="left">95&#x2013;108</td><td align="left">GDAGYSWAKKSKDG</td><td align="left">EGD</td><td align="left">DGL</td><td char="." align="char">0.87185</td><td char="." align="char">0.00</td><td char="." align="char">0.7750</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">128&#x2013;142</td><td align="left">NPVMPYLTAGIAGSQ</td><td align="left">LNP</td><td align="left">SQI</td><td char="." align="char">0.74398</td><td char="." align="char">0.09</td><td char="." align="char">0.6498</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">70&#x2013;85</td><td align="left">KPDDWKAGAFAGWNFQ</td><td align="left">IKP</td><td align="left">FQQ</td><td char="." align="char">0.74048</td><td char="." align="char">0.14</td><td char="." align="char">0.7280</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">107&#x2013;122</td><td align="left">DGLEVKQGFEGSLRAR</td><td align="left">KDG</td><td align="left">ARV</td><td char="." align="char">0.72066</td><td char="." align="char">0.19</td><td char="." align="char">1.4627</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left" rowspan="3">OMP31</td><td align="left">242&#x2013;256</td><td align="left">INMENKVNFHTVRLG</td><td align="left">NIN</td><td align="left">LGL</td><td char="." align="char">0.75919</td><td char="." align="char">0.04</td><td char="." align="char">0.7496</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">240&#x2013;254</td><td align="left">VNINMENKVNFHTVR</td><td align="left">NVN</td><td align="left">VRL</td><td char="." align="char">0.61905</td><td char="." align="char">0.08</td><td char="." align="char">1.0609</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr><tr><td align="left">109&#x2013;123</td><td align="left">ADFQGSTVKSKLVDN</td><td align="left">EAD</td><td align="left">DNG</td><td char="." align="char">0.60720</td><td char="." align="char">0.11</td><td char="." align="char">1.0226</td><td align="left">NON-ALLERGEN</td><td align="left">Non-Toxin</td></tr></tbody></table></table-wrap></p>
        <p id="Par20">The final result from all previous servers for B and T cell epitopes prediction overlapped to conclude that there were (5, 6, and 5) dominant B-cell epitopes, (3, 4, and 4) dominant CTL epitopes, and (4, 5 and 4) dominant THL epitopes for the three target proteins (BvrR, OMP25, and OMP31), respectively (Table <xref rid="Tab18" ref-type="table">18</xref>).<table-wrap id="Tab18"><label>Table 18</label><caption><p>The final overlapped B and T cells epitopes from the different servers used.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Epitopes</th><th align="left" colspan="2">BvrR</th><th align="left" colspan="2">OMP25</th><th align="left" colspan="2">OMP31</th></tr><tr><th align="left">Position</th><th align="left">Sequence</th><th align="left">Position</th><th align="left">Sequence</th><th align="left">Position</th><th align="left">Sequence</th></tr></thead><tbody><tr><td align="left" rowspan="6">B-cell</td><td align="left">44&#x2013;63</td><td align="left">LDGLMARPPNLAIFDIKMPR</td><td align="left">26&#x2013;46</td><td align="left">AIQEQPPVPAPVEVAPQYSWA</td><td align="left">29&#x2013;45</td><td align="left">DIIVAEPAPVAVDTFSW</td></tr><tr><td align="left">126&#x2013;137</td><td align="left">ARRHAKPAGQQA</td><td align="left">52&#x2014;71</td><td align="left">LYLGYGWNKAKTSTVGSIKP</td><td align="left">58&#x2013;82</td><td align="left">GGKFKHPFSGIEQDGAQDFSGSLDV</td></tr><tr><td align="left">85&#x2013;93</td><td align="left">TSKDDEIDEL</td><td align="left">98&#x2014;106</td><td align="left">GYSWAKKSK</td><td align="left">119&#x2013;142</td><td align="left">KLVDNGDLSDIGVAGNLSGDESFV</td></tr><tr><td align="left">193&#x2013;205</td><td align="left">DEQVYVDDRTIDS</td><td align="left">102&#x2013;114</td><td align="left">AKKSKDGLEVKQG</td><td align="left">177&#x2013;198</td><td align="left">KVKTSLSAYDDGESFSAGNSKT</td></tr><tr><td align="left" rowspan="2">208&#x2013;237</td><td align="left" rowspan="2">KRLRKKFKAVDDSFEMIETLYGVGYRFREA</td><td align="left">142&#x2013;155</td><td align="left">QIKLNNGLDDESKF</td><td align="left" rowspan="2">222&#x2013;251</td><td align="left" rowspan="2">YLYTDLGKRSFNYIDEENVNINMENKVNFH</td></tr><tr><td align="left">183&#x2013;200</td><td align="left">QYGNKNYDLAGTTVRNKL</td></tr><tr><td align="left" rowspan="4">CTL</td><td align="left">173&#x2013;181</td><td align="left">SLAQRPGVV</td><td align="left">61&#x2013;69</td><td align="left">AKTSTVGSI</td><td align="left">3&#x2013;11</td><td align="left">SLKGTVMKT</td></tr><tr><td align="left">189&#x2013;197</td><td align="left">DAAYDEQVY</td><td align="left">91&#x2013;99</td><td align="left">YGVEGDAGY</td><td align="left">24&#x2013;32</td><td align="left">SAMAADIIV</td></tr><tr><td align="left" rowspan="2">202&#x2013;210</td><td align="left" rowspan="2">TIDSHIKRL</td><td align="left">159&#x2013;167</td><td align="left">WTAGAGLEA</td><td align="left">167&#x2013;175</td><td align="left">VYGTGGLAY</td></tr><tr><td align="left">181&#x2013;189</td><td align="left">YTQYGNKNY</td><td align="left">216&#x2013;224</td><td align="left">WTLKSEYLY</td></tr><tr><td align="left" rowspan="5">THL</td><td align="left">39&#x2013;53</td><td align="left">DGASALDGLMARPPN</td><td align="left">79&#x2013;87</td><td align="left">FAGWNFQQD</td><td align="left">39&#x2013;47</td><td align="left">AVDTFSWTG</td></tr><tr><td align="left">57&#x2013;65</td><td align="left">FDIKMPRMD</td><td align="left">95&#x2013;108</td><td align="left">GDAGYSWAKKSKDG</td><td align="left">109&#x2013;123</td><td align="left">ADFQGSTVKSKLVDN</td></tr><tr><td align="left">150&#x2013;158</td><td align="left">ERHTCTWKG</td><td align="left">115&#x2013;123</td><td align="left">FEGSLRARV</td><td align="left">216&#x2013;224</td><td align="left">WTLKSEYLY</td></tr><tr><td align="left" rowspan="2">163&#x2013;171</td><td align="left" rowspan="2">LTVTEFLIL</td><td align="left">128&#x2013;142</td><td align="left">NPVMPYLTAGIAGSQIKL</td><td align="left" rowspan="2">245&#x2013;253</td><td align="left" rowspan="2">ENKVNFHTV</td></tr><tr><td align="left">189&#x2013;197</td><td align="left">YDLAGTTVR</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec12">
        <title>Vaccine construction and validation</title>
        <p id="Par21">The chimeric vaccine for the three target proteins was constructed using the final overlapped epitopes from the different servers and linkers. It consists of (3, 4, and 4) CTL epitopes, connected by AAY linkers, (4, 5, and 4) THL epitopes, connected by GPGPG linkers, and (5, 6, and 5) B-cell epitopes connected by KK linkers (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a). The final constructed vaccine length was 698 amino acids. The antigenicity of this designed vaccine was 0.8942 and it is non-allergen and nontoxic.<fig id="Fig3"><label>Figure 3</label><caption><p>Constructed vaccine candidate against BvrR, OMP25, and OMP3 receptor <italic>brucella</italic>. (<bold>a</bold>) The designed vaccine candidate is sequentially like the PADRE sequence (Black color), followed by the next 5 amino acids of EAAAK linker (Red color), then CTL epitopes (Green color) from 19 to 159, then HTL epitopes (Blue color) from 163 to 365, then B-cell epitopes (Purple color) from 371 to 698. All the linkers have been represented in red color. (<bold>b</bold>) The 3D cartoon view of the designed vaccine. (<bold>c</bold>) The Ramachandran plot of the designed vaccine. (<bold>d</bold>) Z score of the designed vaccine.</p></caption><graphic xlink:href="41598_2024_61991_Fig3_HTML" id="MO3"/></fig></p>
        <p id="Par22">The physiochemical properties of the constructed vaccine using ProtParam determined that it contains 698 amino acids and the molecular weight was found to be 74,676.32&#xA0;Da. The theoretical isoelectric point (PI) was obtained as 9.36 specifies it as positive as an isoelectric point above 7.0 shows positively charged proteins. Instability-Index (II) was 24.79; which categorized our vaccine as a stable one. The aliphatic index was 63.01 indicating that the vaccine is more thermostable and can withstand high temperatures. A total number of carbon (C), hydrogen (H), nitrogen (N), oxygen (O), and sulfur (S) were entitled by formula C<sub>3367</sub>H<sub>5188</sub>N<sub>900</sub>O<sub>1003</sub>S<sub>11</sub>. The Grand average of hydropathicity (GRAVY) was -0.561 which indicates this vaccine is more hydrophilic.</p>
      </sec>
      <sec id="Sec13">
        <title>Secondary structure prediction</title>
        <p id="Par23">The SOPMA and PredictProtein servers predicted the designed vaccine consisting of 29.37% alpha helix, 21.63% beta-sheet, 39.40% random coil, 47.28% exposed residues, and 52.71% buried amino acid.</p>
      </sec>
      <sec id="Sec14">
        <title>Tertiary structure prediction, refinement and validation of the constructed vaccine</title>
        <p id="Par24">I-TASSER, AlphaFold colab2, and Swiss model were utilized to predict the 3-D structure of the chimeric vaccine (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b). The best model was chosen to refine via the GalaxyRefine tool which provided five models. The best-refined model of I-TASSER had TM-score (0.89), RMSD (0.62), GDT-HA (0.8764), MolProbity (2.89), clash score (13.91), Ramachandran Favored (81%), QMEAN (0.32), ERRAT score (75.8), Ramachandran plot (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c), and Z score (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>d).</p>
      </sec>
      <sec id="Sec15">
        <title>Molecular docking</title>
        <sec id="Sec16">
          <title>Virtual screening and molecular docking analysis</title>
          <p id="Par25">The MOE docking protocol was used, and parameters were set for docking initial hits into the binding pocket of <italic>Brucella&#x2019;s</italic> three proteins (BvrR, OMP25, and OMP31). Based on docking score, binding energy, and binding affinity calculation, which indicated the effectiveness of these compounds, the top-ranked 20 compounds from lead-like ZINC 20 database and DrugBank database were selected as promising hits for evaluation and revealing significant interactions with most of the important binding pocket residues. For the BvrR protein of the best I-TASSER model, the top-ranked compounds interacted with the following residues: MET1, LYS2, GLU3, ALA4, THR7, GLN8, THR9, LEU47, MET48, PRO51, PRO52, ASN53, ARG74, LYS76, SER77, ASP78, LEU79, PRO80, ASP102, VAL121, ARG124, VAL125, ALA126, ARG127, ARG128, HIS129, ALA130, LYS131, PRO132, ALA133, GLY134, GLN135, GLN136, ALA137, LYS138, GLU150, and ARG151. For OMP25 protein of the best I-TASSER model, the top-ranked compounds interacted with the following residues: GLY57, TRP58, ASN59, LYS60, ASP73, LYS75, ALA76, ALA97, GLY98, TYR99, SER100, TRP101, ALA102, LYS104, SER105, ASP107, LEU109, GLU110, VAL111, GLN113, GLY114, PHE115, GLU116, ALA139, SER141, GLN142, ILE143, LYS144, LEU149, ASP150, ARG156, VAL157, GLY158, TRP159, THR160, ARG180, THR182, TYR184, LEU200, THR202, GLN203, ASP204, ILE205, and ARG206. For the OMP31 protein of the best I-TASSER model, the top-ranked compounds interacted with the following residues: GLY55, TYR56, ALA57, LYS60, VAL82, THR83, ALA84, SER85, GLY86, PHE87, VAL88, GLY89, GLY90, VAL91, PHE111, GLN112, GLY113, SER114, THR115, LEU143, GLU144, THR145, LYS146, VAL147, GLN148, TRP149, PHE150, THR152, ARG154, ALA174, LYS177, LYS197, THR198, LYS199, GLY201, TRP202, THR203, LEU223, THR225, ASP226, ASN246, LYS247, VAL248, ASN249, PHE250, HIS251, THR252, VAL253, and ARG254.</p>
        </sec>
        <sec id="Sec17">
          <title>Binding energy and binding affinity calculations</title>
          <p id="Par26">It is clear from (Tables <xref rid="Tab19" ref-type="table">19</xref>, <xref rid="Tab20" ref-type="table">20</xref> and <xref rid="Tab21" ref-type="table">21</xref>) that the best-predicted lead compound is ZINC ID (022035210), which possessed the docking score (&#x2212;&#xA0;16.8744), the binding energy (&#x2212;&#xA0;13.1624), and the binding affinity (&#x2212;&#xA0;58.3099) for BvrR protein. ZINC ID (02756403) had the docking score, (&#x2212;&#xA0;16.0424), the binding energy (&#x2212;&#xA0;14.1846), and the binding affinity (&#x2212;&#xA0;61.8023) for OMP25, and ZINC ID (22551309) had the docking score (&#x2212;&#xA0;14.7566), the binding energy (&#x2212;&#xA0;11.3077), and the binding affinity (&#x2212;&#xA0;57.0108) for OMP31 protein. Otherwise, (Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref>&#x2013;<xref rid="MOESM1" ref-type="media">3</xref>) showed that DrugBank ID (DB01901) possessed the docking score (&#x2212;&#xA0;22.0345), the binding energy (&#x2212;&#xA0;16.5301), and the binding affinity (&#x2212;&#xA0;201.4108) for BvrR protein. DrugBank ID (DB00569) had the docking score (&#x2212;&#xA0;28.3066), the binding energy (&#x2212;&#xA0;18.9236), and the binding affinity (&#x2212;&#xA0;267.4938) for OMP25. Also, for the OMP31 protein, DrugBank ID (DB01111) owned the docking score (&#x2212;&#xA0;24.7229), the binding energy (&#x2212;&#xA0;18.2337), and the binding affinity (&#x2212;&#xA0;174.4778). In particular, the docked complex of the three target proteins (BvrR, OMP25 and OMP31) with the top five hits of each of them: first from ZINC (ZID 022035210, ZID 003954125, ZID 019366239, ZID 0169129, and ZID 00168942), (ZID 02,756,403, ZID 04086383, ZID 09,172,386, ZID 00172013, and ZID 00602468), and (ZID 22551309, ZID 00154214, ZID 10847947, ZID 00463723, and ZID 04854502) (Figs. <xref rid="Fig4" ref-type="fig">4</xref>, <xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig6" ref-type="fig">6</xref>) and second from DrugBank (DB01901, DB01999, DB01141, DB01741, and DB01753), (DB00569, DB01901, DB01141, DB02516, and DB00362) and (DB00569, DB01111, DB02524, DB00006, and DB01141) (Supplementary Figs.&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>&#x2013;<xref rid="MOESM1" ref-type="media">3</xref>).<table-wrap id="Tab19"><label>Table 19</label><caption><p>Molecular docking of BvrR protein using MOE software integrated with ZINC database and ADMElab-2 server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Compound</th><th align="left" rowspan="2">mseq</th><th align="left" rowspan="2">ZINC database ID</th><th align="left" rowspan="2">Docking score (S)</th><th align="left" rowspan="2">Binding affinity Kcal/Mol</th><th align="left" rowspan="2">Binding energy Kcal/Mol</th><th align="left" colspan="8">Drug like properties</th></tr><tr><th align="left">MW</th><th align="left">Hydrogen bond acceptors</th><th align="left">Hydrogen bond donor</th><th align="left">Topological polar surface area (&#xC5;2) (TPSA)</th><th align="left">No. of Rotatable Bonds (nRot)</th><th align="left">logS</th><th align="left">logD</th><th align="left">logP</th></tr></thead><tbody><tr><td align="left"><bold>1</bold></td><td align="left"><bold>1829</bold></td><td align="left"><bold>022035210</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;16.8744</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;58.3099</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.1624</bold></td><td align="left"><bold>245.21</bold></td><td align="left"><bold>5</bold></td><td align="left"><bold>2</bold></td><td char="." align="char"><bold>47.97</bold></td><td align="left"><bold>8</bold></td><td align="left"><bold>0.496</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;0.525</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;0.859</bold></td></tr><tr><td align="left"><bold>2</bold></td><td align="left"><bold>2009</bold></td><td align="left"><bold>003954125</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;15.5383</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;84.7323</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;12.6866</bold></td><td align="left"><bold>246.04</bold></td><td align="left"><bold>8</bold></td><td align="left"><bold>4</bold></td><td char="." align="char"><bold>149.2</bold></td><td align="left"><bold>4</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;0.915</bold></td><td align="left"><bold>4.76</bold></td><td align="left"><bold>1.352</bold></td></tr><tr><td align="left"><bold>3</bold></td><td align="left"><bold>9132</bold></td><td align="left"><bold>019366239</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;15.0681</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;61.8955</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.0549</bold></td><td align="left"><bold>204.11</bold></td><td align="left"><bold>6</bold></td><td align="left"><bold>4</bold></td><td char="." align="char"><bold>98.66</bold></td><td align="left"><bold>7</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;0.79</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;0.661</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;3.26</bold></td></tr><tr><td align="left"><bold>4</bold></td><td align="left"><bold>12,856</bold></td><td align="left"><bold>01695129</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;15.1195</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;78.1743</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.5454</bold></td><td align="left"><bold>217.97</bold></td><td align="left"><bold>2</bold></td><td align="left"><bold>0</bold></td><td char="." align="char"><bold>26.3</bold></td><td align="left"><bold>4</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;2.408</bold></td><td align="left"><bold>2.65</bold></td><td align="left"><bold>3.271</bold></td></tr><tr><td align="left"><bold>5</bold></td><td align="left"><bold>12,860</bold></td><td align="left"><bold>00168942</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;15.1922</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;72.4002</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.1458</bold></td><td align="left"><bold>280</bold></td><td align="left"><bold>5</bold></td><td align="left"><bold>0</bold></td><td char="." align="char"><bold>73.06</bold></td><td align="left"><bold>3</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;3.488</bold></td><td align="left"><bold>2.461</bold></td><td align="left"><bold>2.176</bold></td></tr><tr><td align="left">6</td><td align="left">14,006</td><td align="left">001737892</td><td align="left">&#x2009;&#x2212;&#x2009;15.1030</td><td align="left">&#x2009;&#x2212;&#x2009;73.0109</td><td align="left">&#x2009;&#x2212;&#x2009;13.7932</td><td align="left">245.17</td><td align="left">6</td><td align="left">6</td><td char="." align="char">118.44</td><td align="left">9</td><td align="left">&#x2009;&#x2212;&#x2009;0.637</td><td align="left">&#x2009;&#x2212;&#x2009;0.677</td><td align="left">&#x2009;&#x2212;&#x2009;2.862</td></tr><tr><td align="left">7</td><td align="left">9</td><td align="left">00408917</td><td align="left">&#x2009;&#x2212;&#x2009;14.0722</td><td align="left">&#x2009;&#x2212;&#x2009;64.4047</td><td align="left">&#x2009;&#x2212;&#x2009;13.8712</td><td align="left">321.1</td><td align="left">5</td><td align="left">1</td><td char="." align="char">68.63</td><td align="left">3</td><td align="left">&#x2009;&#x2212;&#x2009;5.527</td><td align="left">3.385</td><td align="left">4.555</td></tr><tr><td align="left">8</td><td align="left">1769</td><td align="left">091723860</td><td align="left">&#x2009;&#x2212;&#x2009;14.1525</td><td align="left">&#x2009;&#x2212;&#x2009;70.9786</td><td align="left">&#x2009;&#x2212;&#x2009;11.9068</td><td align="left">237.16</td><td align="left">6</td><td align="left">3</td><td char="." align="char">80.06</td><td align="left">3</td><td align="left">&#x2009;&#x2212;&#x2009;0.407</td><td align="left">&#x2009;&#x2212;&#x2009;0.509</td><td align="left">&#x2009;&#x2212;&#x2009;1.188</td></tr><tr><td align="left">9</td><td align="left">1866</td><td align="left">020270251</td><td align="left">&#x2009;&#x2212;&#x2009;14.2118</td><td align="left">&#x2009;&#x2212;&#x2009;72.7570</td><td align="left">&#x2009;&#x2212;&#x2009;11.1898</td><td align="left">213.18</td><td align="left">4</td><td align="left">1</td><td char="." align="char">27.74</td><td align="left">4</td><td align="left">0.322</td><td align="left">0.181</td><td align="left">&#x2009;&#x2212;&#x2009;0.574</td></tr><tr><td align="left">10</td><td align="left">5632</td><td align="left">07080053</td><td align="left">&#x2009;&#x2212;&#x2009;14.3759</td><td align="left">&#x2009;&#x2212;&#x2009;61.5902</td><td align="left">&#x2009;&#x2212;&#x2009;12.2912</td><td align="left">319.09</td><td align="left">5</td><td align="left">1</td><td char="." align="char">68.54</td><td align="left">8</td><td align="left">&#x2009;&#x2212;&#x2009;4.267</td><td align="left">2.663</td><td align="left">3.023</td></tr><tr><td align="left">11</td><td align="left">8073</td><td align="left">02348022</td><td align="left">&#x2009;&#x2212;&#x2009;14.2576</td><td align="left">&#x2009;&#x2212;&#x2009;67.8386</td><td align="left">&#x2009;&#x2212;&#x2009;14.0710</td><td align="left">395.23</td><td align="left">7</td><td align="left">0</td><td char="." align="char">67.52</td><td align="left">3</td><td align="left">&#x2009;&#x2212;&#x2009;4.29</td><td align="left">3.362</td><td align="left">4.326</td></tr><tr><td align="left">12</td><td align="left">8812</td><td align="left">40943553</td><td align="left">&#x2009;&#x2212;&#x2009;14.4593</td><td align="left">&#x2009;&#x2212;&#x2009;58.2046</td><td align="left">&#x2009;&#x2212;&#x2009;12.5358</td><td align="left">427.02</td><td align="left">5</td><td align="left">1</td><td char="." align="char">56.79</td><td align="left">8</td><td align="left">&#x2009;&#x2212;&#x2009;6.506</td><td align="left">3.7</td><td align="left">4.739</td></tr><tr><td align="left">13</td><td align="left">9051</td><td align="left">005274090</td><td align="left">&#x2009;&#x2212;&#x2009;14.1097</td><td align="left">&#x2009;&#x2212;&#x2009;68.4637</td><td align="left">&#x2009;&#x2212;&#x2009;14.0478</td><td align="left">246.12</td><td align="left">7</td><td align="left">5</td><td char="." align="char">129.72</td><td align="left">8</td><td align="left">&#x2009;&#x2212;&#x2009;0.804</td><td align="left">0.115</td><td align="left">&#x2009;&#x2212;&#x2009;2.621</td></tr><tr><td align="left">14</td><td align="left">9065</td><td align="left">07175417</td><td align="left">&#x2009;&#x2212;&#x2009;14.6310</td><td align="left">&#x2009;&#x2212;&#x2009;93.4404</td><td align="left">&#x2009;&#x2212;&#x2009;14.3095</td><td align="left">403.12</td><td align="left">6</td><td align="left">1</td><td char="." align="char">73.86</td><td align="left">10</td><td align="left">&#x2009;&#x2212;&#x2009;5.982</td><td align="left">3.75</td><td align="left">4.32</td></tr><tr><td align="left">15</td><td align="left">9395</td><td align="left">22435215</td><td align="left">&#x2009;&#x2212;&#x2009;14.1051</td><td align="left">&#x2009;&#x2212;&#x2009;97.8297</td><td align="left">&#x2009;&#x2212;&#x2009;12.8480</td><td align="left">449.18</td><td align="left">7</td><td align="left">1</td><td char="." align="char">78.95</td><td align="left">9</td><td align="left">&#x2009;&#x2212;&#x2009;4.081</td><td align="left">2.834</td><td align="left">2.817</td></tr><tr><td align="left">16</td><td align="left">9434</td><td align="left">003040197</td><td align="left">&#x2009;&#x2212;&#x2009;14.3342</td><td align="left">&#x2009;&#x2212;&#x2009;62.9283</td><td align="left">&#x2009;&#x2212;&#x2009;11.6448</td><td align="left">232.03</td><td align="left">6</td><td align="left">2</td><td char="." align="char">95.55</td><td align="left">4</td><td align="left">&#x2009;&#x2212;&#x2009;0.524</td><td align="left">&#x2009;&#x2212;&#x2009;1.426</td><td align="left">&#x2009;&#x2212;&#x2009;2.011</td></tr><tr><td align="left">17</td><td align="left">10,148</td><td align="left">21305182</td><td align="left">&#x2009;&#x2212;&#x2009;14.3352</td><td align="left">&#x2009;&#x2212;&#x2009;55.2878</td><td align="left">&#x2009;&#x2212;&#x2009;14.2352</td><td align="left">300.2</td><td align="left">5</td><td align="left">3</td><td char="." align="char">72.94</td><td align="left">7</td><td align="left">&#x2009;&#x2212;&#x2009;1.538</td><td align="left">1.542</td><td align="left">1.139</td></tr><tr><td align="left">18</td><td align="left">14,385</td><td align="left">00172116</td><td align="left">&#x2009;&#x2212;&#x2009;14.8699</td><td align="left">&#x2009;&#x2212;&#x2009;88.2810</td><td align="left">&#x2009;&#x2212;&#x2009;14.8585</td><td align="left">311.03</td><td align="left">4</td><td align="left">0</td><td char="." align="char">43.85</td><td align="left">3</td><td align="left">&#x2009;&#x2212;&#x2009;4.376</td><td align="left">3.424</td><td align="left">3.454</td></tr><tr><td align="left">19</td><td align="left">15,390</td><td align="left">00497800</td><td align="left">&#x2009;&#x2212;&#x2009;14.2955</td><td align="left">&#x2009;&#x2212;&#x2009;55.4569</td><td align="left">&#x2009;&#x2212;&#x2009;14.1880</td><td align="left">314.02</td><td align="left">4</td><td align="left">2</td><td char="." align="char">65.98</td><td align="left">1</td><td align="left">&#x2009;&#x2212;&#x2009;4.598</td><td align="left">3.083</td><td align="left">3.74</td></tr><tr><td align="left">20</td><td align="left">15,650</td><td align="left">74065906</td><td align="left">&#x2009;&#x2212;&#x2009;14.5277</td><td align="left">&#x2009;&#x2212;&#x2009;71.8478</td><td align="left">&#x2009;&#x2212;&#x2009;12.5528</td><td align="left">299.16</td><td align="left">4</td><td align="left">1</td><td char="." align="char">55.4</td><td align="left">6</td><td align="left">&#x2009;&#x2212;&#x2009;3.724</td><td align="left">3.258</td><td align="left">3.171</td></tr></tbody></table><table-wrap-foot><p>Significant values are in<bold> bold</bold>.</p></table-wrap-foot></table-wrap><table-wrap id="Tab20"><label>Table 20</label><caption><p>Molecular docking of OMP25 protein using MOE software integrated with ZINC database and ADMElab-2 server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Compound</th><th align="left" rowspan="2">mseq</th><th align="left" rowspan="2">ZINC database ID</th><th align="left" rowspan="2">Docking score (S)</th><th align="left" rowspan="2">Binding affinity Kcal/Mol</th><th align="left" rowspan="2">Binding energy Kcal/Mol</th><th align="left" colspan="8">Drug like properties</th></tr><tr><th align="left">MW</th><th align="left">Hydrogen bond acceptors</th><th align="left">Hydrogen bond donor</th><th align="left">Topological polar surface area (&#xC5;2)(TPSA)</th><th align="left">No. of Rotatable Bonds (nRot)</th><th align="left">logS</th><th align="left">logD</th><th align="left">logP</th></tr></thead><tbody><tr><td align="left"><bold>1</bold></td><td align="left"><bold>1823</bold></td><td align="left"><bold>02756403</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;16.0424</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;61.8023</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;14.1846</bold></td><td char="." align="char"><bold>430.06</bold></td><td align="left"><bold>5</bold></td><td align="left"><bold>2</bold></td><td char="." align="char"><bold>58.95</bold></td><td align="left"><bold>6</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;6.152</bold></td><td char="." align="char"><bold>3.895</bold></td><td align="left"><bold>4.895</bold></td></tr><tr><td align="left"><bold>2</bold></td><td align="left"><bold>1430</bold></td><td align="left"><bold>04086383</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;15.4545</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;80.6489</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;12.3045</bold></td><td char="." align="char"><bold>332.08</bold></td><td align="left"><bold>3</bold></td><td align="left"><bold>2</bold></td><td char="." align="char"><bold>41.13</bold></td><td align="left"><bold>7</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;6.154</bold></td><td char="." align="char"><bold>4.521</bold></td><td align="left"><bold>4.693</bold></td></tr><tr><td align="left"><bold>3</bold></td><td align="left"><bold>1769</bold></td><td align="left"><bold>09172386</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;15.7381</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;66.3356</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;12.5221</bold></td><td char="." align="char"><bold>400.07</bold></td><td align="left"><bold>4</bold></td><td align="left"><bold>1</bold></td><td char="." align="char"><bold>51.22</bold></td><td align="left"><bold>8</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;4.475</bold></td><td char="." align="char"><bold>3.611</bold></td><td align="left"><bold>4.318</bold></td></tr><tr><td align="left"><bold>4</bold></td><td align="left"><bold>6642</bold></td><td align="left"><bold>00172013</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;15.1870</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;68.2207</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;14.3979</bold></td><td char="." align="char"><bold>273.09</bold></td><td align="left"><bold>4</bold></td><td align="left"><bold>3</bold></td><td char="." align="char"><bold>45.32</bold></td><td align="left"><bold>6</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;4.025</bold></td><td char="." align="char"><bold>3.492</bold></td><td align="left"><bold>3.017</bold></td></tr><tr><td align="left"><bold>5</bold></td><td align="left"><bold>845</bold></td><td align="left"><bold>00602468</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;14.1645</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;88.3150</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.0884</bold></td><td char="." align="char"><bold>420.14</bold></td><td align="left"><bold>4</bold></td><td align="left"><bold>1</bold></td><td char="." align="char"><bold>55.76</bold></td><td align="left"><bold>9</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;5.027</bold></td><td char="." align="char"><bold>4.042</bold></td><td align="left"><bold>4.7</bold></td></tr><tr><td align="left">6</td><td align="left">1248</td><td align="left">06385634</td><td align="left">&#x2009;&#x2212;&#x2009;14.3651</td><td align="left">&#x2009;&#x2212;&#x2009;75.6116</td><td align="left">&#x2009;&#x2212;&#x2009;13.4581</td><td char="." align="char">269.14</td><td align="left">3</td><td align="left">0</td><td char="." align="char">29.54</td><td align="left">6</td><td align="left">&#x2009;&#x2212;&#x2009;3.151</td><td char="." align="char">3.263</td><td align="left">3.33</td></tr><tr><td align="left">7</td><td align="left">1376</td><td align="left">00144608</td><td align="left">&#x2009;&#x2212;&#x2009;14.4405</td><td align="left">&#x2009;&#x2212;&#x2009;69.2788</td><td align="left">&#x2009;&#x2212;&#x2009;13.8851</td><td char="." align="char">308.05</td><td align="left">3</td><td align="left">1</td><td char="." align="char">24.5</td><td align="left">2</td><td align="left">&#x2009;&#x2212;&#x2009;6.628</td><td char="." align="char">3.934</td><td align="left">4.912</td></tr><tr><td align="left">8</td><td align="left">1695</td><td align="left">06774077</td><td align="left">&#x2009;&#x2212;&#x2009;14.2986</td><td align="left">&#x2009;&#x2212;&#x2009;61.8526</td><td align="left">&#x2009;&#x2212;&#x2009;13.4795</td><td char="." align="char">301.1</td><td align="left">4</td><td align="left">0</td><td char="." align="char">42.16</td><td align="left">4</td><td align="left">&#x2009;&#x2212;&#x2009;6.661</td><td char="." align="char">4.171</td><td align="left">5.182</td></tr><tr><td align="left">9</td><td align="left">1756</td><td align="left">09022581</td><td align="left">&#x2009;&#x2212;&#x2009;14.3340</td><td align="left">&#x2009;&#x2212;&#x2009;68.3018</td><td align="left">&#x2009;&#x2212;&#x2009;12.3861</td><td char="." align="char">439.09</td><td align="left">7</td><td align="left">0</td><td char="." align="char">89.98</td><td align="left">9</td><td align="left">&#x2009;&#x2212;&#x2009;4.207</td><td char="." align="char">2.217</td><td align="left">2.079</td></tr><tr><td align="left">10</td><td align="left">1767</td><td align="left">09162570</td><td align="left">&#x2009;&#x2212;&#x2009;14.3654</td><td align="left">&#x2009;&#x2212;&#x2009;66.0381</td><td align="left">&#x2009;&#x2212;&#x2009;14.4081</td><td char="." align="char">441.14</td><td align="left">8</td><td align="left">2</td><td char="." align="char">100.99</td><td align="left">11</td><td align="left">&#x2009;&#x2212;&#x2009;4.626</td><td char="." align="char">2.365</td><td align="left">2.958</td></tr><tr><td align="left">11</td><td align="left">1779</td><td align="left">70821007</td><td align="left">&#x2009;&#x2212;&#x2009;14.3297</td><td align="left">&#x2009;&#x2212;&#x2009;64.1927</td><td align="left">&#x2009;&#x2212;&#x2009;13.4248</td><td char="." align="char">256.02</td><td align="left">5</td><td align="left">4</td><td char="." align="char">83.8</td><td align="left">4</td><td align="left">&#x2009;&#x2212;&#x2009;2.613</td><td char="." align="char">2.008</td><td align="left">1.764</td></tr><tr><td align="left">12</td><td align="left">1784</td><td align="left">01936510</td><td align="left">&#x2009;&#x2212;&#x2009;14.5485</td><td align="left">&#x2009;&#x2212;&#x2009;60.1780</td><td align="left">&#x2009;&#x2212;&#x2009;13.9095</td><td char="." align="char">520.97</td><td align="left">6</td><td align="left">1</td><td char="." align="char">81.7</td><td align="left">10</td><td align="left">&#x2009;&#x2212;&#x2009;6.241</td><td char="." align="char">3.565</td><td align="left">5.663</td></tr><tr><td align="left">13</td><td align="left">1818</td><td align="left">03679565</td><td align="left">&#x2009;&#x2212;&#x2009;14.1939</td><td align="left">&#x2009;&#x2212;&#x2009;74.5382</td><td align="left">&#x2009;&#x2212;&#x2009;13.4694</td><td char="." align="char">388.03</td><td align="left">6</td><td align="left">0</td><td char="." align="char">73.81</td><td align="left">6</td><td align="left">&#x2009;&#x2212;&#x2009;5.846</td><td char="." align="char">3.659</td><td align="left">4.67</td></tr><tr><td align="left">14</td><td align="left">1842</td><td align="left">23801148</td><td align="left">&#x2009;&#x2212;&#x2009;14.3834</td><td align="left">&#x2009;&#x2212;&#x2009;65.4343</td><td align="left">&#x2009;&#x2212;&#x2009;14.2173</td><td char="." align="char">139.11</td><td align="left">3</td><td align="left">2</td><td char="." align="char">46.33</td><td align="left">1</td><td align="left">&#x2009;&#x2212;&#x2009;0.127</td><td char="." align="char">0.65</td><td align="left">&#x2009;&#x2212;&#x2009;1.511</td></tr><tr><td align="left">15</td><td align="left">1859</td><td align="left">08440448</td><td align="left">&#x2009;&#x2212;&#x2009;14.3806</td><td align="left">&#x2009;&#x2212;&#x2009;64.4445</td><td align="left">&#x2009;&#x2212;&#x2009;13.1837</td><td char="." align="char">139.11</td><td align="left">3</td><td align="left">2</td><td char="." align="char">46.33</td><td align="left">1</td><td align="left">&#x2009;&#x2212;&#x2009;0.127</td><td char="." align="char">0.65</td><td align="left">&#x2009;&#x2212;&#x2009;1.511</td></tr><tr><td align="left">16</td><td align="left">1864</td><td align="left">02286212</td><td align="left">&#x2009;&#x2212;&#x2009;14.5748</td><td align="left">&#x2009;&#x2212;&#x2009;61.0770</td><td align="left">&#x2009;&#x2212;&#x2009;14.1747</td><td char="." align="char">387.19</td><td align="left">9</td><td align="left">2</td><td char="." align="char">109.04</td><td align="left">5</td><td align="left">&#x2009;&#x2212;&#x2009;2.361</td><td char="." align="char">0.78</td><td align="left">0.759</td></tr><tr><td align="left">17</td><td align="left">1910</td><td align="left">02011239</td><td align="left">&#x2009;&#x2212;&#x2009;14.4531</td><td align="left">&#x2009;&#x2212;&#x2009;71.4605</td><td align="left">&#x2009;&#x2212;&#x2009;13.4548</td><td char="." align="char">376.25</td><td align="left">3</td><td align="left">1</td><td char="." align="char">26.71</td><td align="left">3</td><td align="left">&#x2009;&#x2212;&#x2009;4.9</td><td char="." align="char">4.276</td><td align="left">4.652</td></tr><tr><td align="left">18</td><td align="left">2003</td><td align="left">00203409</td><td align="left">&#x2009;&#x2212;&#x2009;14.1781</td><td align="left">&#x2009;&#x2212;&#x2009;76.6683</td><td align="left">&#x2009;&#x2212;&#x2009;12.5920</td><td char="." align="char">333.08</td><td align="left">5</td><td align="left">2</td><td char="." align="char">75.63</td><td align="left">7</td><td align="left">&#x2009;&#x2212;&#x2009;3.255</td><td char="." align="char">2.267</td><td align="left">3.033</td></tr><tr><td align="left">19</td><td align="left">2016</td><td align="left">00857577</td><td align="left">&#x2009;&#x2212;&#x2009;14.3100</td><td align="left">&#x2009;&#x2212;&#x2009;77.4464</td><td align="left">&#x2009;&#x2212;&#x2009;12.6678</td><td char="." align="char">380.09</td><td align="left">5</td><td align="left">2</td><td char="." align="char">59.59</td><td align="left">5</td><td align="left">&#x2009;&#x2212;&#x2009;7.023</td><td char="." align="char">3.846</td><td align="left">5.156</td></tr><tr><td align="left">20</td><td align="left">2801</td><td align="left">03438390</td><td align="left">&#x2009;&#x2212;&#x2009;14.5130</td><td align="left">&#x2009;&#x2212;&#x2009;62.2155</td><td align="left">&#x2009;&#x2212;&#x2009;15.7829</td><td char="." align="char">257.11</td><td align="left">4</td><td align="left">1</td><td char="." align="char">55.4</td><td align="left">6</td><td align="left">&#x2009;&#x2212;&#x2009;3.265</td><td char="." align="char">2.383</td><td align="left">2.447</td></tr></tbody></table><table-wrap-foot><p>Significant values are in <bold>bold</bold>.</p></table-wrap-foot></table-wrap><table-wrap id="Tab21"><label>Table 21</label><caption><p>Molecular docking of OMP31 protein using MOE software integrated with ZINC database and ADMElab-2 server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Compound</th><th align="left" rowspan="2">mseq</th><th align="left" rowspan="2">ZINC database ID</th><th align="left" rowspan="2">Docking score (S )</th><th align="left" rowspan="2">Binding affinity Kcal/Mol</th><th align="left" rowspan="2">Binding energy Kcal/Mol</th><th align="left" colspan="8">Drug like properties</th></tr><tr><th align="left">MW</th><th align="left">Hydrogen bond acceptors</th><th align="left">Hydrogen bond donor</th><th align="left">Topological polar surface area (&#xC5;2)(TPSA)</th><th align="left">No. of rotatable bonds (nRot)</th><th align="left">logS</th><th align="left">logD</th><th align="left">logP</th></tr></thead><tbody><tr><td align="left"><bold>1</bold></td><td align="left"><bold>2339</bold></td><td align="left"><bold>22551309</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;14.7566</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;57.0108</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;11.3077</bold></td><td align="left"><bold>436.05</bold></td><td align="left"><bold>5</bold></td><td align="left"><bold>1</bold></td><td char="." align="char"><bold>66.48</bold></td><td align="left"><bold>7</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;4.317</bold></td><td align="left"><bold>3.077</bold></td><td align="left"><bold>3.526</bold></td></tr><tr><td align="left"><bold>2</bold></td><td align="left"><bold>55</bold></td><td align="left"><bold>00154214</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.3158</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;67.0866</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;11.7225</bold></td><td align="left"><bold>331.12</bold></td><td align="left"><bold>8</bold></td><td align="left"><bold>3</bold></td><td char="." align="char"><bold>113.73</bold></td><td align="left"><bold>9</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;4.364</bold></td><td align="left"><bold>2.58</bold></td><td align="left"><bold>2.432</bold></td></tr><tr><td align="left"><bold>3</bold></td><td align="left"><bold>118</bold></td><td align="left"><bold>10847947</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.4718</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;66.4300</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.2362</bold></td><td align="left"><bold>413.08</bold></td><td align="left"><bold>7</bold></td><td align="left"><bold>2</bold></td><td char="." align="char"><bold>98.66</bold></td><td align="left"><bold>6</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;4.38</bold></td><td align="left"><bold>2.749</bold></td><td align="left"><bold>2.285</bold></td></tr><tr><td align="left"><bold>4</bold></td><td align="left"><bold>1</bold></td><td align="left"><bold>00463723</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.2875</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;79.1861</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;9.8985</bold></td><td align="left"><bold>286.17</bold></td><td align="left"><bold>4</bold></td><td align="left"><bold>1</bold></td><td char="." align="char"><bold>49.41</bold></td><td align="left"><bold>9</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;3.032</bold></td><td align="left"><bold>2.621</bold></td><td align="left"><bold>2.762</bold></td></tr><tr><td align="left"><bold>5</bold></td><td align="left"><bold>215</bold></td><td align="left"><bold>04854502</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;13.3222</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;89.6962</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;10.6307</bold></td><td align="left"><bold>357.21</bold></td><td align="left"><bold>6</bold></td><td align="left"><bold>1</bold></td><td char="." align="char"><bold>55.73</bold></td><td align="left"><bold>6</bold></td><td align="left"><bold>&#x2009;&#x2212;&#x2009;4.369</bold></td><td align="left"><bold>3.356</bold></td><td align="left"><bold>2.916</bold></td></tr><tr><td align="left">6</td><td align="left">498</td><td align="left">00209757</td><td align="left">&#x2009;&#x2212;&#x2009;13.2673</td><td align="left">&#x2009;&#x2212;&#x2009;67.5074</td><td align="left">&#x2009;&#x2212;&#x2009;11.6586</td><td align="left">232.1</td><td align="left">2</td><td align="left">0</td><td char="." align="char">28.72</td><td align="left">2</td><td align="left">&#x2009;&#x2212;&#x2009;4.925</td><td align="left">3.577</td><td align="left">3.629</td></tr><tr><td align="left">7</td><td align="left">549</td><td align="left">01997915</td><td align="left">&#x2009;&#x2212;&#x2009;13.1373</td><td align="left">&#x2009;&#x2212;&#x2009;68.6614</td><td align="left">&#x2009;&#x2212;&#x2009;10.3566</td><td align="left">300.21</td><td align="left">2</td><td align="left">2</td><td char="." align="char">40.46</td><td align="left">1</td><td align="left">&#x2009;&#x2212;&#x2009;4.06</td><td align="left">4.526</td><td align="left">4.621</td></tr><tr><td align="left">8</td><td align="left">3314</td><td align="left">00249136</td><td align="left">&#x2009;&#x2212;&#x2009;13.0843</td><td align="left">&#x2009;&#x2212;&#x2009;77.5276</td><td align="left">&#x2009;&#x2212;&#x2009;11.5416</td><td align="left">281.04</td><td align="left">2</td><td align="left">1</td><td char="." align="char">29.1</td><td align="left">3</td><td align="left">&#x2009;&#x2212;&#x2009;3.899</td><td align="left">3.454</td><td align="left">3.821</td></tr><tr><td align="left">9</td><td align="left">2330</td><td align="left">08406377</td><td align="left">&#x2009;&#x2212;&#x2009;13.3601</td><td align="left">&#x2009;&#x2212;&#x2009;71.4889</td><td align="left">&#x2009;&#x2212;&#x2009;10.9435</td><td align="left">382.15</td><td align="left">6</td><td align="left">1</td><td char="." align="char">65.01</td><td align="left">4</td><td align="left">&#x2009;&#x2212;&#x2009;5.409</td><td align="left">2.374</td><td align="left">4.335</td></tr><tr><td align="left">10</td><td align="left">2382</td><td align="left">04249312</td><td align="left">&#x2009;&#x2212;&#x2009;13.3235</td><td align="left">&#x2009;&#x2212;&#x2009;65.1034</td><td align="left">&#x2009;&#x2212;&#x2009;10.9282</td><td align="left">382.18</td><td align="left">9</td><td align="left">2</td><td char="." align="char">108.15</td><td align="left">4</td><td align="left">&#x2009;&#x2212;&#x2009;2.817</td><td align="left">1.537</td><td align="left">1.253</td></tr><tr><td align="left">11</td><td align="left">2544</td><td align="left">00213986</td><td align="left">&#x2009;&#x2212;&#x2009;13.2476</td><td align="left">&#x2009;&#x2212;&#x2009;55.7252</td><td align="left">&#x2009;&#x2212;&#x2009;11.8620</td><td align="left">315.1</td><td align="left">9</td><td align="left">1</td><td char="." align="char">110.37</td><td align="left">3</td><td align="left">&#x2009;&#x2212;&#x2009;2.359</td><td align="left">1.035</td><td align="left">0.733</td></tr><tr><td align="left">12</td><td align="left">2606</td><td align="left">01185059</td><td align="left">&#x2009;&#x2212;&#x2009;13.8139</td><td align="left">&#x2009;&#x2212;&#x2009;71.8234</td><td align="left">&#x2009;&#x2212;&#x2009;12.6702</td><td align="left">352.96</td><td align="left">2</td><td align="left">1</td><td char="." align="char">29.1</td><td align="left">4</td><td align="left">&#x2009;&#x2212;&#x2009;6.712</td><td align="left">3.493</td><td align="left">4.87</td></tr><tr><td align="left">13</td><td align="left">2671</td><td align="left">03763174</td><td align="left">&#x2009;&#x2212;&#x2009;13.0252</td><td align="left">&#x2009;&#x2212;&#x2009;55.6920</td><td align="left">&#x2009;&#x2212;&#x2009;10.9952</td><td align="left">487.14</td><td align="left">6</td><td align="left">1</td><td char="." align="char">68.23</td><td align="left">8</td><td align="left">&#x2009;&#x2212;&#x2009;4.161</td><td align="left">3.796</td><td align="left">4.338</td></tr><tr><td align="left">14</td><td align="left">4621</td><td align="left">04945141</td><td align="left">&#x2009;&#x2212;&#x2009;13.2982</td><td align="left">&#x2009;&#x2212;&#x2009;62.6498</td><td align="left">&#x2009;&#x2212;&#x2009;9.7842</td><td align="left">411.19</td><td align="left">9</td><td align="left">0</td><td char="." align="char">83.52</td><td align="left">5</td><td align="left">&#x2009;&#x2212;&#x2009;4.282</td><td align="left">3.137</td><td align="left">2.848</td></tr><tr><td align="left">15</td><td align="left">2976</td><td align="left">06291344</td><td align="left">&#x2009;&#x2212;&#x2009;13.0929</td><td align="left">&#x2009;&#x2212;&#x2009;77.4419</td><td align="left">&#x2009;&#x2212;&#x2009;10.8202</td><td align="left">358.19</td><td align="left">6</td><td align="left">1</td><td char="." align="char">67.87</td><td align="left">7</td><td align="left">&#x2009;&#x2212;&#x2009;4.898</td><td align="left">2.706</td><td align="left">3.352</td></tr><tr><td align="left">16</td><td align="left">3029</td><td align="left">23007714</td><td align="left">&#x2009;&#x2212;&#x2009;13.0467</td><td align="left">&#x2009;&#x2212;&#x2009;59.5558</td><td align="left">&#x2009;&#x2212;&#x2009;11.7799</td><td align="left">391.15</td><td align="left">6</td><td align="left">0</td><td char="." align="char">69.63</td><td align="left">5</td><td align="left">&#x2009;&#x2212;&#x2009;5.156</td><td align="left">4.033</td><td align="left">4.148</td></tr><tr><td align="left">17</td><td align="left">3101</td><td align="left">00365021</td><td align="left">&#x2009;&#x2212;&#x2009;13.1618</td><td align="left">&#x2009;&#x2212;&#x2009;77.2706</td><td align="left">&#x2009;&#x2212;&#x2009;10.5110</td><td align="left">281.14</td><td align="left">3</td><td align="left">1</td><td char="." align="char">38.33</td><td align="left">4</td><td align="left">&#x2009;&#x2212;&#x2009;5.046</td><td align="left">3.534</td><td align="left">3.911</td></tr><tr><td align="left">18</td><td align="left">5803</td><td align="left">06540519</td><td align="left">&#x2009;&#x2212;&#x2009;13.0573</td><td align="left">&#x2009;&#x2212;&#x2009;66.0322</td><td align="left">&#x2009;&#x2212;&#x2009;10.7564</td><td align="left">320.14</td><td align="left">7</td><td align="left">3</td><td char="." align="char">98.72</td><td align="left">7</td><td align="left">&#x2009;&#x2212;&#x2009;1.952</td><td align="left">1.589</td><td align="left">1.386</td></tr><tr><td align="left">19</td><td align="left">7074</td><td align="left">00458067</td><td align="left">&#x2009;&#x2212;&#x2009;13.6052</td><td align="left">&#x2009;&#x2212;&#x2009;64.8078</td><td align="left">&#x2009;&#x2212;&#x2009;13.1387</td><td align="left">319</td><td align="left">3</td><td align="left">0</td><td char="." align="char">29.54</td><td align="left">6</td><td align="left">&#x2009;&#x2212;&#x2009;3.675</td><td align="left">3.006</td><td align="left">3.273</td></tr><tr><td align="left">20</td><td align="left">7128</td><td align="left">00156973</td><td align="left">&#x2009;&#x2212;&#x2009;13.0802</td><td align="left">&#x2009;&#x2212;&#x2009;67.6662</td><td align="left">&#x2009;&#x2212;&#x2009;11.2834</td><td align="left">129.08</td><td align="left">3</td><td align="left">2</td><td char="." align="char">49.33</td><td align="left">1</td><td align="left">0.025</td><td align="left">&#x2009;&#x2212;&#x2009;0.678</td><td align="left">&#x2009;&#x2212;&#x2009;2.836</td></tr></tbody></table><table-wrap-foot><p>Significant values are in <bold>bold</bold>.</p></table-wrap-foot></table-wrap><fig id="Fig4"><label>Figure 4</label><caption><p>The docking binding mode of BvrR protein and ZINC database. (<bold>A</bold>) ZID 022035210, (<bold>B</bold>) ZID 00395425, (<bold>C</bold>) ZID 019366239, (<bold>D</bold>) ZID 01695129, and (<bold>E</bold>) ZID 00168942.</p></caption><graphic xlink:href="41598_2024_61991_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Figure 5</label><caption><p>The docking binding mode of OMP25 protein and ZINC database. (<bold>A</bold>) ZID 02756403, (<bold>B</bold>) ZID 0486383, (<bold>C</bold>) ZID 09172386, (<bold>D</bold>) ZID 00172013, and (<bold>E</bold>) ZID 00602468.</p></caption><graphic xlink:href="41598_2024_61991_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Figure 6</label><caption><p>The docking binding mode of OMP31 protein and ZINC database (<bold>A</bold>) ZID 22551309, (<bold>B</bold>) ZID 00154214, (<bold>C</bold>) ZID 10847947, (<bold>D</bold>) ZID 00463723, and (<bold>E</bold>) ZID 04854502.</p></caption><graphic xlink:href="41598_2024_61991_Fig6_HTML" id="MO6"/></fig></p>
        </sec>
        <sec id="Sec18">
          <title>Toxicity prediction</title>
          <p id="Par27">The ProTox II server was used to predict the top five lead compounds from the ZINC database for each protein. As shown in (Table <xref rid="Tab22" ref-type="table">22</xref>), these compounds had almost the same probability. Furthermore, they exhibited no toxicity with nephrotoxicity, cardiotoxicity, carcinogenicity, mutagenicity, cytotoxicity, blood&#x2013;brain barrier (BBB) penetration, clinical toxicity, or nutritional toxicity, as shown in (Fig.&#xA0;<xref rid="Fig7" ref-type="fig">7</xref>).<table-wrap id="Tab22"><label>Table 22</label><caption><p>Toxicity prediction of the best lead compounds of each protein using ProTox II server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Target</th><th align="left">Prediction</th><th align="left">Probability</th></tr></thead><tbody><tr><td align="left" rowspan="8">Three target proteins (BvrR, OMP25, and OMP31)</td><td align="left">Nephrotoxicity</td><td align="left">Inactive</td><td align="left">0.90</td></tr><tr><td align="left">Cardiotoxicity</td><td align="left">Inactive</td><td align="left">0.77</td></tr><tr><td align="left">Carcinogenicity</td><td align="left">Inactive</td><td align="left">0.62</td></tr><tr><td align="left">Mutagenicity</td><td align="left">Inactive</td><td align="left">0.97</td></tr><tr><td align="left">Cytotoxicity</td><td align="left">Inactive</td><td align="left">0.93</td></tr><tr><td align="left">BBB-barrier</td><td align="left">Inactive</td><td align="left">1</td></tr><tr><td align="left">Clinical toxicity</td><td align="left">Inactive</td><td align="left">0.56</td></tr><tr><td align="left">Nutritional toxicity</td><td align="left">Inactive</td><td align="left">0.74</td></tr></tbody></table></table-wrap><fig id="Fig7"><label>Figure 7</label><caption><p>Toxicity prediction of the lead compound using ProTox II server.</p></caption><graphic xlink:href="41598_2024_61991_Fig7_HTML" id="MO7"/></fig></p>
        </sec>
        <sec id="Sec19">
          <title>Binding interactions of finally selected compounds</title>
          <p id="Par28">In the docking studies, it was observed that all the finally selected hits showed significant binding interactions with the important residues of the target proteins. The previously listed 15 compounds from the ZINC database, which demonstrated a strong binding affinity, lower binding energy, and good docking score, were observed and showed the binding interaction with the three target proteins binding site residues.</p>
          <p id="Par29">For the BvrR target protein, Gln 135 residue made a polar interaction with the (ZINC 019366239) compound and acted as a donor. Also, (the ZINC 022035210) compound established interactions with Arg 128 residue, which had two donor interactions, and Asp 102 residue which performed as a hydrogen acceptor from NH&#x2009;+&#x2009;. Gln 135 residue of docking pose of (ZINC 003954125) compound display as a donor. In (ZINC 01695129) compound, it made polar and acidic interactions with Glu 150 and Gln 135 residues, which behaved as hydrogen acceptors and as donors, respectively. What&#x2019;s more, Arg 74 and 128 were involved in basic interactions with the (ZINC 00168942) compound. They exhibited as donors and made arene-cation interactions with benzene rings, respectively (Fig.&#xA0;<xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8"><label>Figure 8</label><caption><p>Ligand interaction of BvrR protein and molecules from ZINC database.</p></caption><graphic xlink:href="41598_2024_61991_Fig8_HTML" id="MO8"/></fig></p>
          <p id="Par30">For the OMP25 target protein, Lys 75 residue had basic interaction and made an arene-cation with the benzene ring of the (ZINC 02756403) compound. While Trp 101 and Arg 156 residues were involved in greasy and basic interactions, respectively in the (ZINC 04086383) compound and do arene-cation interaction with the benzene ring of the compound. According to the docking pose of the (ZINC 00172013) compound, basic interactions with Lys 75 and Arg 156 residues occurred. They made arene-cation with the benzene ring of the ligand and acted as donors for carbonyl oxygen, respectively. Also, Trp 101 has a greasy interaction and activates arene-arene with the benzene ring of the ligand. Moreover, Lys 75 and Arg 156 residues were involved in different basic interactions with the (ZINC 09172386) compound and made arene-cation with its benzene ring. Furthermore, Arg 156 residue interacted with the (ZINC 00602468) compound and had two interactions; it operated as a donor for carbonyl oxygen and performed arene-cation with the benzene ring of the compound (the same as what Lys 75 residue made). Additionally, Trp 101 created an arene-arene interaction benzene ring with the ligand (Fig.&#xA0;<xref rid="Fig9" ref-type="fig">9</xref>).<fig id="Fig9"><label>Figure 9</label><caption><p>Ligand interaction of OMP25 protein and molecules from the ZINC database.</p></caption><graphic xlink:href="41598_2024_61991_Fig9_HTML" id="MO9"/></fig></p>
          <p id="Par31">It was observed that the compound (ZINC 00154214) established an interaction with the Gly 90 residue of the OMP31 target protein. This residue acted as a donor of hydrogen to a hydroxyl group of the compound. While Ser 114 residue interacted with the (ZINC 00463723) compound and displayed as an acceptor of hydrogen. Also, Ser 114 and Gly 113 residues interacted with (ZINC 04854502) compounds and exhibited as donors. Furthermore, (ZINC 10847947) compound made interactions with Ser 114 and Thr 252 residues, which played as hydrogen acceptors from nitrogen monohydride and acceptor, respectively. According to the docking pose of the (ZINC 22551309) compound, Gln 112 interacted with it and operated as an acceptor, and Phe150 made an arene-arene with a benzene ring of it (Fig.&#xA0;<xref rid="Fig10" ref-type="fig">10</xref>).<fig id="Fig10"><label>Figure 10</label><caption><p>Ligand interaction of OMP31 protein and molecules from the ZINC database.</p></caption><graphic xlink:href="41598_2024_61991_Fig10_HTML" id="MO10"/></fig></p>
        </sec>
      </sec>
      <sec id="Sec20">
        <title>Molecular dynamic simulation</title>
        <p id="Par32">To predict the nature and the interactions of the docked proteins with their best ligands, a molecular dynamics simulations (MDS) study was applied to BvrR&#x2009;+&#x2009;ZINC 022035210, OMP25&#x2009;+&#x2009;ZINC 02756403, and OMP31&#x2009;+&#x2009;ZINC 22551309 complexes. The study used parameters such as root mean square deviations (RMSDs), gyration radius (Rg), root mean square fluctuations (RMSFs), and solvent-accessible surface area (SASA).</p>
        <p id="Par33">The process had a time function of 100&#xA0;ns, and the changes in bonds and trajectories were analyzed. The RMSD values of the BvrR protein and its ligand were initially observed to increase gradually from 1 to 2&#xA0;nm. This trend continued until 38&#xA0;ns of simulation had elapsed, at which point they began fluctuating widely. Overall, the RMSD values ranged from 3 to 6&#xA0;nm until the end of the simulations. The average RMSF value was 0.20&#x2009;&#xB1;&#x2009;0.08&#xA0;nm, with greater fluctuations observed in residues 130 to 140 and 1 to 10. The average Rg was 1.99&#x2009;&#xB1;&#x2009;0.02&#xA0;nm, with fluctuation decreasing from 2.05&#xA0;nm to 1.95&#xA0;nm. Similarly, the SASA had an average of 140.45&#x2009;&#xB1;&#x2009;4.23 nm<sup>2</sup> and remained stable until 80&#xA0;ns, after which it decreased to 130 nm<sup>2</sup> (Fig.&#xA0;<xref rid="Fig11" ref-type="fig">11</xref>).<fig id="Fig11"><label>Figure 11</label><caption><p>Molecular dynamic simulation of the docked BvrR protein and ZINC 022035210 complex generated at 100 ns. (<bold>a</bold>) RMSD, (<bold>b</bold>) RMSF, (<bold>c</bold>) Rg, and (<bold>d</bold>) SASA.</p></caption><graphic xlink:href="41598_2024_61991_Fig11_HTML" id="MO11"/></fig></p>
        <p id="Par34">The OMP25 and its ligand (ZINC 02756403) were initially observed to increase gradually from 0.4 to 2.4&#xA0;nm. This trend continued until 50&#xA0;ns of simulation, then stable region of 2.5&#xA0;nm during the simulation period of 60 to 100&#xA0;ns (Fig.&#xA0;<xref rid="Fig12" ref-type="fig">12</xref>).<fig id="Fig12"><label>Figure 12</label><caption><p>Molecular dynamic simulation of the docked OMP25 protein and ZINC 02756403 complex generated at 100 ns. (<bold>a</bold>) RMSD, (<bold>b</bold>) RMSF, (<bold>c</bold>) Rg, and (<bold>d</bold>) SASA.</p></caption><graphic xlink:href="41598_2024_61991_Fig12_HTML" id="MO12"/></fig></p>
        <p id="Par35">The OMP31 and its ligand (ZINC 22551309) showed highly fluctuating RMSD values with a small stable region of 1.7&#xA0;nm during the simulation period of 3 to 18&#xA0;ns. The RMSF showed an average of 0.35&#x2009;&#xB1;&#x2009;0.18&#xA0;nm, and the highest fluctuating area was between 50 to 80 amino acids. The average Rg value was 2.04&#x2009;&#xB1;&#x2009;0.06&#xA0;nm, with stability at 2.05&#xA0;nm within the range of 10 to 80&#xA0;ns and 1.95&#xA0;nm within the range of 85 to 100&#xA0;ns, supporting the stability of the SASA values throughout the simulation period, with an average of 166.96&#x2009;&#xB1;&#x2009;7.14 nm<sup>2</sup> (Fig.&#xA0;<xref rid="Fig13" ref-type="fig">13</xref>).<fig id="Fig13"><label>Figure 13</label><caption><p>Molecular dynamic simulation of the docked OMP31 protein and ZINC 22551309 complex generated at 100 ns. (<bold>a</bold>) RMSD, (<bold>b</bold>) RMSF, (<bold>c</bold>) Rg, and (<bold>d</bold>) SASA.</p></caption><graphic xlink:href="41598_2024_61991_Fig13_HTML" id="MO13"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec21">
      <title>Discussion</title>
      <p id="Par36">Brucellosis is the most prevalent zoonotic disease globally, causing immense economic losses<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Its pathogenicity is due to its virulence factors that facilitate intracellular replication and survival adaptation<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. This leads to over 500,000 new infection cases annually<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. According to prior studies, the BvrR/BvrS system is a master regulator of the homeostasis of the cell membrane, nitrogen, and carbon metabolism, and virulence proteins such as OMPs<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. The BvrR protein identified one domain using the CDD server which is OmpR. It is defined as a DNA-binding response regulator and belongs to the OmpR family that contains winged helix-turn-helix (wHTH) and REC domains. Histidine kinases (HK) and a response regulator protein (RR) are two common components used in the majority of bacterial signal-transduction systems<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Our result was agreed with Ref.<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> who identified that the BvrR protein has sequence that responsible for regulation of the OMP25 protein. The regulatory domain phosphorylation generates a conformational change that leads to the activation of a related domain, which influences the response<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. The phosphorylable aspartate residue is located in the conserved acidic pocket that serves as the active site<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. The OmpR/PhoB subfamily is the largest subfamily of RRs and harbors several transcriptional regulators, including the Trans_reg_C domain located at the BvrR protein's C-terminal. This domain is typically accompanied by the REC domain to perform a DNA binding function<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Because of these domain structures, the BvrR protein is considered the transductor of environmental signals and adaptation of the intracellular lifestyle of <italic>Brucella</italic> and this is the same finding of Ref.<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>.</p>
      <p id="Par37">Additionally, OMP25 and OMP31 proteins were stable, very conservative, difficult to degrade, and triggered potent immune response<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. These two proteins were identified with the same domain, LomR, using the CDD server and this agreed with Ref.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> who discovered the conserved candidate antigens among three <italic>Brucella</italic> species. It is described as opacity proteins and associated surface antigens [membrane/envelope biosynthesis/Cell wall]<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The Opacity-associated (Opa) adhesin proteins are the main phase-variable proteins present in Pathogenic <italic>Neisseria</italic> species at the outer membrane, enabling them to evade the human immune system for extended periods, just like <italic>Brucella</italic>. These proteins have a role in bacterial adhesion, entrance, and interaction with the host immune system inhibition in T, and B cells and innate inflammatory reactions<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Furthermore, these proteins are linked to other porins, which act as large aqueous channels permitting the entry and selection of hydrophilic substances through a molecular sieve in the gram-negative bacteria cell wall<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p>
      <p id="Par38">Therefore, it was significant to select these three target proteins (BvrR, OMP25, and OMP31) as candidate proteins for constructing a multi-epitope vaccine against <italic>Brucella</italic> due to their important structural function. As far as we are aware, none of these three candidate proteins have been used to design multi-epitope vaccines based on them. Hence, this study gave comprehensive insights into the initial stages of vaccine development, including the secondary and tertiary structure of proteins, and cell epitopes. The secondary and tertiary structures of these three target proteins are analyzed to obtain the allocation and the percentage of alpha-helix, beta-sheet, random coil, and beta-turn in the protein structure. The random coil and beta-turn regions, primarily on the protein surface, are crucial for forming linear B cell epitope regions<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, while the alpha-helix and beta-sheet are necessary for preserving the protein's secondary structure integrity<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. The prediction of the secondary structure in this study using the PredictProtein server agreed with a study conducted by Ref.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. This study combines immunoinformatics and virtual screening techniques to identify potential epitopes for a designed multi-epitope vaccine against brucellosis and potential drug candidates for inhibiting the BvrR, OMP25, and OMP31 proteins in <italic>Brucella</italic>.</p>
      <p id="Par39">A posttranslational modification (PTM) detects the overall protein structure and function in several biological processes including replication, transcription, translation, apoptosis, cell signaling, and others<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Protein phosphorylation is considered one of the most common and vital PTMs, as various enzymes and receptors are activated or deactivated through phosphorylation or dephosphorylation actions, via kinases as well as phosphatases<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Casein kinase II (CK-2), is an&#xA0;active Ser/Thr protein kinase that phosphorylates many numbers of substrates, regulates several signaling pathways, and is associated with a wide range of human diseases, especially tumors<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Myristoylation is the lipid modification process of the protein, which is important in protein&#x2013;protein interactions, cell signaling, and targeting proteins to the plasma membrane and endomembrane systems<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. Protein glycosylation is deemed to be one of the most significant PTMs, and more than half of all proteins in nature are anticipated to be glycosylated. Putative N-glycosylation locations are specific only to the consensus sequence Asn-Xaa-Ser/Thr. However, protein folding plays an integral part in regulating N-glycosylation, and the existence of the consensus tripeptide alone cannot determine whether an asparagine residue is glycosylated<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>.</p>
      <p id="Par40">Research on&#xA0;<italic>Brucella</italic>&#xA0;subunit vaccines has mainly concentrated on protein vaccines, DNA vaccines,&#xA0;and lipopolysaccharide vaccines. With the quick development of bioinformatics, it is now possible to identify the epitopes of diverse antigens using in silico to create a unique vaccination candidate that can trigger desired immune responses<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. An essential part of the <italic>Brucella</italic> infection's early phases is played by humoral immunity. However, cellular immunity is primarily responsible for the successful immune response when <italic>Brucella</italic> is present inside the cell<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Active T cells are crucial for the immunological response to <italic>Brucella</italic>. Most vaccines, however, can only boost B-cell immunity. <italic>Brucella</italic> is successfully exposed to the outside of cells by CD8&#x2009;+&#x2009;T cells, which also activates additional germicidal processes.&#xA0;Taking into account the requirement for CD4&#x2009;+&#x2009;T cells to initiate a proper antibody immune response. The epitope prediction, vaccine construction, and validation have been carried out in this study and our result was agreed with Ref.<sup><xref ref-type="bibr" rid="CR42">42</xref>&#x2013;<xref ref-type="bibr" rid="CR47">47</xref></sup> who designed various vaccines against <italic>Brucella</italic>, SARS-CoV-2, and <italic>Staphylococcus aureus</italic>. EAAAK, GPGPG, and AAY linkers were used to connect B-cell, T-cell and helper epitopes. These linkers mitigate the formation of novel epitopes, which is a significant challenge in enhancing recombinant vaccines, while also boosting binding and expression. The EAAAK linker was chosen as an adjuvant linker. The GPGPG aids in triggering the immune response by enhancing the HTL. To prevent the development of new epitopes, the CTL epitopes were connected using AAY<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. The immunogenicity, non-allergenicity, and toxicity of these epitopes were evaluated through the application of immunoinformatic tools, and the effectiveness of such tools was examined in the research conducted by Ref.<sup><xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup>. The constructed vaccine is highly recommended to be a synthetic multi-epitope vaccine in the future, based on B-T cell epitopes for activation of particular B cells, CTL, and THL to produce full coverage protection and long-lasting immune response in vivo.</p>
      <p id="Par41">Virtual screening techniques are currently considered to be effective means for accelerating the drug discovery process. Docking seeks to anticipate the structure of the ligand&#x2013;protein interaction by investigating the conformational space of the ligands within the protein's binding site<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Here, the docking protocol implemented in the MOE program was applied. The ligands were ordered according to the results of the binding free energy calculation using the Generalized-Born Volume Integral/Weighted Surface Area (GBVI/WSA) in the S field, which is the result of the final stage. The GBVI/WSA is a scoring function that determines the ligand's free energy of binding from a specific position. Lower scores corresponded to more favorable poses for all grading criteria. Following docking and scoring, ranked compounds are post-processed by considering factors such as binding scores derived, the accuracy of the generated pose, metabolic liabilities, unwanted chemical moieties, chemical diversity, desired physicochemical qualities, and lead-likeness. After post-processing, a select few compounds are revealed, and these are tested experimentally<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>.</p>
      <p id="Par42">Because drug-like compounds have favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, drug-likeness is a crucial factor<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. The drug score, which assesses a compound's overall potential to be a drug, combines drug-likeness, LogP, logS, MW, and toxicity concerns into one important value. The features of each hit ligand were examined for Lipinski's rule of five to determine the druggability of the recovered hits and this agreed with Ref.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. According to Lipinski's "rule of five," drug-like molecules require a MW of less than 500&#xA0;Da, a logP value of less than 5, and hydrogen bond acceptors and donors of less than 10 and 5, respectively; otherwise, they will have poor penetration or absorption<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. In the present study, a potent inhibitor of <italic>Brucella</italic> BvrR, OMP25, and OMP31 proteins was successfully identified using a SBVS of the ZINC 20 and DrugBank databases. The top five hits of the BvrR, OMP25, and OMP31 proteins from ZINC were (ZID 022035210, ZID 003954125, ZID 019366239, ZID 01695129, and ZID 00168942), (ZID 02756403, ZID 04086383, ZID 09172386, ZID 00172013, and ZID 00602468) and (ZID 22551309, ZID 00154214, ZID 10847947, ZID 00463723 and ZID 04854502), respectively. These compounds could be considered as lead molecules for inhibition of the three target proteins and exhibit favorable ADMET parameters according to the score of Lipinski&#x2019;s rule. Otherwise, the best ligands from DrugBank (DB01901, DB01999, DB01141, DB01741, and DB01753), (DB00569, DB01901, DB01141, DB02516, and DB00362) and (DB00569, DB01111, DB02524, DB00006, and DB01141) of BvrR, OMP25, and OMP31 proteins, respectively, were not compatible to Lipinski&#x2019;s rule for estimation the ADMET parameters because of MW more than 500&#xA0;Da, hydrogen bond acceptor more than ten, and hydrogen bond donor more than five. Toxicity risk alerts are an indication that the drawn structure may be harmful concerning the risk category specified<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>.</p>
      <p id="Par43">Through immunoinformatics and virtual screening, the research focused on the identification of potential epitopes, which enabled the designing of a multi-epitope vaccine against brucellosis and the identification of potential drug candidates for the BvrR, OMP25, and OMP31 proteins in <italic>Brucella</italic>. The implementation of this strategy resulted in leading molecules that satisfied Lipinski's rule of five and also the right ADMET parameters. These findings may play a critical role in vaccine development and anti-<italic>Brucella</italic> drug discovery. However, more research is warranted to confirm the vaccine protein epitopes and lead compounds in vitro and in vivo.</p>
    </sec>
    <sec id="Sec22">
      <title>Conclusion</title>
      <p id="Par44">In conclusion, domain prediction comes first in target structure prediction. Several bioinformatics servers were used in this study to analyze, predict, and identify protein binding motifs related to the biological functions of the three target proteins (BvrR, OMP25, and OMP31). In addition, this approach predicted regions that were conserved within a family, secondary structure, solvent accessibility, tertiary structure, interaction motifs, and PTM sites. The best models of the 3-D structural proteins for the three target proteins were obtained from AlphaFold and I-TASSER servers after refinement and energy minimization according to C-score, TM-score, RMSD, and Z-score. The other aim of this study was to predict and design a multiepitope vaccine and a new potential drug that can be safe, enter the organism, reach its biological target, and elicit the desired effect for brucellosis in animals and humans, respectively. The three target proteins revealed (5, 6, and 5), (3, 4, and 4), and (4, 5, and 4) dominant B cell, CTL, and THL epitopes prediction, respectively. These overlapped epitopes were used to design a chimeric vaccine with 698 aa, that are highly recommended to be used as MEV and manufactural as a synthetic peptide or vector-based candidate vaccine. Additionally, in this present study, a potent inhibitor of <italic>Brucella</italic> BvrR, OMP25, and OMP31 proteins was successfully identified as a prospective drug with novel binding qualities, better mutant potency profile, unique mechanisms of action, increased potency, and pharmacokinetics through SBVS of the ZINC 20 lead database screening collection. Finally, we reach the best five ligands for each protein as the lead compound to inhibit the function of the three target proteins (BvrR, OMP25, and OMP31). The integration of protein modeling and functional analysis of the three target proteins led to detect the active site, which was utilized in the development of vaccine design using epitope prediction and drug design using virtual screening. The confirmation of the hypothesized epitopes will be performed, and the current lead compounds will be enhanced through additional research. Therefore, there is a requirement for more in vitro and in vivo tests so that the safety, efficacy, and toxicity of the vaccine and drug products can be confirmed. The study has pointed out how medicinal remedies may be designed using bioinformatics, virtual screening, and experimental validation.</p>
    </sec>
    <sec id="Sec23">
      <title>Materials and methods</title>
      <sec id="Sec24">
        <title>Data retrieval</title>
        <p id="Par45">We retrieved the three target protein sequences of <italic>Brucella</italic> from the UniProt Knowledgebase (UniProtKB). BvrR protein is 237 amino acids (accession number O67996), OMP25 protein is 213 amino acids (accession number Q44664), and OMP31 protein is 261 amino acids (accession number F8WJS1).</p>
      </sec>
      <sec id="Sec25">
        <title>Domain prediction</title>
        <p id="Par46">The initial step for the 3-D structure prediction is domain separation accurately. The domains of the three proteins (BvrR, OMP25, and OMP31) were predicted using CDD tool<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> and SMART tool<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. CDD is a primary sequence annotation tool that discovers new domain families and gives names and attributions for conserved domain architectures. SMART is a comprehensive analysis tool that can predict protein domain architecture, motif, protein classification, and multiple sequence alignment, providing additional information regarding a protein's structural features, evolutionary origin, and function.</p>
      </sec>
      <sec id="Sec26">
        <title>Secondary structural and solvent accessibility prediction</title>
        <p id="Par47">Nine servers were used for secondary structural and solvent accessibility prediction: PSIPRED<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>, NPS@ SOPMA<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>, CFSSP<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>, PSSpre<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>, Lambada Predict Protein<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>, GOR<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>, PredictProtein<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>, PROTEUS2<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, and RaptorX server. All these servers are established on neural networks in their methods, while PSIPRED applies two feed-forward neural networks and RaptorX relies on a deep learning machine<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. The prediction from different servers increases the level of accuracy and reliability of the result by deepening the consensus between them. This approach decreases the error occurrence, while the precision of the secondary structural elements and the solvent accessibility value in a protein sequence increase.</p>
      </sec>
      <sec id="Sec27">
        <title>3D structure prediction</title>
        <p id="Par48">The Robetta server<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>, Swiss-Model server<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>, I-TASSER server<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>, and AlphaFold server<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> were used for homology modeling prediction. Meta-servers like the LOMETS3 server use fold recognition prediction<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. For the <italic>ab-initio</italic> structure method, the I-TASSER, Phyre2 servers<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>, C-QUARK server<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, and CEthreader<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> were used. Employing multiple servers for the prediction of 3D structures assures the utilization of several techniques and algorithms, this indirectly contributes to the accuracy of the predictions. Additionally, fusing findings from multiple devices takes care of any biases that can be in individual devices&#x2019; algorithms. I-TASSER was the best server according to CASP 11, CASP 12, CASP 13, and CASP 14, while AlphaFold was the best one for CASP 15.</p>
      </sec>
      <sec id="Sec28">
        <title>Model refinement</title>
        <p id="Par49">The DeepRefiner<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>, Galaxy WEB<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>, trRossetta<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>, Modrefiner<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>, PREFMD<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>, and ReFOLD<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> were used. These servers&#x2019; function is to simultaneously enhance local and global structural properties of the basic models, bringing them closer to the native state while requiring little computational effort. The refining approach consists of two steps: the first stage optimizes the hydrogen bonding (HB) network, while the second step uses composite physics and knowledge-based force fields to apply atomic-level energy reduction to the optimized model<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>.</p>
      </sec>
      <sec id="Sec29">
        <title>Model evaluation</title>
        <p id="Par50">The two biggest problems in protein structure prediction are sampling and rating structural models. To rank and assess protein structural models, new large-scale model quality assessment (QA) techniques are combined with model clustering. We evaluated the refinement category predictions through different measures (RMSD, TM-score, Z-score, QMEAN, MolProbity score, clash score, overall quality, and Ramachandran Favored (RF)). These measures evaluated complementary aspects of model quality including dihedral angles, distributions of inter-atomic connections, and overall fold. SAVES meta server<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>, PROCHECK server<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>, TM-Score server<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>, TM-align server<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>, QMEAN<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>, Structure Assessment server<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, and trRossetta<sup><xref ref-type="bibr" rid="CR77">77</xref></sup> were used for the evaluation of the three target protein structure prediction.</p>
      </sec>
      <sec id="Sec30">
        <title>Functional motif prediction</title>
        <p id="Par51">The primary advantage of motifs is that they can find remote sequence relationships and protein&#x2013;protein interactions (PPI). There are two methods for obtaining information on motifs. The first method involved using the PROSITE server, which matched regular expressions with a query sequence<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. The second method involved employing a SMART server that expressed the sequence data from a multiple sequence alignment using probabilistic models after applying HMMs to retain the information. It also exposed intrinsic features like signal sequences, transmembrane helices, compositionally biased regions, and coiled-coil regions, in addition to domains<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Also, MotifFinder and Motif Scan tools were used<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>.</p>
      </sec>
      <sec id="Sec31">
        <title>Structural classification</title>
        <p id="Par52">InterPro, SUPERFAMILY 2.0, and CATH databases were used. The InterPro database creates a complete resource for protein classification by combining signatures denoting similar families, domains, or locations with extra data like descriptions, literature references, and GO keywords<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. Also, the SUPERFAMILY 2.0 database covers&#xA0;superfamily&#xA0;domain annotations for millions of protein sequences that are taken from the NCBI and the UniProtKB<sup><xref ref-type="bibr" rid="CR88">88</xref></sup>. Additionally, the CATH database also recognizes domains in protein structures from the wwPDB and categorizes these into evolutionary superfamilies, providing structural and functional annotations<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>.</p>
      </sec>
      <sec id="Sec32">
        <title>B cell epitope prediction</title>
        <p id="Par53">Prediction of B cell epitope in a more effective way to replace antigens for antibody production. For linear B cell epitope prediction, SVMTriP<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>, Bepipred 2.0 at Immune Epitope Database and Analysis Resource (IEDB), and BCEPS servers were used<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Based on sequence properties of the antigen employing amino acid scales and HMMs, all of these servers are regarded as the best in terms of accuracy and area under the curve (AUC)<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. However, antibodies can recognize discontinuous B-cell epitopes in over 90% of cases. These discontinuous epitopes are made up of sequences that are connected by protein folding characteristics but are separated by long-distance pathogenic protein sequences<sup><xref ref-type="bibr" rid="CR91">91</xref></sup>. The ElliPro server was used to predict 3-D structures using B-cell epitopes<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>.</p>
      </sec>
      <sec id="Sec33">
        <title>T cell epitope prediction</title>
        <p id="Par54">MHC I and MHC II molecules present T cell epitopes, which are recognized by two different T cell subsets, CD8&#x2009;+&#x2009;and CD4&#x2009;+&#x2009;T cells, respectively. The human leucocyte antigen (HLA) gene complex is also known as human MHC. After becoming activated, CD4&#x2009;+&#x2009;T cells recognize HLA-II-restricted antigenic epitopes with lengths of 9 to 22 amino acids and develop into T helper lymphocytes (THL). After being activated, CD8&#x2009;+&#x2009;T cells recognize HLA-I-restricted 8&#x2013;12 amino acid residue epitopes and undergo differentiation into cytotoxic T lymphocytes (CTLs). HLA-A * 0101 and HLA-A * 0201 discerned by MHC -I and HLA-DRB * 0701 and HLA-DRB * 0901 discerned by MHC -II were selected in the used servers<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. RANKPEP<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>, SYFPEITHI<sup><xref ref-type="bibr" rid="CR94">94</xref></sup>, and MHCII-NP<sup><xref ref-type="bibr" rid="CR95">95</xref></sup> tools were used.</p>
      </sec>
      <sec id="Sec34">
        <title>Prediction of antigenicity, allergenicity, and toxicity</title>
        <p id="Par55">To predict the antigenicity, the VaxiJen v2.0 server was used<sup><xref ref-type="bibr" rid="CR96">96</xref></sup>. Then, the AllergenFP v.1.0 server was applied to calculate the protein&#x2019;s total sensitivity<sup><xref ref-type="bibr" rid="CR97">97</xref></sup>. In addition, the ToxinPred server was used to predict the toxicity of each selected epitope<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>.</p>
      </sec>
      <sec id="Sec35">
        <title>Vaccine construction and validation</title>
        <p id="Par56">Vaccine construction was done using the PADRE (peptide AKFVAAWTLKAAA) sequence as an adjuvant to bind to the N-terminal of the vaccine. Four main types of linkers such as EAAAK, GPGPG, AAY, and KK were used as described in Ref.<sup><xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR99">99</xref></sup>. The final overlapped epitopes from B-cell, CTL, and HLT epitopes were merged to reduce the size of the constructed vaccine. Consequently, the adjuvant, EAAAK, and the linkers of the antigenic epitopes are fused in the order of the adjuvant sequence, CTL, AAY, HTL, GPGPG, B-cell, and KK, to eventually get a consolidated and highly potent vaccine.</p>
        <p id="Par57">After designing the vaccine, the antigenicity, allergenicity, and toxicity of the final constructed vaccine were predicted by Vaxijen v2.0, AllergenFP v.1.0, and ToxinPred servers, respectively. The physicochemical properties also were computed using Expasy's ProtParam<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>.</p>
      </sec>
      <sec id="Sec36">
        <title>Secondary, tertiary structure prediction and refinement of the chimeric vaccine</title>
        <p id="Par58">The secondary prediction of the constructed vaccine was predicted using SOMPA and PredictProtein servers. The tertiary structure prediction was carried out using I-TASSER, AlphaFold, and Swiss Model servers. Then, the 3-D structure of the chimeric vaccine was refined by the Galaxy Refine server<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. The refined 3-D structure of the vaccine was validated by the structural assessment server, ERRAT, and SAVES meta-server<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>.</p>
      </sec>
      <sec id="Sec37">
        <title>Protein preparation schemes for SBVS</title>
        <p id="Par59">Proper structure-based virtual screening (SBVS) is based on appropriate starting structures for the protein and the ligand. The recommended approach is to first calculate the protonation statuses of the amino acids in the protein and then energy minimization using MOE software version 2009<sup><xref ref-type="bibr" rid="CR101">101</xref></sup>. The default energy minimization parameters were applied, with the forcefield being MMFF94x and a gradient of 0.05, with the "calculate forcefield partial charge" option enabled. The subsequent steps involve assigning hydrogen atoms to improve protein hydrogen bonds and implementing an ideal hydrogen bond network<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>.</p>
      </sec>
      <sec id="Sec38">
        <title>Binding site identification</title>
        <p id="Par60">Executing SBVS frequently also requires binding site detection. The target binding site should ideally be a pocket, typically concave, with several possible hydrogen bond acceptors and donors as well as hydrophobic characteristics. The assignment of hydrogen atoms and improvement of protein hydrogen bonds by an ideal hydrogen bond network is the subsequent step<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. The MOE program's "Site Finder" feature identified the binding site.</p>
      </sec>
      <sec id="Sec39">
        <title>Compound database preparation for SBVS</title>
        <p id="Par61">The next critical phase of the SBVS process is the creation of compound databases. Small compound databases used in SBVS contain drug-like compounds that are frequently publicly available or may be obtained through purchase or synthesis and have desirable properties, including stability and solubility in aqueous media. ZINC20 database<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> and DrugBank 5.0 database<sup><xref ref-type="bibr" rid="CR105">105</xref></sup> were used for virtual screening. 3,687,621 and 11,586 drug lead molecules from the ZINC20 database and DrugBank 5.0 database, respectively were selected and are ready to be screened virtually.</p>
      </sec>
      <sec id="Sec40">
        <title>Molecular docking</title>
        <p id="Par62">Each molecule in the library is virtually docked into the target binding site for each of the three target proteins (BvrR, OMP25, and OMP31) using the MOE program following protein structure preparation<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>. The first scoring function and refinement were adjusted to default London dG and forcefield, respectively. The resulting binding interactions between these hits and protein observed by evaluating binding energy, binding affinity, and docking score were analyzed for binding interactions using LigPlot, which is implemented in MOE<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>.</p>
      </sec>
      <sec id="Sec41">
        <title>ADMET prediction (adsorption, distribution, metabolism, excretion and toxicity)</title>
        <p id="Par63">The docking findings were filtered based on the binding affinity scores and ADME properties since the early assessment of ADME properties can significantly reduce the likelihood of pharmacokinetics-related failure in the clinical phases<sup><xref ref-type="bibr" rid="CR108">108</xref></sup>. In silico screening of the pharmacological properties of ADME was performed and the compounds were evaluated for drug-likeness using the ADMETlab 2.0 web tool<sup><xref ref-type="bibr" rid="CR109">109</xref></sup>. The toxicity of the lead compounds was predicted using ProTox II server<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>. The drug-likeness prediction relied on several rules, including Lipinski, Pfizer, Golden, and GSK. The pharmacokinetics properties observed were molecular weight (MW), H-bond Donor, H-bond Acceptor, No. of Rotatable Bonds (nRot), Topological polar surface area (TPSA), LogS, LogD, and LogP (partition coefficient)<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>.</p>
      </sec>
      <sec id="Sec42">
        <title>Molecular dynamics simulation</title>
        <p id="Par64">GROMACS-2021.3 was utilized to carry out a molecular dynamic simulation of the three target proteins and the best protein&#x2013;ligand complexes. The interactions were estimated using the CHARMM27 force field, TIP3P water molecule model, and cubic box set at a 10 &#xC5; distance from the surrounding edges. Additionally, Na&#x2009;+&#x2009;and Cl&#x2013; ions at a concentration of 0.15M were applied<sup><xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR112">112</xref></sup>. The electrostatic interactions were evaluated using the particle-Ewald summation<sup><xref ref-type="bibr" rid="CR113">113</xref></sup>, while the estimation of van der Waals (VdW) interactions employed a 10 nm cut-off. The systems were energy-minimized for 5000 steps using the steepest descent and conjugate gradient algorithms followed by NPT and NVT equilibrium phases. Each process lasted 500 ps, and an integration step of 2fs was used<sup><xref ref-type="bibr" rid="CR114">114</xref>,<xref ref-type="bibr" rid="CR115">115</xref></sup>. Subsequently, MD simulation production runs were conducted for 100 ns, with snapshots taken every 10 ps for analysis purposes<sup><xref ref-type="bibr" rid="CR116">116</xref>,<xref ref-type="bibr" rid="CR117">117</xref></sup>. The Bibliotheca Alexandrina Supercomputing unit was used for all production runs. Results of the MD simulations were analyzed using the GROMACS-2021.3 package, which included the analysis of protein root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (RG), and solvent-accessible surface area (SASA).</p>
      </sec>
      <sec id="Sec43">
        <title>Ethics approval/declarations</title>
        <p id="Par65">This research complies with relevant institutional, national, and international guidelines and legislation. This research does not include any studies with human participants or animals performed by authors.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <sec id="Sec44">
        <title>Supplementary Information</title>
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2024_61991_MOESM1_ESM.pdf"><caption><p>Supplementary Information.</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary Information</title>
      <p>The online version contains supplementary material available at 10.1038/s41598-024-61991-7.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors thank the Academy of Scientific Research and Technology (Scientists for Next Generation, cycle7) for funding this study.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>AE and MEH led work on this study, wrote the main manuscript text, and prepared all the figures. MEH contributed to the investigations. MN, and AS supervised and contributed to the conceptualization of the study. MMS conduct the MDS. All authors reviewed the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>All the primary data used in the study were downloaded from UniProt Knowledgebase (UniProtKB) (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/">https://www.uniprot.org/</ext-link>) with accession numbers O67996, Q44664, and F8WJS1. The datasets supporting the conclusions of this article are included within the article (and its additional files).</p>
    </notes>
    <notes id="FPar1" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par66">The authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>G</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name></person-group><article-title>Brucellosis in the middle East: A persistent medical, socioeconomic and political issue</article-title><source>J. Chemother.</source><year>2007</year><volume>19</volume><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">17594917</pub-id>
</element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbel</surname><given-names>M</given-names></name></person-group><article-title>Brucellosis: An overview</article-title><source>Emerg. Infect. Dis.</source><year>1997</year><volume>3</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">9204307</pub-id>
</element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x142;owacka</surname><given-names>P</given-names></name><name><surname>Zakowska</surname><given-names>D</given-names></name><name><surname>Naylor</surname><given-names>K</given-names></name><name><surname>Niemcewicz</surname><given-names>M</given-names></name><name><surname>Bielawska-Dr&#xF3;zd</surname><given-names>A</given-names></name></person-group><article-title>Brucella&#x2014;Virulence factors, pathogenesis and treatment</article-title><source>Pol. J. Microbiol.</source><year>2018</year><volume>67</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">30015453</pub-id>
</element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivas-Solano</surname><given-names>O</given-names></name><etal/></person-group><article-title>The regulon of <italic>Brucella</italic>
<italic>abortus</italic> two-component system BvrR/BvrS reveals the coordination of metabolic pathways required for intracellular life</article-title><source>PLoS One</source><year>2022</year><volume>17</volume><fpage>e0274397</fpage><pub-id pub-id-type="pmid">36129877</pub-id>
</element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Design of a new multi-epitope vaccine against Brucella based on T and B cell epitopes</article-title><source>Epidemiol. Infect.</source><year>2021</year><pub-id pub-id-type="doi">10.1017/S0950268821001229</pub-id><pub-id pub-id-type="pmid">34668464</pub-id>
</element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Brucella downregulates tumor necrosis factor-&#x3B1; to promote intracellular survival via Omp25 regulation of different microRNAs in porcine and murine macrophages</article-title>
          <source>Front. Immunol.</source>
          <year>2018</year>
          <volume>8</volume>
          <fpage>1</fpage>
          <lpage>17</lpage>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Brucella spp. Omp25 promotes proteasome-mediated cGAS degradation to attenuate IFN-&#x3B2; production</article-title>
          <source>Front. Microbiol.</source>
          <year>2021</year>
          <volume>12</volume>
          <fpage>1</fpage>
          <lpage>17</lpage>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Omp31 of <italic>Brucella</italic> inhibits NF-&#x3BA;B p65 signaling pathway by inducing autophagy in BV-2 microglia</article-title><source>Neurochem. Res.</source><year>2021</year><volume>46</volume><fpage>3264</fpage><lpage>3272</lpage><pub-id pub-id-type="pmid">34536195</pub-id>
</element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group><article-title>OMP31 of <italic>Brucella</italic>
<italic>melitensis</italic> 16M impairs the apoptosis of macrophages triggered by TNF-&#x3B1;</article-title><source>Exp. Ther. Med.</source><year>2016</year><volume>12</volume><fpage>2783</fpage><lpage>2789</lpage><pub-id pub-id-type="pmid">27698784</pub-id>
</element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><etal/></person-group><article-title>The immunogenicity of OMP31 peptides and its protection against <italic>Brucella</italic>
<italic>melitensis</italic> infection in Mice</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>3512</fpage><pub-id pub-id-type="pmid">30837598</pub-id>
</element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>K</given-names></name><etal/></person-group><article-title>integrated bioinformatics-based subtractive genomics approach to decipher the therapeutic drug target and its possible intervention against Brucellosis</article-title><source>Bioengineering</source><year>2022</year><volume>9</volume><fpage>633</fpage><pub-id pub-id-type="pmid">36354544</pub-id>
</element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Bateer</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>The genome sequence of <italic>Brucella</italic>
<italic>abortus</italic> vaccine strain A19 provides insights on its virulence attenuation compared to Brucella abortus strain 9&#x2013;941</article-title><source>Gene</source><year>2022</year><volume>830</volume><fpage>146521</fpage><pub-id pub-id-type="pmid">35447245</pub-id>
</element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitencourt-Ferreira</surname><given-names>G</given-names></name><name><surname>de Azevedo</surname><given-names>WF</given-names></name></person-group><article-title>Homology modeling of protein targets with MODELLER</article-title><source>Methods Mol. Biol.</source><year>2019</year><volume>2053</volume><fpage>231</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">31452109</pub-id>
</element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortuza</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Improving fragment-based ab initio protein structure assembly using low-accuracy contact-map predictions</article-title><source>Nat. Commun.</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41467-021-25316-w</pub-id><pub-id pub-id-type="pmid">34408149</pub-id>
</element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naveed</surname><given-names>M</given-names></name><etal/></person-group><article-title>A reverse vaccinology approach to design an mRNA-based vaccine to provoke a robust immune response against HIV-1</article-title><source>Acta Biochim. Pol.</source><year>2023</year><volume>70</volume><fpage>407</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">37329562</pub-id>
</element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalal</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name><name><surname>Uddin</surname><given-names>R</given-names></name></person-group><article-title>Immunoinformatic-guided designing of multi-epitope vaccine construct against <italic>Brucella</italic>
<italic>Suis</italic> 1300</article-title><source>Immunol. Res.</source><year>2022</year><volume>71</volume><fpage>247</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">36459272</pub-id>
</element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yurina</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Adianingsih</surname>
              <given-names>OR</given-names>
            </name>
          </person-group>
          <article-title>Predicting epitopes for vaccine development using bioinformatics tools</article-title>
          <source>Ther. Adv. Vaccines Immunother.</source>
          <year>2022</year>
          <volume>10</volume>
          <fpage>251513552211002</fpage>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naveed</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of <italic>Melia</italic>
<italic>azedarach</italic> plant extracts activity against hypothetical protein of <italic>Mycobacterium</italic>
<italic>tuberculosis</italic> via GC-MS analysis and in silico approaches</article-title>
          <source>J. Comput. Biophys. Chem.</source>
          <year>2024</year>
          <volume>23</volume>
          <fpage>299</fpage>
          <lpage>320</lpage>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studer</surname><given-names>G</given-names></name><etal/></person-group><article-title>QMEANDisCo&#x2014;Distance constraints applied on model quality estimation</article-title><source>Bioinformatics</source><year>2020</year><volume>36</volume><fpage>1765</fpage><lpage>1771</lpage><pub-id pub-id-type="pmid">31697312</pub-id>
</element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawood</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Brucellae as resilient intracellular pathogens: Epidemiology, host&#x2013;pathogen interaction, recent genomics and proteomics approaches, and future perspectives</article-title><source>Front. Vet. Sci.</source><year>2023</year><pub-id pub-id-type="doi">10.3389/fvets.2023.1255239</pub-id><pub-id pub-id-type="pmid">37876633</pub-id>
</element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elrashedy</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immune response and recent advances in diagnosis and control of brucellosis</article-title>
          <source>Ger. J. Vet. Res.</source>
          <year>2022</year>
          <volume>2</volume>
          <fpage>10</fpage>
          <lpage>24</lpage>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Macedo</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Brucella-associated cervical bursitis in cattle</article-title><source>Trop. Anim. Health Prod.</source><year>2019</year><volume>51</volume><fpage>697</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">30414020</pub-id>
</element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#xFC;derlin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Structural features discriminating hybrid histidine kinase Rec domains from response regulator homologs</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>1002</fpage><pub-id pub-id-type="pmid">36864019</pub-id>
</element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram&#xED;rez-Gonz&#xE1;lez</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Prediction of structure and molecular interaction with DNA of BvrR, a virulence-associated regulatory protein of Brucella</article-title><source>Molecules</source><year>2019</year><volume>24</volume><fpage>3137</fpage><pub-id pub-id-type="pmid">31470504</pub-id>
</element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Stock</surname><given-names>AM</given-names></name></person-group><article-title>Biological insights from structures of two-component proteins</article-title><source>Annu. Rev. Microbiol.</source><year>2009</year><volume>63</volume><fpage>133</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">19575571</pub-id>
</element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structural insights into the transcription activation mechanism of the global regulator GlnR from actinobacteria</article-title><source>Proc. Natl. Acad. Sci.</source><year>2023</year><pub-id pub-id-type="doi">10.1073/pnas.2300282120</pub-id><pub-id pub-id-type="pmid">38157451</pub-id>
</element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehghani</surname><given-names>S</given-names></name><name><surname>Sabzehei</surname><given-names>F</given-names></name><name><surname>Taromchi</surname><given-names>AH</given-names></name><name><surname>Mobaien</surname><given-names>AR</given-names></name><name><surname>Arsang-Jang</surname><given-names>S</given-names></name></person-group><article-title>Hybrid recombinant Omp 22, 25, and 31 immunodominant epitopes can be used for serodiagnosis of brucellosis</article-title><source>J. Immunol. Methods</source><year>2021</year><volume>497</volume><fpage>113123</fpage><pub-id pub-id-type="pmid">34428402</pub-id>
</element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hisham</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ashhab</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Identification of cross-protective potential antigens against pathogenic <italic>Brucella</italic> spp. through combining pan-genome analysis with reverse vaccinology</article-title>
          <source>J. Immunol. Res.</source>
          <year>2018</year>
          <volume>2018</volume>
          <fpage>1</fpage>
          <lpage>15</lpage>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y-F</given-names></name><etal/></person-group><article-title>Identification of bacterial surface antigens by screening peptide phage libraries using whole bacteria cell-purified antisera</article-title><source>Front. Microbiol.</source><year>2017</year><pub-id pub-id-type="doi">10.3389/fmicb.2017.00082</pub-id><pub-id pub-id-type="pmid">29403451</pub-id>
</element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadarangani</surname><given-names>M</given-names></name><name><surname>Hoe</surname><given-names>JC</given-names></name><name><surname>Makepeace</surname><given-names>K</given-names></name><name><surname>van der Ley</surname><given-names>P</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name></person-group><article-title>Phase variation of Opa proteins of <italic>Neisseria</italic>
<italic>meningitidis</italic> and the effects of bacterial transformation</article-title><source>J. Biosci.</source><year>2016</year><volume>41</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">26949083</pub-id>
</element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prajapati</surname><given-names>JD</given-names></name><name><surname>Kleinekath&#xF6;fer</surname><given-names>U</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name></person-group><article-title>How to enter a bacterium: Bacterial porins and the permeation of antibiotics</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><fpage>5158</fpage><lpage>5192</lpage><pub-id pub-id-type="pmid">33724823</pub-id>
</element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Design of a multi-epitope vaccine candidate against <italic>Brucella</italic>
<italic>melitensis</italic></article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">34992227</pub-id>
</element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Design of a recombinant multivalent epitope vaccine based on SARS-CoV-2 and its variants in immunoinformatics approaches</article-title><source>Front. Immunol.</source><year>2022</year><pub-id pub-id-type="doi">10.3389/fimmu.2022.884433</pub-id><pub-id pub-id-type="pmid">37408838</pub-id>
</element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Bioinformatics analysis of Omp19 and Omp25 proteins for designing multi-epitope vaccines against Brucella</article-title><source>Medicine (Baltimore)</source><year>2023</year><volume>102</volume><fpage>e33182</fpage><pub-id pub-id-type="pmid">36930131</pub-id>
</element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Tak</surname>
              <given-names>I-R</given-names>
            </name>
            <etal/>
            <etal/>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Tak</surname>
              <given-names>I-R</given-names>
            </name>
            <etal/>
            <etal/>
          </person-group>
          <article-title>Posttranslational modifications of proteins and their role in biological processes and associated diseases</article-title>
          <source>Protein Modificomics</source>
          <year>2019</year>
          <publisher-name>Elsevier</publisher-name>
          <fpage>1</fpage>
          <lpage>35</lpage>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardito</surname><given-names>F</given-names></name><name><surname>Giuliani</surname><given-names>M</given-names></name><name><surname>Perrone</surname><given-names>D</given-names></name><name><surname>Troiano</surname><given-names>G</given-names></name><name><surname>Muzio</surname><given-names>LL</given-names></name></person-group><article-title>The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)</article-title><source>Int. J. Mol. Med.</source><year>2017</year><volume>40</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">28656226</pub-id>
</element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgo</surname><given-names>C</given-names></name><name><surname>D&#x2019;Amore</surname><given-names>C</given-names></name><name><surname>Sarno</surname><given-names>S</given-names></name><name><surname>Salvi</surname><given-names>M</given-names></name><name><surname>Ruzzene</surname><given-names>M</given-names></name></person-group><article-title>Protein kinase CK2: A potential therapeutic target for diverse human diseases</article-title><source>Signal Transduct. Target. Ther.</source><year>2021</year><volume>6</volume><fpage>183</fpage><pub-id pub-id-type="pmid">33994545</pub-id>
</element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udenwobele</surname><given-names>DI</given-names></name><etal/></person-group><article-title>Myristoylation: An important protein modification in the immune response</article-title><source>Front. Immunol.</source><year>2017</year><pub-id pub-id-type="doi">10.3389/fimmu.2017.00751</pub-id><pub-id pub-id-type="pmid">28713376</pub-id>
</element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y-S</given-names></name><etal/></person-group><article-title>N-Glycan&#x2013;dependent protein folding and endoplasmic reticulum retention regulate GPI-anchor processing</article-title><source>J. Cell Biol.</source><year>2018</year><volume>217</volume><fpage>585</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">29255114</pub-id>
</element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elhag</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abdelmoneim</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Sati</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
          <article-title>Design of epitope based peptide vaccine against <italic>Brucella</italic> abortus OmpW family protein using immunoinformatics</article-title>
          <source>bioRxiv</source>
          <year>2021</year>
          <volume>52</volume>
          <fpage>1</fpage>
          <lpage>14</lpage>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bioinformatics analysis of candidate proteins Omp2b, P39 and BLS for <italic>Brucella</italic> multivalent epitope vaccines</article-title><source>Microb. Pathog.</source><year>2020</year><volume>147</volume><fpage>104318</fpage><pub-id pub-id-type="pmid">32531499</pub-id>
</element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naveed</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of bacterial strains and development of anmRNA-based vaccine to Combat antibiotic resistance in <italic>Staphylococcus</italic>
<italic>aureus</italic> via in vitro and in silico approaches</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><fpage>1039</fpage><pub-id pub-id-type="pmid">37189657</pub-id>
</element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mohammad Hasani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mohammadi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sekhavati</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Region-based epitope prediction, docking and dynamic studies of OMP31 as a dominant antigen in human and sheep Brucella</article-title>
          <source>Int. J. Pept. Res. Ther.</source>
          <year>2020</year>
          <volume>26</volume>
          <fpage>413</fpage>
          <lpage>421</lpage>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarrahimofrad</surname><given-names>H</given-names></name><name><surname>Zamani</surname><given-names>J</given-names></name><name><surname>Hamblin</surname><given-names>MR</given-names></name><name><surname>Darvish</surname><given-names>M</given-names></name><name><surname>Mirzaei</surname><given-names>H</given-names></name></person-group><article-title>A designed peptide-based vaccine to combat <italic>Brucella</italic>
<italic>melitensis</italic>, <italic>B</italic>. <italic>suis</italic> and <italic>B</italic>. <italic>abortus</italic>: Harnessing an epitope mapping and immunoinformatics approach</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>155</volume><fpage>113557</fpage><pub-id pub-id-type="pmid">36115112</pub-id>
</element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirohi</surname><given-names>PR</given-names></name><name><surname>Gupta</surname><given-names>J</given-names></name><name><surname>Somvanshi</surname><given-names>P</given-names></name><name><surname>Prajapati</surname><given-names>VK</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name></person-group><article-title>Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein</article-title><source>J. Biomol. Struct. Dyn.</source><year>2022</year><volume>40</volume><fpage>3347</fpage><lpage>3358</lpage><pub-id pub-id-type="pmid">33246394</pub-id>
</element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazdani</surname><given-names>Z</given-names></name><name><surname>Rafiei</surname><given-names>A</given-names></name><name><surname>Ghoreyshi</surname><given-names>M</given-names></name><name><surname>Abediankenari</surname><given-names>S</given-names></name></person-group><article-title>In silico analysis of a candidate multi - epitope peptide vaccine against human brucellosis</article-title><source>Mol. Biotechnol.</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s12033-023-00698-y</pub-id><pub-id pub-id-type="pmid">36940016</pub-id>
</element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Design of a new multi-epitope vaccine against <italic>Brucella</italic> based on T and B cell epitopes using bioinformatics methods</article-title><source>Epidemiol. Infect.</source><year>2021</year><volume>149</volume><fpage>e136</fpage><pub-id pub-id-type="pmid">34032200</pub-id>
</element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Epitope identification and designing a potent multi-epitope vaccine construct against SARS-CoV-2 including the emerging variants</article-title><source>J. Glob. Infect. Dis.</source><year>2022</year><volume>14</volume><fpage>24</fpage><pub-id pub-id-type="pmid">35418729</pub-id>
</element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunoinformatics approaches to explore <italic>Helicobacter</italic>
<italic>pylori</italic> proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>13321</fpage><pub-id pub-id-type="pmid">31527719</pub-id>
</element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ras-Carmona</surname><given-names>A</given-names></name><name><surname>Pelaez-Prestel</surname><given-names>HF</given-names></name><name><surname>Lafuente</surname><given-names>EM</given-names></name><name><surname>Reche</surname><given-names>PA</given-names></name></person-group><article-title>Bceps: A web server to predict linear B cell epitopes with enhanced immunogenicity and cross-reactivity</article-title><source>Cells</source><year>2021</year><volume>10</volume><fpage>2744</fpage><pub-id pub-id-type="pmid">34685724</pub-id>
</element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukhari</surname><given-names>SNH</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Haq</surname><given-names>E</given-names></name><name><surname>Mehbodniya</surname><given-names>A</given-names></name><name><surname>Webber</surname><given-names>J</given-names></name></person-group><article-title>Machine learning techniques for the prediction of B-Cell and T-cell epitopes as potential vaccine targets with a specific focus on SARS-CoV-2 pathogen: A review</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><fpage>146</fpage><pub-id pub-id-type="pmid">35215090</pub-id>
</element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nitulescu</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Virtual screening algorithms in drug discovery: A review focused on machine and deep learning methods</article-title>
          <source>Drugs Drug Candidates</source>
          <year>2023</year>
          <volume>2</volume>
          <fpage>311</fpage>
          <lpage>334</lpage>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyedele</surname><given-names>A-QK</given-names></name><etal/></person-group><article-title>Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices</article-title><source>Mol. Divers.</source><year>2022</year><pub-id pub-id-type="doi">10.1007/s11030-022-10523-4</pub-id><pub-id pub-id-type="pmid">36271195</pub-id>
</element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Athar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sona</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Bekono</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Ntie-Kang</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Fundamental physical and chemical concepts behind &#x201C;drug-likeness&#x201D; and &#x201C;natural product-likeness&#x201D;</article-title>
          <source>Phys. Sci. Rev.</source>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.1515/psr-2018-0101</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roskoski</surname><given-names>R</given-names></name></person-group><article-title>Rule of five violations among the FDA-approved small molecule protein kinase inhibitors</article-title><source>Pharmacol. Res.</source><year>2023</year><volume>191</volume><fpage>106774</fpage><pub-id pub-id-type="pmid">37075870</pub-id>
</element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naveed</surname><given-names>M</given-names></name><etal/></person-group><article-title>The natural breakthrough: Phytochemicals as potent therapeutic agents against spinocerebellar ataxia type 3</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><fpage>1529</fpage><pub-id pub-id-type="pmid">38233440</pub-id>
</element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>The conserved domain database in 2023</article-title><source>Nucleic Acids Res.</source><year>2023</year><volume>51</volume><fpage>D384</fpage><lpage>D388</lpage><pub-id pub-id-type="pmid">36477806</pub-id>
</element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letunic</surname><given-names>I</given-names></name><name><surname>Khedkar</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name></person-group><article-title>SMART: Recent updates, new developments and status in 2020</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>D458</fpage><lpage>D460</lpage><pub-id pub-id-type="pmid">33104802</pub-id>
</element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>DWA</given-names></name><name><surname>Jones</surname><given-names>DT</given-names></name></person-group><article-title>The PSIPRED protein analysis workbench: 20 years on</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>W402</fpage><lpage>W407</lpage><pub-id pub-id-type="pmid">31251384</pub-id>
</element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Combet</surname><given-names>C</given-names></name><name><surname>Blanchet</surname><given-names>C</given-names></name><name><surname>Geourjon</surname><given-names>C</given-names></name><name><surname>Del&#xE9;age</surname><given-names>G</given-names></name></person-group><article-title>NPS@: Network protein sequence analysis</article-title><source>Trends Biochem. Sci.</source><year>2000</year><volume>25</volume><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">10694887</pub-id>
</element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <mixed-citation publication-type="other">Kumar, T. A. CFSSP: Chou and Fasman secondary structure prediction server (2013). 10.5281/ZENODO.50733.</mixed-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>A comparative assessment and analysis of 20 representative sequence alignment methods for protein structure prediction</article-title><source>Sci. Rep.</source><year>2013</year><volume>3</volume><fpage>2619</fpage><pub-id pub-id-type="pmid">24018415</pub-id>
</element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olenyi</surname><given-names>T</given-names></name><etal/></person-group><article-title>LambdaPP: Fast and accessible protein-specific phenotype predictions</article-title><source>Protein Sci.</source><year>2023</year><pub-id pub-id-type="doi">10.1002/pro.4524</pub-id><pub-id pub-id-type="pmid">36454227</pub-id>
</element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kouza</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Faraggi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kolinski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kloczkowski</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <source>The GOR Method of Protein Secondary Structure Prediction and Its Application as a Protein Aggregation Prediction Tool</source>
          <year>2017</year>
          <publisher-name>Springer New York</publisher-name>
          <fpage>7</fpage>
          <lpage>24</lpage>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>J</given-names></name><etal/></person-group><article-title>ProNA2020 predicts protein&#x2013;DNA, protein&#x2013;RNA, and protein&#x2013;protein binding proteins and residues from sequence</article-title><source>J. Mol. Biol.</source><year>2020</year><volume>432</volume><fpage>2428</fpage><lpage>2443</lpage><pub-id pub-id-type="pmid">32142788</pub-id>
</element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomerie</surname><given-names>S</given-names></name><etal/></person-group><article-title>PROTEUS2: A web server for comprehensive protein structure prediction and structure-based annotation</article-title><source>Nucleic Acids Res.</source><year>2008</year><volume>36</volume><fpage>W202</fpage><lpage>W209</lpage><pub-id pub-id-type="pmid">18483082</pub-id>
</element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Accurate de novo prediction of protein contact map by ultra-deep learning model</article-title><source>PLOS Comput. Biol.</source><year>2017</year><volume>13</volume><fpage>e1005324</fpage><pub-id pub-id-type="pmid">28056090</pub-id>
</element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DE</given-names></name><name><surname>Chivian</surname><given-names>D</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name></person-group><article-title>Protein structure prediction and analysis using the Robetta server</article-title><source>Nucleic Acids Res.</source><year>2004</year><volume>32</volume><fpage>W526</fpage><lpage>W531</lpage><pub-id pub-id-type="pmid">15215442</pub-id>
</element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biasini</surname><given-names>M</given-names></name><etal/></person-group><article-title>SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>W252</fpage><lpage>W258</lpage><pub-id pub-id-type="pmid">24782522</pub-id>
</element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><etal/></person-group><article-title>I-TASSER-MTD: A deep-learning-based platform for multi-domain protein structure and function prediction</article-title><source>Nat. Protoc.</source><year>2022</year><volume>17</volume><fpage>2326</fpage><lpage>2353</lpage><pub-id pub-id-type="pmid">35931779</pub-id>
</element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><etal/></person-group><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">34265844</pub-id>
</element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group><article-title>LOMETS3: Integrating deep learning and profile alignment for advanced protein template recognition and function annotation</article-title><source>Nucleic Acids Res.</source><year>2022</year><volume>50</volume><fpage>W454</fpage><lpage>W464</lpage><pub-id pub-id-type="pmid">35420129</pub-id>
</element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>LA</given-names></name><name><surname>Mezulis</surname><given-names>S</given-names></name><name><surname>Yates</surname><given-names>CM</given-names></name><name><surname>Wass</surname><given-names>MN</given-names></name><name><surname>Sternberg</surname><given-names>MJE</given-names></name></person-group><article-title>The Phyre2 web portal for protein modeling, prediction and analysis</article-title><source>Nat. Protoc.</source><year>2015</year><volume>10</volume><fpage>845</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">25950237</pub-id>
</element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group><article-title>Detecting distant-homology protein structures by aligning deep neural-network based contact maps</article-title><source>PLOS Comput. Biol.</source><year>2019</year><volume>15</volume><fpage>e1007411</fpage><pub-id pub-id-type="pmid">31622328</pub-id>
</element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuvo</surname><given-names>MH</given-names></name><name><surname>Gulfam</surname><given-names>M</given-names></name><name><surname>Bhattacharya</surname><given-names>D</given-names></name></person-group><article-title>DeepRefiner: High-accuracy protein structure refinement by deep network calibration</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>W147</fpage><lpage>W152</lpage><pub-id pub-id-type="pmid">33999209</pub-id>
</element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Seok</surname><given-names>C</given-names></name></person-group><article-title>GalaxyWEB server for protein structure prediction and refinement</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>40</volume><fpage>W294</fpage><lpage>W297</lpage><pub-id pub-id-type="pmid">22649060</pub-id>
</element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The trRosetta server for fast and accurate protein structure prediction</article-title><source>Nat. Protoc.</source><year>2021</year><volume>16</volume><fpage>5634</fpage><lpage>5651</lpage><pub-id pub-id-type="pmid">34759384</pub-id>
</element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>How significant is a protein structure similarity with TM-score = 0.5?</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>889</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">20164152</pub-id>
</element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>L</given-names></name><name><surname>Feig</surname><given-names>M</given-names></name></person-group><article-title>PREFMD: A web server for protein structure refinement via molecular dynamics simulations</article-title><source>Bioinformatics</source><year>2018</year><volume>34</volume><fpage>1063</fpage><lpage>1065</lpage><pub-id pub-id-type="pmid">29126101</pub-id>
</element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adiyaman</surname><given-names>R</given-names></name><name><surname>McGuffin</surname><given-names>LJ</given-names></name></person-group><article-title>ReFOLD3: Refinement of 3D protein models with gradual restraints based on predicted local quality and residue contacts</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>W589</fpage><lpage>W596</lpage><pub-id pub-id-type="pmid">34009387</pub-id>
</element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colovos</surname><given-names>C</given-names></name><name><surname>Yeates</surname><given-names>TO</given-names></name></person-group><article-title>Verification of protein structures: Patterns of nonbonded atomic interactions</article-title><source>Protein Sci.</source><year>1993</year><volume>2</volume><fpage>1511</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">8401235</pub-id>
</element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <mixed-citation publication-type="other">Laskowski, R. A., MacArthur, M. W. &amp; Thornton, J. M. PROCHECK&#x202F;: validation of protein-structure coordinates, 684&#x2013;687. 10.1107/97809553602060000882 (2012).</mixed-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>TM-align: A protein structure alignment algorithm based on the TM-score</article-title><source>Nucleic Acids Res.</source><year>2005</year><volume>33</volume><fpage>2302</fpage><lpage>2309</lpage><pub-id pub-id-type="pmid">15849316</pub-id>
</element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benkert</surname><given-names>P</given-names></name><name><surname>Biasini</surname><given-names>M</given-names></name><name><surname>Schwede</surname><given-names>T</given-names></name></person-group><article-title>Toward the estimation of the absolute quality of individual protein structure models</article-title><source>Bioinformatics</source><year>2011</year><volume>27</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">21134891</pub-id>
</element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigrist</surname><given-names>CJA</given-names></name><etal/></person-group><article-title>New and continuing developments at PROSITE</article-title><source>Nucleic Acids Res.</source><year>2012</year><volume>41</volume><fpage>D344</fpage><lpage>D347</lpage><pub-id pub-id-type="pmid">23161676</pub-id>
</element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hau</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Pagni</surname><given-names>M</given-names></name></person-group><article-title>HitKeeper, a generic software package for hit list management</article-title><source>Source Code Biol. Med.</source><year>2007</year><volume>2</volume><fpage>2</fpage><pub-id pub-id-type="pmid">17391514</pub-id>
</element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>M</given-names></name><etal/></person-group><article-title>The InterPro protein families and domains database: 20 years on</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>D344</fpage><lpage>D354</lpage><pub-id pub-id-type="pmid">33156333</pub-id>
</element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandurangan</surname><given-names>AP</given-names></name><name><surname>Stahlhacke</surname><given-names>J</given-names></name><name><surname>Oates</surname><given-names>ME</given-names></name><name><surname>Smithers</surname><given-names>B</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name></person-group><article-title>The SUPERFAMILY 2.0 database: A significant proteome update and a new webserver</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>D490</fpage><lpage>D494</lpage><pub-id pub-id-type="pmid">30445555</pub-id>
</element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sillitoe</surname><given-names>I</given-names></name><etal/></person-group><article-title>CATH: Increased structural coverage of functional space</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>D266</fpage><lpage>D273</lpage><pub-id pub-id-type="pmid">33237325</pub-id>
</element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>SVMTriP: A method to predict antigenic epitopes using support vector machine to integrate tri-peptide similarity and propensity</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e45152</fpage><pub-id pub-id-type="pmid">22984622</pub-id>
</element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Potocnakova</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bhide</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pulzova</surname>
              <given-names>LB</given-names>
            </name>
          </person-group>
          <article-title>An introduction to B-cell epitope mapping and in silico epitope prediction</article-title>
          <source>J. Immunol. Res.</source>
          <year>2016</year>
          <volume>2016</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ponomarenko</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ElliPro: A new structure-based tool for the prediction of antibody epitopes</article-title>
          <source>BMC Bioinform.</source>
          <year>2008</year>
          <pub-id pub-id-type="doi">10.1186/1471-2105-9-514</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reche</surname><given-names>PA</given-names></name><name><surname>Reinherz</surname><given-names>EL</given-names></name></person-group><article-title>Prediction of peptide-MHC binding using profiles</article-title><source>Methods Mol. Biol.</source><year>2007</year><volume>409</volume><fpage>185</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">18450001</pub-id>
</element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rammensee</surname><given-names>HG</given-names></name><name><surname>Bachmann</surname><given-names>J</given-names></name><name><surname>Emmerich</surname><given-names>NPN</given-names></name><name><surname>Bachor</surname><given-names>OA</given-names></name><name><surname>Stevanovi&#x107;</surname><given-names>S</given-names></name></person-group><article-title>SYFPEITHI: Database for MHC ligands and peptide motifs</article-title><source>Immunogenetics</source><year>1999</year><volume>50</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">10602881</pub-id>
</element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S</given-names></name><etal/></person-group><article-title>Determination of a predictive cleavage motif for eluted major histocompatibility complex class II ligands</article-title><source>Front. Immunol.</source><year>2018</year><pub-id pub-id-type="doi">10.3389/fimmu.2018.01795</pub-id><pub-id pub-id-type="pmid">30555484</pub-id>
</element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doytchinova</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Flower</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines</article-title>
          <source>BMC Bioinform.</source>
          <year>2007</year>
          <volume>8</volume>
          <fpage>4</fpage>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>I</given-names></name><name><surname>Naneva</surname><given-names>L</given-names></name><name><surname>Doytchinova</surname><given-names>I</given-names></name><name><surname>Bangov</surname><given-names>I</given-names></name></person-group><article-title>AllergenFP: Allergenicity prediction by descriptor fingerprints</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>846</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">24167156</pub-id>
</element-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><etal/></person-group><article-title>In silico approach for predicting toxicity of peptides and proteins</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e73957</fpage><pub-id pub-id-type="pmid">24058508</pub-id>
</element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naveed</surname><given-names>M</given-names></name><etal/></person-group><article-title>Design of a novel multiple epitope-based vaccine: An immunoinformatics approach to combat SARS-CoV-2 strains</article-title><source>J. Infect. Public Health</source><year>2021</year><volume>14</volume><fpage>938</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">34119848</pub-id>
</element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Gasteiger</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Walker</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protein identification and analysis tools on the ExPASy server</article-title>
          <source>The Proteomics Protocols Handbook</source>
          <year>2005</year>
          <publisher-name>Springer</publisher-name>
          <fpage>571</fpage>
          <lpage>607</lpage>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhady</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Molecular docking and dynamics simulation study of hyrtios erectus isolated <italic>Scalarane</italic>
<italic>Sesterterpenes</italic> as potential SARS-CoV-2 dual target inhibitors</article-title><source>Biology (Basel)</source><year>2021</year><volume>10</volume><fpage>389</fpage><pub-id pub-id-type="pmid">34062724</pub-id>
</element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madushanka</surname><given-names>A</given-names></name><name><surname>Moura</surname><given-names>RT</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Kraka</surname><given-names>E</given-names></name></person-group><article-title>Quantum mechanical assessment of protein-ligand hydrogen bond strength patterns: Insights from semiempirical tight-binding and local vibrational mode theory</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><fpage>6311</fpage><pub-id pub-id-type="pmid">37047283</pub-id>
</element-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>W-H</given-names></name><name><surname>Kumazawa</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Hirokawa</surname><given-names>T</given-names></name><name><surname>Kihara</surname><given-names>D</given-names></name></person-group><article-title>Current challenges and opportunities in designing protein-protein interaction targeted drugs</article-title><source>Adv. Appl. Bioinform. Chem.</source><year>2020</year><volume>13</volume><fpage>11</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">33209039</pub-id>
</element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>ZINC20&#x2014;A free ultralarge-scale chemical database for ligand discovery</article-title><source>J. Chem. Inf. Model.</source><year>2020</year><volume>60</volume><fpage>6065</fpage><lpage>6073</lpage><pub-id pub-id-type="pmid">33118813</pub-id>
</element-citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><etal/></person-group><article-title>DrugBank 5.0: A major update to the DrugBank database for 2018</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D1074</fpage><lpage>D1082</lpage><pub-id pub-id-type="pmid">29126136</pub-id>
</element-citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Mackerell</surname><given-names>AD</given-names></name></person-group><article-title>Computer-aided drug design methods</article-title><source>Methods Mol. Biol.</source><year>2017</year><volume>1520</volume><fpage>85</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">27873247</pub-id>
</element-citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laskowski</surname><given-names>RA</given-names></name><name><surname>Swindells</surname><given-names>MB</given-names></name></person-group><article-title>LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery</article-title><source>J. Chem. Inf. Model.</source><year>2011</year><volume>51</volume><fpage>2778</fpage><lpage>2786</lpage><pub-id pub-id-type="pmid">21919503</pub-id>
</element-citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>DW</given-names></name><name><surname>Craighead</surname><given-names>JL</given-names></name><name><surname>Economides</surname><given-names>C</given-names></name><name><surname>Rosenthal</surname><given-names>J</given-names></name></person-group><article-title>Clinical development success rates for investigational drugs</article-title><source>Nat. Biotechnol.</source><year>2014</year><volume>32</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">24406927</pub-id>
</element-citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>G</given-names></name><etal/></person-group><article-title>ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>W5</fpage><lpage>W14</lpage><pub-id pub-id-type="pmid">33893803</pub-id>
</element-citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>P</given-names></name><name><surname>Eckert</surname><given-names>AO</given-names></name><name><surname>Schrey</surname><given-names>AK</given-names></name><name><surname>Preissner</surname><given-names>R</given-names></name></person-group><article-title>ProTox-II: A webserver for the prediction of toxicity of chemicals</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>W257</fpage><lpage>W263</lpage><pub-id pub-id-type="pmid">29718510</pub-id>
</element-citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutzner</surname><given-names>C</given-names></name><etal/></person-group><article-title>More bang for your buck: Improved use of GPU nodes for GROMACS 2018</article-title><source>J. Comput. Chem.</source><year>2019</year><volume>40</volume><fpage>2418</fpage><lpage>2431</lpage><pub-id pub-id-type="pmid">31260119</pub-id>
</element-citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><article-title>CHARMM36m: An improved force field for folded and intrinsically disordered proteins</article-title><source>Nat. Methods</source><year>2017</year><volume>14</volume><fpage>71</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">27819658</pub-id>
</element-citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darden</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>York</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pedersen</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Particle mesh Ewald: An N&#xB7;log(N) method for Ewald sums in large systems</article-title>
          <source>J. Chem. Phys.</source>
          <year>1993</year>
          <volume>98</volume>
          <fpage>10089</fpage>
          <lpage>10092</lpage>
        </element-citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussi</surname><given-names>G</given-names></name><name><surname>Donadio</surname><given-names>D</given-names></name><name><surname>Parrinello</surname><given-names>M</given-names></name></person-group><article-title>Canonical sampling through velocity rescaling</article-title><source>J. Chem. Phys.</source><year>2007</year><pub-id pub-id-type="doi">10.1063/1.2408420</pub-id><pub-id pub-id-type="pmid">17212484</pub-id>
</element-citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parrinello</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure and pair potentials: A molecular-dynamics study</article-title>
          <source>Phys. Rev. Lett.</source>
          <year>1980</year>
          <volume>45</volume>
          <fpage>1196</fpage>
          <lpage>1199</lpage>
        </element-citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Delineating the conformational dynamics of intermediate structures on the unfolding pathway of &#x3B2;-lactoglobulin in aqueous urea and dimethyl sulfoxide</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><volume>38</volume><fpage>5027</fpage><lpage>5036</lpage><pub-id pub-id-type="pmid">31744390</pub-id>
</element-citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakash</surname><given-names>A</given-names></name><etal/></person-group><article-title>Elucidation of stable intermediates in urea-induced unfolding pathway of human carbonic anhydrase IX</article-title><source>J. Biomol. Struct. Dyn.</source><year>2018</year><volume>36</volume><fpage>2391</fpage><lpage>2406</lpage><pub-id pub-id-type="pmid">28705076</pub-id>
</element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>